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Anthropogenically-derived substances, including pharmaceuticals and personal 
care products, endocrine-disrupting chemicals, and pesticides, are increasingly being 
detected in drinking water supplies and wastewater effluents.  Concerns over the presence 
of these compounds in water supplies include their ability to impart toxicological activity, 
their capacity to spread antibiotic resistance, and their potential to affect cell-signaling 
processes.  For these reasons, water treatment processes geared towards removal of these 
trace organic contaminants are vital. 
 
In this work, ozone was used to treat four pharmaceutical contaminants:  
ciprofloxacin, cyclophosphamide, erythromycin, and ifosfamide.  Ciprofloxacin and 
erythromycin are antibiotic/antimicrobial compounds, and cyclophosphamide and 
ifosfamide are chemotherapy agents.  Ozone effectively transformed all four 
pharmaceuticals, even in the presence of background natural organic matter, which exerts 
a considerable ozone demand.  The apparent rate constants for the reaction of the 
pharmaceuticals with ozone at pH 7 were determined:  3.03 M-1s-1 for cyclophosphamide; 
7.38 M-1s-1 for ifosfamide; 1.57×104 M-1s-1 for ciprofloxacin; and 7.18×104 M-1s-1 for 
erythromycin.  Cyclophosphamide and ifosfamide, which do not react quickly with 
ozone, exhibited high rate constants (2.7×109 M-1s-1) for transformation by hydroxyl 
radicals, which are formed through ozone decomposition.  Nevertheless, complete 
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removal of cyclophosphamide and ifosfamide was achievable using a novel continuous 
aqueous ozone addition reactor and an ozone-based advanced oxidation process 
(peroxone). 
 
In ozone-based processes, pharmaceuticals are systematically transformed via 
complex oxidative pathways towards CO2, H2O, and the oxidized forms of other 
elements.  Intermediate oxidation products containing oxygen atoms or hydroxyl groups 
substituted into the chemical structure of the parent pharmaceutical were identified using 
liquid chromatography-mass spectrometry (LC-MS).  Given the structural similarity of 
intermediate oxidation products to the parent pharmaceuticals, an antimicrobial activity 
assay was employed to monitor the removal of pharmacological activity associated with 
ciprofloxacin, erythromycin, and their respective intermediate oxidation products 
throughout treatment.  For solutions containing ciprofloxacin or erythromycin, ozone was 
able to completely eliminate the corresponding antimicrobial activity.  Ciprofloxacin 
intermediate oxidation products were pharmacologically active; however, erythromycin’s 
intermediate products did not contribute to the residual antimicrobial activity.  These 
results suggest that the design of conventional and advanced ozone-based processes must 
incorporate ozone demand from background organic matter and account for destruction 
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CHAPTER 1:  INTRODUCTION 
 
This is an especially interesting time in the field of environmental engineering.  In 
the past, water and wastewater treatment for specific compounds were reactionary 
measures aimed at resolving issues surrounding the contamination of water supplies.  In 
fact, the birth of the modern environmental movement can be considered a reaction to 
Rachel Carson’s landmark book, Silent Spring (Carson, 1962).  With the rapid advances 
in environmental engineering since the 1970s, we are now in a unique position to 
engineer treatment processes aimed at removing emerging contaminants from water 
sources.  The focus of this dissertation is on the removal of pharmacologically active 
compounds (PhACs) from water. 
 
The sheer number of chemical compounds that the human population produces 
and employs is intimidating.  PhACs represent only a small portion of these compounds.  
While it is difficult to estimate the total number of PhACs used in the world, 7,929 
approved drugs are listed in the National Institutes of Health (NIH) Chemical Genomics 
Center (NCGC) pharmaceutical collection (NPC) browser (Huang et al., 2011).  From 
2004 to 2008, global pharmaceutical sales grew from $578 billion to over $735 billion 
(IMS Health, 2007).   
 
Documentation of the presence of such compounds in water  is widespread, with 
PhACs being detected in surface waters on every continent (Ternes, 1998; Stumpf et al., 
1999; Schulz and Peall, 2000; Kolpin et al., 2002; Falconer et al., 2006; Kim et al., 2007; 
Hale et al., 2008).  The concentrations of PhACs in the environment tend to range from 
less than 1 ng/L to several μg/L (Ternes, 1998; Kolpin et al., 2002; Kim et al., 2007).  
However, exceptions exist; most notably, Larsson et al. (2007) reported ciprofloxacin 
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concentrations up to 31 mg/L in the wastewater effluent of a treatment plant serving 
ninety bulk drug manufacturers. 
 
 A considerable amount of research has concentrated on assessing the impact of 
pharmaceuticals and personal care products (PPCPs), endocrine-disrupting chemicals 
(EDCs), and pesticides/insecticides, among other chemicals, on aquatic life.  Aquatic life 
is especially susceptible to hydrophobic contaminants, including many of the EDCs and 
PhACs, because of the potential for bioaccumulation in low trophic levels and 
biomagnification of these compounds in the marine food chain (Tyler et al., 1998; Vos et 
al., 2000).  The impact of PhACs on human health is not yet fully understood; however, 
progress has been made in three major areas of study:  direct impacts on human cells 
(Pomati et al., 2006), spread of antibiotic resistance (Schwartz et al., 2003; Duong et al., 
2008; Szczepanowski et al., 2009), and indirect impacts on cell signaling processes 
(Linares et al., 2006; Fajardo and Martínez, 2008).  To lessen the threat from PhAC 
contamination, several states (Maine, 2005; California, 2007; Iowa, 2007; Oregon, 2007; 
Wisconsin, 2007; Pennsylvania, 2008) have enacted legislation to encourage proper 
disposal of unused and expired medication.  On the federal level, concern over the 
presence of PhACs in the environment has prompted Congress to propose adding 
hazardous pharmaceutical wastes to The Universal Waste Rule (EPA, 2008). 
 
PROBLEM STATEMENT 
 Research efforts aimed at identifying the capabilities of water treatment plants to 
remove pharmaceuticals in various background water quality matrices are ongoing 
(Steger-Hartmann et al., 1997; Ternes, 1998; Stumpf et al., 1999; Adams et al., 2002; 
Westerhoff et al., 2005).  Several research studies have focused on oxidation and 
advanced oxidation processes (AOPs) for removal of PhACs due to process flexibility, 
ease of installation, and competitive economics (Huber et al., 2003; Snyder et al., 2006).  
Ozone-based processes have great potential, as reflected in their increasingly frequent use 
in water reuse scenarios (Halliday, 2006; APTwater, 2011; Windhoek, 2011).  The work 
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of von Gunten has demonstrated the use of aqueous ozone stock solutions for various 
purposes, including the determination of ozone‒PhAC reaction kinetics (Dodd et al., 
2006), PhAC transformation for specific ozone doses (Suarez et al., 2007), and 
measurement of hydroxyl radical exposure (Elovitz and von Gunten, 1999; Elovitz et al., 
2000).  This body of literature builds on earlier work by Hoigné, Staehelin, and Bader 
(Hoigné and Bader, 1976; Staehelin and Hoigné, 1982) in understanding ozone 
decomposition in water and reaction chemistry with chemical contaminants. 
 
Oxidative treatment is a transformative process.  DeWitte et al. (2008) identified 
some of the operative ciprofloxacin transformations during ozonation; the chemical 
structures of the twelve intermediate oxidation products that were suggested are markedly 
similar to the structure of ciprofloxacin.  Since pharmacological activity is a strong 
function of chemical structure (Lemke and Williams, 2008), one key hypothesis 
associated with this research is that some oxidative intermediate products may exert 
pharmacological or toxicological activity.  In the past few years, several researchers 
(Suarez et al., 2007; Baeza, 2008; Dodd et al., 2009; Paul et al., 2010) have used an 
antimicrobial susceptibility assay (NCCLS, 2004) to describe treatment efficiency in 
terms of pharmacological activity.  The ability to monitor residual antimicrobial activity 
allows for pragmatic treatment goals (i.e., treatment goals based upon removal of the 




 The overall goal of this research was to develop an approach for considering 
water treatment of PhACs in terms of not only parent compound removal but also 
elimination of residual pharmacological activity.  In this research, four pharmaceuticals 
(i.e., ciprofloxacin, cyclophosphamide, erythromycin, and ifosfamide) were employed to 
build a comprehensive story about how transformation of parent compounds by 
ozonation and advanced oxidation processes relates to the elimination of pharmacological 
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activity in a water treatment context.  To elucidate this relationship, the following 
objectives were undertaken: 
 
1. To investigate the transformation of the four compounds of concern in the ozone 
and peroxone systems; 
2. To describe the kinetics of degradation of the four compounds of concern with 
aqueous ozone and hydroxyl radicals; 
3. To identify the early intermediate oxidation products for the compounds of 
concern; 
4. To measure the antimicrobial activity of water sources containing ciprofloxacin 
and erythromycin throughout the treatment process; and, 
5. To characterize the impact of natural organic matter (NOM) on the transformation 




The findings from Objective 1 were employed to determine the suitability of 
ozone-based processes to treat PhACs.  In Objective 2, the rate constants for the PhACs 
of concern with ozone and hydroxyl radicals were found to enable prediction of PhAC 
transformation in treatment processes where ozone exposure and hydroxyl radical 
exposure can be controlled.  The intermediate oxidation products formed through PhAC 
reaction with ozone and hydroxyl radicals were identified in Objective 3.  The cumulative 
findings from Objectives 1-2 illustrate the amount and rate of PhAC transformation 
expected in ozone-based processes; furthermore, the structures of the resulting 
intermediate oxidation products were characterized in Objective 3.  For the four PhACs 
of concern, the structures of intermediate products suggested their relative ability to exert 
a specific biological response.  For ciprofloxacin and erythromycin, the ability of 
intermediate oxidation products to maintain residual antimicrobial activity was tested in 
Objective 4; however, for cyclophosphamide and ifosfamide, the discussion was limited 
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to the theoretical potential for intermediate oxidation products to manifest 
pharmacological activity.  Finally, the impacts of NOM (Objective 5) on pharmaceutical 
oxidation in ozone-based systems were investigated in terms of parent compound 
transformation, intermediate product formation, and elimination of residual 
pharmacological activity. 
 
The chapters of this dissertation are organized as follows.  Chapter 2 contains an 
extensive literature review of pharmaceutical presence in water sources, the chemistry of 
the four compounds studied in this research, ozone chemistry, ozone application 
strategies (gaseous vs. aqueous ozone addition), and the impact of NOM on ozone 
processes.  Chapter 3 describes the materials and methods employed in the research with 
a particular emphasis on the analytical methods used to measure pharmaceuticals, the 
experimental designs employed for ozone experiments, and the antimicrobial activity 
protocols utilized to measure residual antimicrobial activity.  Chapter 4 discusses ozone 
and peroxone treatment of the two chemotherapy agents (cyclophosphamide and 
ifosfamide), including identification of rate constants using the novel continuous aqueous 
ozone addition reactor, demonstration of the impact of DOC on transformation, and 
characterization of intermediate oxidation products.  Chapter 5 presents results showing 
ciprofloxacin oxidation in a continuous aqueous ozone addition reactor and how the 
presence and composition of NOM can impact not only ciprofloxacin transformation, but 
also antimicrobial activity elimination.  Chapter 6 examines the transformation kinetics of 
erythromycin and a major erythromycin metabolic product, anhydroerythromycin A, with 
ozone, the intermediate oxidation products formed via ozonation, and the antimicrobial 
activity of erythromycin, anhydroerythromycin A, and their intermediate oxidation 
products.  Chapters 4 through 6 were written as drafts of papers to be submitted for 
publication in refereed journals and therefore repeat, in abbreviated form, some of the 
background and methods from Chapters 2 and 3.  Chapter 7 draws conclusions about the 





The significance of this research lies in the extension of the results to water and 
wastewater treatment applications.  Of particular interest is the application for water 
reuse scenarios.  One of the most contentious aspects of water reuse and wastewater 
reclamation is the ability for trace organic contaminants to pass through treatment 
processes and enter drinking water supplies.  Many water reuse facilities employ tertiary 
treatment processes aimed at disinfection and treatment of trace organic contaminants 
(Halliday, 2006; APTwater, 2011; Windhoek, 2011).  As ozonation is a typical unit 
process employed in water reuse scenarios, understanding the ability of the ozone process 
to remove trace organic contaminants, including pharmacologically active compounds, 
from the water source is crucial.   
 
As the length of the pathway between wastewater and drinking water is reduced, 
the efficacy of ozonation processes needs to be better understood and changes to 
traditional ozonation processes need to be developed.  This dissertation introduces the 
employment of two novel ozone processes to determine the kinetics of PhAC 
transformation by ozone and hydroxyl radicals:  the continuous aqueous ozone addition 
reactor and the continuous peroxone addition reactor.  In the first scenario, a highly 
concentrated ozone solution is continuously pumped into a reactor containing the water 
of interest; in the second scenario, hydrogen peroxide and the highly concentrated ozone 
solution are concurrently pumped into a reactor containing the water of interest. 
 
  Finally, this research takes important strides beyond many previous ozone-based 
research efforts.  Traditionally, researchers have investigated individual aspects of ozone 
treatment processes relevant to water treatment scenarios.  In this body of work, I 
demonstrate not only the ability of ozone-based treatment processes to transform 
pharmaceuticals, but also the impact of NOM on the removal efficiency of 
pharmaceuticals; furthermore, I characterize intermediate oxidation products.  Perhaps 
the most important aspect of this research is the measurement of residual antimicrobial 
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activity throughout treatment processes for ciprofloxacin and erythromycin.  As treatment 
goals should be based upon the ability of the water to exert a biological response, 
demonstrating the means to measure the residual pharmacological activity is extremely 





CHAPTER 2:  LITERATURE REVIEW 
 
 
In Pharma-ecology:  The Occurrence and Fate of Pharmaceuticals and Personal 
Care Products in the Environment, Jjemba (2008) states, “The human impulse for a cure 
runs quite deep, and our first instinct whenever we feel sick or heading toward sickness is 
to medicate.”  This impulse has contributed to the rapid rise of the pharmaceutical 
industry, and our increased consumption of various medications.  As with many other 
anthropogenically-derived substances, increased consumption inevitably leads to 
environmental contamination. 
 
PHARMACEUTICALS IN THE ENVIRONMENT 
The presence of trace organic compounds, and pharmacologically active 
compounds (PhACs) in particular, in global water supplies has been widely documented 
during the last decade (Halling-Sorensen et al., 1998; Daughton and Ternes, 1999; 
Kolpin et al., 2002).  Halling-Sorensen et al.’s (1998) review article discussed the 
presence of pharmaceutical substances in groundwater, river water, sediments, ocean 
dumping sites, and soils; the paper goes on to describe studies investigating the 
biodegradability, sorption, and toxicity of pharmaceutical substances in a variety of 
media.  In the conclusion of the article, Halling-Sorensen et al. note that “further research 
in this hitherto little explored field would be necessary to assess the environmental risk 
involved in exposing medical substances to the environment.”  In 1999, Daughton and 
Ternes asked whether pharmaceuticals and personal care products are “agents of subtle 
change.”  In this landmark review, Daughton and Ternes (1999) aimed “to catalyze a 
discussion in the environmental science community to determine the significance of 
PPCPs in the environment.”  A few years later, Kolpin et al. (2002) documented the 
results of a nationwide reconnaissance conducted by the United States Geological Survey 
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(USGS) to assess the presence of trace organic contaminants, including pharmaceuticals, 
personal care products, hormones, pesticides, and plasticizers, among other wastewater-
derived contaminants, in U.S. surface water.  That study sampled from 139 streams 
across 30 U.S. states; the analytical methods developed for the study were able to test for 
95 different trace organic contaminants (TrOCs) found in municipal wastewater.  Of the 
95 compounds investigated, 82 compounds were detected at least once in the study; 
furthermore, 80% of the 139 streams investigated contained at least one compound.  
Kolpin et al. (2002) interpreted these results as evidence that TrOCs pass through 
wastewater treatment and persist in the environment. 
 
In 2008, this issue was brought to the public’s attention through an Associated 
Press news report by Donn et al. (2008).  The journalists contacted water utilities around 
the country and inquired as to whether pharmaceuticals had been detected in drinking 
water supplies or finished drinking water.  This report was distributed in major 
newspapers around the country with headlines such as AP Probe Finds Drugs in 
Drinking Water (Donn et al., 2008).  The original article opens with the following 
statement:  “A vast array of pharmaceuticals – including antibiotics, anti-convulsants, 
mood stabilizers and sex hormones – have been found in the drinking water supplies of at 
least 41 million Americans…”  Other findings from this report include the following: 
 
“Officials in Philadelphia said testing there discovered 56 pharmaceuticals or 
byproducts in treated drinking water, including medicines for pain, infection, high 
cholesterol, asthma, epilepsy, mental illness and heart problems. Sixty-three 
pharmaceuticals or byproducts were found in the city's watersheds. 
 
Anti-epileptic and anti-anxiety medications were detected in a portion of the treated 
drinking water for 18.5 million people in Southern California. 
 
A sex hormone was detected in San Francisco's drinking water.”  (Donn et al., 2008) 
 
Needless to say, this article generated a media frenzy regarding the presence of 
pharmaceuticals in drinking water; that frenzy has resulted in increased research activity 
with respect to treatment processes aimed at removing trace organic contaminants in 
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water and wastewater treatment plants.  As mentioned above, the first major articles 
addressing the issue of pharmaceutical presence in the environment came in the late 
1990s.  Figure 2-1 shows the number of SciFinder returns for two separate searches:  (1) 
“”pharmaceutical” & “environment” & “contamination” and (2) “pharmaceutical” & 
“water treatment.”  In the mid-late 1990s, the slope of the curve steepens.  Recall that this 
period coincides with publication of the first major articles (Halling-Sorensen et al., 
1998; Daughton and Ternes, 1999) calling attention to this topic.  The dates for release of 
the Kolpin et al. (2002) and Donn et al. (2008) studies are also superimposed on the plot.  
Clearly, release of these reports coincided with increased research activity in this field. 
 
 
Figure 2-1. SciFinder returns for keywords relating to pharmaceutical presence in 






Avenues for Pharmaceutical Introduction into the Environment 
Daughton (2007) recently published a figure documenting the avenues for 
pharmaceutical contamination of the environment, including usage by individuals and 
pets, release of treated/untreated hospital wastes to domestic sewage systems, release to 
private septic/leach fields, applications of biosolids to agricultural land, direct release to 
open waters via washing, bathing, and swimming, discharge of regulated/controlled 
industrial manufacturing waste streams, disposal to landfills, release to open waters from 
aquaculture, and release of drugs that serve as pest control agents, among others.  In this 
dissertation, the focus rests on wastewater treatment plants (WWTPs).  In WWTPs, the 
two major avenues for pharmaceutical contamination are excretion of unmetabolized 
pharmaceuticals from the human body and improper disposal of medication. 
 
Excretion of pharmaceuticals and active metabolites from the human body 
(Lienert et al., 2007) is a direct function of drug uptake into plasma, metabolism of the 
drug, and the urinary excretion rate (Lemke and Williams, 2008).  The excretion rate of 
pharmaceuticals depends on the chemical structure and properties of individual 









F  Eq. 2-1 
 
In Eq. 2-1, Fex is the urinary excretion factor, MPhAC,urine is the mass of the parent 
pharmaceuticals excreted in the urine, and MPhAC,dose is the mass of parent pharmaceutical 
dosed to the patient.  Additionally, the administered dose can also affect the excretion 
factor.  For example, ifosfamide administered at low doses (1.5 g/m2 oral dose) 
demonstrates an excretion factor of 12-18%; however, at high doses (5 g/m2 IV dose and 
1.5 g/m2 oral dose) shows a much higher excretion factor, 53.1±9.6% (Brunton et al., 
2006).  Here, the m2 refers to body surface area, which is calculated as a function of 
height and weight.  Other compounds demonstrate a wide range of urinary excretion 
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factors; for instance, heparin, an anticoagulant, exhibits negligible urinary excretion, and 
metformin, one of the most widely prescribed antidiabetic drugs, has a urinary excretion 
factor of 99.9% (Brunton et al., 2006).  While other factors are involved, higher excretion 
factors correlate to higher PhAC concentrations in raw wastewater. 
 
Disposal of unused or expired medication has been a topic of recent investigations 
(Bound et al., 2006; Braund et al., 2009; Glassmeyer et al., 2009).  Glassmeyer et al. 
(2009) found that only 2% of respondents from the United States used all of their 
medication, while 7.2% of respondents did not dispose of unused medications, 1.4% 
returned the unused medication to the pharmacy, 35.4% disposed of unused medication 
down the sink or toilet, and 54% disposed of unused medication in the garbage.  Disposal 
of medication down the sink or toilet constitutes improper disposal due to the potential 
for pharmacologically active compounds to enter the aquatic environment and drinking 
water supplies.  Bound et al. (2006) found that the disposal method for unused 
medications by people in the United Kingdom varied by pharmaceutical class.  For 
example, 75.3% of respondents said that they dispose of antihistamines into the trash, 
9.1% into the toilet/sink, and 14.3% are returned to the pharmacy; however, 66.7% of 
respondents said that dispose of antidepressants in the trash, and the other 33.3% return 
unused antidepressants to the pharmacy.  Later, Braund et al. (2009) found that the 
disposal method for unused medications in New Zealand varies depending on the 
medication formulation (i.e., liquid, tablet/capsule, or ointment/cream).  Liquid 
medications are more likely to be disposed of into the sink/toilet, whereas 
tablets/capsules and ointments/creams are more likely to be disposed of into the garbage 
(Braund et al., 2009).  Recently, legislative action in the United States has aimed to 
decrease the amount of PhACs entering wastewater streams through improper disposal of 
unused and/or expired medication.  
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LEGISLATION OF PHARMACEUTICAL CONTAMINANTS 
 
The Office of National Drug Control Policy published a document titled “Proper 
Disposal of Prescription Drugs” in October, 2009 (ONDCP, 2009).  In that document, 
citizens are advised to only flush drugs approved for flushing by the Federal Drug 
Administration (FDA, 2010); the FDA list contains 27 drugs.  If the drugs are not 
recommended for flushing, citizens are told to use community drug take-back programs 
or household hazardous waste collection events.  If drug collection programs are not 
available, citizens are told to mix the drugs with cat litter or coffee grounds, seal the 
mixture in a disposable container or sealable bag, and to dispose of the container in the 
trash.   
 
In 2005, Maine became the first state to legislate the disposal of unused 
pharmaceuticals.  Title 22 §2700 of the Maine Revised Statutes (Maine, 2005) 
established the Unused Pharmaceutical Disposal Program, the purpose of which is “to 
ensure the safe, effective, and proper disposal of unused pharmaceuticals.”  The 
legislation calls for the creation of a system that provides for the return of unused 
pharmaceuticals through the use of prepaid mailing envelopes (Maine, 2005).  Since that 
time, a number of other states have enacted similar bills; short descriptions of those bills 
(California, 2007; Iowa, 2007; Oregon, 2007; Wisconsin, 2007; Pennsylvania, 2008; 




Table 2-1. State bills relating to regulation of unused pharmaceuticals. 
State Year Bill Description 
Maine 2005 
Revised Statutes Title 
22 § 2700 
Unused Pharmaceutical Disposal Program 
collects unused pharmaceuticals and ensures 
safe, effective, and proper disposal. 
California 2007 
Public Resources 
Code § 47120-47126 
The new sections of the code tasked state 
agencies with developing a model for the 
safe take-back of drugs and the diversion of 
drug waste for use or sale. 
Iowa 2007 Senate File 579 
This act appropriated $225,000 for a 
pharmaceutical collection and disposal pilot 
project. 
Oregon 2007 Senate Bill 737 
The bill relates to bettering water quality.  
One of the measures listed is the institution 
of pharmaceutical take-back programs. 
Wisconsin 2007 Senate Bill 40 
The bill makes amendments to household 
hazardous waste laws. 
Pennsylvania 2008 House Bill 2073 
The Pharmaceutical Drug Disposal Act 
requires pharmaceutical retailers to establish 
means for collecting pharmaceutical drugs 
for proper disposal. 
Virginia 2008 House Bill 86 
The bill created the Unused Pharmaceutical 
Disposal Program, which establishes a 
system for returning unused pharmaceuticals 
to a single collection location. 
 
 
Concern over the presence of PhACs in the environment has prompted Congress 
to propose adding hazardous pharmaceutical wastes to The Universal Waste Rule (EPA, 
2008).  The proposed regulation would essentially mandate pharmaceutical waste 
collection guidelines to minimize the amount of pharmaceuticals being introduced into 
the environment; however, the rule relies on pharmacies, hospitals, physicians’ offices, 
dentists’ offices, outpatient care centers, ambulatory health care services, residential care 
facilities, veterinary clinics, and other facilities that generate hazardous pharmaceutical 
wastes to act as collection centers for expired and unused medications.  Although this 





While states are starting to adopt legislation requiring proper handling and 
disposal of unused and expired medication, treatment of pharmaceuticals in wastewater 
streams or drinking water sources has not yet been included in legislation.  Given the 
media buzz generated by the 2008 Associated Press article (Donn et al., 2008), future 
legislation on the discharge of pharmacologically active compounds from wastewater 
treatment plants is expected.  In fact, the EPA’s Candidate Contaminant List 3 (CCL3) 
lists several PPCPs and EDCs including 1,4-diozane, 17α-ethinylestradiol, 2-
methoxyethanol, 2-propen-1-ol, benzyl chloride, cobalt, equilenin, equilin, erythromycin, 
17β-estradiol, estriol, estrone, mestranol, nitrobenzene, nitroglycerin, 19-norethisterone, 
σ-toluidine, quinoline, tellurium, and, triethylamine (EPA, 2009).  Selection of a 
contaminant to the EPA CCL3 means that these chemicals are currently being considered 
for regulation under the Safe Drinking Water Act; therefore, it seems likely that future 
contaminant candidate lists will also include pharmaceuticals.  For that reason, study of 
the ability of water treatment processes to treat PhACs is merited.  In this research, 




PHARMACEUTICALS OF CONCERN IN THIS STUDY 
 
This study focused on four pharmacologically active compounds (PhACs):  
ciprofloxacin, cyclophosphamide, ifosfamide, and erythromycin.  Salient information for 
the four compounds of concern is provided in Table 2-2.  These compounds represent 
two pharmaceutical classes, namely, antibiotic (ciprofloxacin and erythromycin) and 
chemotherapy agents (cyclophosphamide and ifosfamide).  Clearly, these compounds are 
distinctly different in their degree of aromaticity, molecular weight, and speciation; 
however, they also demonstrate chemical similarities, especially the two chemotherapy 
agents, cyclophosphamide and ifosfamide, which are structural isomers.  In this case, 
cyclophosphamide and ifosfamide were both studied to determine how the placement of 
the two chloroethyl functional groups affects transformation kinetics with ozone and 




Ciprofloxacin is a second generation fluoroquinolonic antibiotic.  Shortly after the 
introduction of fluoroquinolonic antibiotics in the late 1980s, ciprofloxacin became the 
most widely used antibiotic in the world (Norrby and Lietman, 1993).    In 2006, 
ciprofloxacin ranked 139th in pharmaceutical sales with $755 million in sales 
(Humphreys, 2007).  As of 2006, ciprofloxacin had generated a lifetime sales profit of 
$19 billion (Finch and Hunter, 2006); and in 2009, fluoroquinolones were the third most 
profitable class of antibiotics with sales of $7.1 billion (Hamad, 2010).  Ciprofloxacin is 
widely prescribed for urinary tract infections, cystitis, diarrhea, Typhoid fever, sinusitis, 
and gonorrhea, among others (FDA, 2004).  Most notably, ciprofloxacin was prescribed 
for anthrax infections (Meyerhoff et al., 2004).  Given the extremely active research into 
newer fluoroquinolones (De Souza, 2005), ciprofloxacin use is beginning to decline; 
however, it is still a widely prescribed pharmaceutical (Prescription, 2011).  The mode of 
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action for ciprofloxacin, as well as the other three pharmaceuticals of concern, is 
provided in Table 2-3. 
 
Table 2-2. Salient information for the chemicals of concern. 








Class Antibiotic Antibiotic 
CAS Number 85721-33-1 114-07-8 
pKa 6.2, 8.8 8.8 
Fex (%) 50 ± 5 12 ± 7 








Class Chemotherapy Agent Chemotherapy Agent 
CAS Number 50-18-0 3778-73-2 
pKa 2.84 - 6.5 1.45 - 4.0 
Fex (%) 6.5 ± 4.3 
12-18 (low dose), 


















































Table 2-3. Mode of action for PhACs of concern. 
Pharmaceutical Mode of Action 
Ciprofloxacin 
Inhibits DNA gyrase and topoisomerase IV, which relieve 
stress during DNA unwinding.  Inhibition of these enzymes 
disallows bacterial DNA separation, thereby inhibiting cell 
division. 
Erythromycin 
Binds to the 50S subunit of the bacterial 70S rRNA complex.  
Erythromycin interferes with aminoacyl translocation, 
preventing the transfer of the tRNA bound at the A site of the 
rRNA complex to the P site of the rRNA complex.  Without 
this translocation, the A site remains occupied, which 
interferes with the production of functionally useful proteins. 
Cyclophosphamide 
Cyclophosphamide is metabolized by cytochrome P450 to 4-
hydroxycyclophosphamide, which is then metabolized to 
phosphoramide mustard.  Phosphoramide mustard forms DNA 
crosslinks between and within DNA strands at guanine N-7 
positions. 
Ifosfamide 
Ifosfamide is metabolized by cytochrome P450 to 4-
hydroxyifosfamide, which is then metabolized to 
isophosphoramide mustard.  Isophosphoramide mustard forms 




Erythromycin was discovered in 1952 when it was isolated from the metabolic 
products of a strain of Streptomyces erythreus (McGuire et al., 1952).  Erythromycin is a 
broad-spectrum antibiotic in the macrolide family, and it is prescribed for bacterial 
infections like bronchitis, diphtheria, Legionnaires’ disease, pertussis, pneumonia, and 
ear, urinary tract, and skin infections, among others (Wishart et al., 2008).  Since the 
discovery of erythromycin, a number of other macrolide compounds have been 
developed, including clarithromycin (1970s), azithromycin (1980), roxithromycin (1987), 
and telithromycin (1998); regardless, erythromycin remains one of the most successful 
drugs of all time (Omura, 2002; Pal, 2006).  In 2009, macrolides were the fourth most 




Cyclophosphamide and Ifosfamide 
Cyclophosphamide and ifosfamide are structural isomers.  These compounds are 
prodrugs, meaning that cyclophosphamide and ifosfamide, themselves, are 
pharmacologically inactive; the compounds are converted into their active forms during 
metabolism.  First, the two compounds are converted to 4-hydroxycyclophosphamide and 
4-hydroxyifosfamide, respectively, which are also prodrugs (Low et al., 1983).  The 4-
hydroxy derivatives are further metabolized to the reactive mustards, phosphoramide 
mustard (cyclophosphamide) and isophosphoramide mustard (ifosfamide), respectively 
(Low et al., 1983).  The reactive mustards are cytotoxic and work by alkylating DNA, 
prohibiting separation of DNA strands during replication (Fleming, 1997).  In addition to 
being cytotoxic, cyclophosphamide and ifosfamide are teratogenic, mutagenic, and 
carcinogenic (Bus et al., 1973; Murthy et al., 1973; Mohn and Ellenberger, 1976).  The 
concentrations associated with cyclophosphamide and ifosfamide toxicity are organism 
dependent.   
 
Environmental Presence of Compounds of Concern 
As discussed in a previous section, many avenues exist for pharmacologically 
active compounds to enter the environment; however, for the compounds studied in this 
research, the major source is wastewater treatment plants (WWTPs).  The excretion 
factors for the four pharmaceuticals of concern range from 6.5% to 50%, indicating that a 
relatively large fraction of the consumed pharmaceuticals is excreted and sent to 
WWTPs.  As a result, all four of these compounds have been detected in hospital 
wastewater, wastewater treatment plant influent, wastewater treatment plant effluent, and 
surface water (Table 2-4).  While the measured concentrations vary by compound, PhAC 
concentrations in hospital wastewater can be relatively high (1-150 µg/L).  Due to 
dilution and some removal in wastewater treatment plants, surface water concentrations 
were low for all four compounds, typically on the order of tens of ng/L or less.  Two 
notable exceptions to this trend are the following:  Larsson et al. (2007) reported 
concentrations of 28-31 mg/L ciprofloxacin in effluent from a WWTP serving about 90 
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bulk drug manufacturers and Kolpin et al. (2002) detected surface water erythromycin 
concentrations of up to 1.7 µg/L.  The presence of the four chemicals of concern in 
surface waters suggests the potential for occurrence in drinking water but no literature 






Table 2-4. Detection of the four pharmaceuticals of concern. 
Drug Source Concentration (ng/L) Concentration Type Reference 
Ciprofloxacin 
Groundwater nd * range Barnes et al., 2008 
Hospital WW 140,000 max Vasconcelos et al., 2009 
Hospital WW nd – 54,049 range Thomas et al., 2007 
Hospital WW 1,100 – 25,800 range Duong et al., 2008 
Hospital WW (treated) 3,700 average Duong et al., 2008 
Surface water nd - 26.15 range Calamari et al., 2003 
Surface water 26 average Castiglioni et al., 2004 
Surface water nd-18 range Golet et al., 2002 
Surface water nd range Tamtam et al., 2008 
Surface water nd – 36 range Vieno et al., 2007 
Surface water nd  - 30 range Kolpin et al., 2002 
WW effluent 62-106 range Golet et al., 2002 
WW effluent nd – 400 range Miao et al., 2004 
WW effluent 251 median Zuccato et al., 2005 
WW effluent nd – 2,700 range Bhandari et al., 2008 
WW effluent nd - 742 range Thomas et al., 2007 
WW effluent 45 - 405 range Golet et al., 2001 
WW effluent 28,000,000 – 31,000,000 range Larsson et al., 2007 
WW influent 313-568 range Golet et al., 2002 
WW influent nd - 4600 range Bhandari et al., 2008 
WW influent nd - 5876 range Thomas et al., 2007 
Cyclophosphamide 
Hospital WW nd - 21 range Thomas et al., 2007 
Surface water nd range Calamari et al., 2003 
Surface water 0.05 - 0.17 range Buerge et al., 2006 
WW effluent 0.6 median Zuccato et al., 2005 
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Drug Source Concentration (ng/L) Concentration Type Reference 
Cyclophosphamide 
WW effluent nd range Thomas et al., 2007 
WW effluent 2 - 10 range Buerge et al., 2006 
WW effluent nd - 17 range Steger-Hartmann et al., 1997 
WW effluent 6 average Kim et al., 2009 
WW influent nd range Thomas et al., 2007 
WW influent 2 - 11 range Buerge et al., 2006 
WW influent nd - 143 range Steger-Hartmann et al., 1997 
Ifosfamide 
Hospital WW nd - 338 range Thomas et al., 2007 
Surface water nd - 0.14 range Buerge et al., 2006 
WW effluent nd - 71 range Thomas et al., 2007 
WW effluent nd - 6 range Buerge et al., 2006 
WW influent nd range Thomas et al., 2007 
WW influent nd - 5 range Buerge et al., 2006 
Erythromycin 
Groundwater nd range Barnes et al., 2008 
Reclaimed WW 154 - 611 range Kinney et al., 2006 
Surface water 1.40-15.90 range Calamari et al., 2003 
Surface water 5 average Castiglioni et al., 2004 
Surface water nd - 6.9 range Hao et al., 2006 
Surface water nd – 1,700 range Kolpin et al., 2002 
WW effluent 838 maximum Miao et al., 2004 
WW effluent 47.4 median Zuccato et al., 2005 
WW effluent nd range Ternes et al., 2003 
WW effluent 110 average Kim et al., 2009 
WW effluent 6,000 maximum Hirsch et al., 1999 
WW influent 620 average Ternes et al., 2003 
* nd = non-detect
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HUMAN AND ENVIRONMENTAL HEALTH THREAT FROM PHAC PRESENCE IN DRINKING 
WATER SUPPLIES 
 
  Based upon their pharmaceutical class, the four compounds listed above are of 
concern due to documented and perceived threats to human and environmental health.  
Pomati and coworkers (2006; 2007; 2008) have undertaken several studies to investigate 
the effects of 13 pharmaceuticals on Escherichia coli, zebrafish liver, human embryonic 
kidney, and human ovarian carcinoma cells.  They have found that trace levels of 
pharmaceuticals can inhibit the growth of human embryonic kidney cells by up to 30% 
(Pomati et al., 2006), and that the pharmacological activity of drug mixtures can vary 
from that of individual compounds (Pomati et al., 2008).  These findings are of great 
importance because they include the first toxicological investigation into the effects of 
trace levels of (non-endocrine disrupting) PhAC mixtures on human cells.  In addition to 
effects of trace organic contaminants on proliferation of select bacterial and mammalian 
cell lines, other human health and environmental concerns include the spread of antibiotic 
resistance, toxicity, and interruption of cell signaling processes. 
 
As mentioned in a previous section, several authors have detected antibiotic 
resistance genes in and downstream from wastewater treatment plants (Schwartz et al., 
2003; Volkmann et al., 2004; Mispagel and Gray, 2005; Baquero et al., 2008; Duong et 
al., 2008; Szczepanowski et al., 2009).  While hundreds of antibiotic resistance genes 
have been detected in wastewater treatment plants and in wastewater treatment plant 
effluent, consider the Szczepanowski et al. (2009) paper that identified the following 
ciprofloxacin resistance genes:  qnrB1, qnrB2, qnrB5, qnr, and qnrS2, as well as general 
quinolone resistance genes such as qnrB4; all of these genes were found in the activated 
sludge tank and the final WWTP effluent.  Erythromycin resistance genes were also 
detected:  ereA2, ereA, ereB, mph(B), mph(A), mph, ermA, ermB, mef(A), mefE, mefI, 
mel, msrA, and mexD, as well as general macrolide resistance genes like mphBM 
(Szczepanowski et al., 2009).  All of these genes were detected in the activated sludge 
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tank; however, only ereA2, ereA, mph(B), mph(A), mph, ermB, mel, and mexD, were 
found within the viable microorganism population in the final WWTP effluent.  Clearly, 
antibiotic resistance is widespread in wastewater treatment plants and wastewater 
treatment plant effluent.  Previous research has described wastewater effluent as the third 
tier of the transfer of antibiotic resistance, with the first tier composed of antibiotic use in 
animals and humans and the second tier composed of hospitals, long-term care facilities, 
and farms (Baquero et al., 2008). 
  
Documented evidence describes the decreasing susceptibility of microorganisms 
in patients to fluoroquinolones, including ciprofloxacin (Ridley and Threlfall, 1998; 
Karlowsky et al., 2002; Bhavnani et al., 2003).  In the Bhavnani et al. (2003) paper, the 
authors compiled data from 174 hospitals and reported that the median susceptibility of 
Pseudomonas aeruginosa to ciprofloxacin fell from 84% in 1993 to 71% in 1999.  
Similar concerns exist for erythromycin (Seppala et al., 1992; Descheemaeker et al., 
2000) and other macrolides.  In Finland, erythromycin resistance in Group A streptococci 
rose from 4% in 1988 to 24% in 1990 (Seppala et al., 1992).  To combat antibiotic 
resistance, several countries have actually lowered consumption of antibiotic 
medications; in fact, between 2000 and 2009, France and Japan decreased antibiotic 
usage by 21% and 15%, respectively (Hamad, 2010). 
 
Several authors (Kummerer et al., 1997; Steger-Hartmann et al., 1997; Buerge et 
al., 2006; Johnson et al., 2007; Chen et al., 2008) have indicated concern for the presence 
of chemotherapy agents in the environment.  The basis for this concern often stems from 
the fact that chemotherapy agents tend to exhibit carcinogenicity, mutagenicity, 
teratogenicity, and embryotoxicity, among other toxic effects.  The mechanism of action 
for cyclophosphamide and ifosfamide was described above in Table 2-3; recall that these 
compounds are metabolized into products that alkylate DNA (Low et al., 1983; Fleming, 
1997).  No research efforts have investigated whether environmental degradation of 
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chemotherapy agents can lead to formation of the active compounds; furthermore, the 
excretion of metabolic products is not typically reported. 
 
Recently, an increasing amount of attention has been given to characterization of 
the sub-lethal effects caused by PhACs, and antibiotics in particular.  In 2006, Linares et 
al. (2006) reported on the ability of antibiotics to act as intermicrobial signaling agents 
rather than “weapons.”  In that study, the authors reported that ciprofloxacin induced 
expression of 1.4% and repressed expression of 3.8% of a specific subset of 555 genes.  
In conclusion, the authors state that “subinhibitory concentrations of antibiotics can 
produce specific changes in the behavior of susceptible bacteria.”  Fajardo and Martinez 
(2008) also reported that low concentrations of antibiotics can trigger specific 
transcriptional responses; the authors reference the inhibition of the quorum sensing 
response by macrolides as an example of how antibiotics can affect cell signaling 
processes.  Quorum sensing is the regulation of gene expression in response to changes in 
cell density.  Davies et al. (2006) assembled a table showing a snapshot of the functional 
groups of genes affected by subinhibitory concentrations of antibiotics.  In that work, the 
authors describe several effects caused by fluoroquinolones and macrolides, including the 
ability of fluoroquinolones to reduce hemolytic activity and induce colicin synthesis in E. 
coli.  They also documented the ability of macrolides to decrease biofilm formation in 
Mycobacterium fortuitum and to inhibit quorum sensing in Pseudomonas aeruginosa 
(Davies et al., 2006).  Most of these subinhibitory effects are organism dependent, but 
regardless of the specific effect, more research into the implications for ecological 






WATER AND WASTEWATER TREATMENT OF TRACE ORGANIC CONTAMINANTS 
 
Shortly after publication of the initial review articles (Halling-Sorensen et al., 
1998; Daughton and Ternes, 1999) documenting the presence of pharmaceuticals in the 
environment, a number of research investigations targeting water and wastewater 
treatment of pharmaceuticals and other TrOCs were undertaken.  Several authors have 
documented the transport of PPCPs and EDCs through wastewater treatment processes 
(Ternes, 1998; Stumpf et al., 1999; Thomas et al., 2007; Okuda et al., 2008).  Similar 
studies have been conducted at drinking water treatment plants (Ternes et al., 2002; 
Stackelberg et al., 2004; Vieno et al., 2007).  This review focuses on drinking water 
treatment processes employed to remove PhACs from various water sources. 
 
  Adams et al. (2002) treated Missouri River water spiked with seven antibiotics at 
concentrations of 50 μg/L using conventional water treatment processes, including the 
following:  coagulation/flocculation/sedimentation with alum and iron salts, excess lime / 
soda ash softening, ultraviolet irradiation (at disinfection dosages), ion exchange, 
sorption onto powdered activated carbon (PAC), reverse osmosis, chlorination, and 
ozonation.  Their results showed that coagulation, softening, UV disinfection, and ion 
exchange did not demonstrate high removal efficiencies for the seven antibiotics of 
concern.  The other processes (PAC, reverse osmosis, chlorination, and ozonation) all 
demonstrated high potential to treat the seven antibiotics employed in this study.  
Ultimately, this work established which unit processes could successfully treat 
pharmaceuticals in water matrices.  Other efforts focused on testing the treatment 
efficacy of many unit processes have yielded similar results.  For example, Westerhoff et 
al. (2005) investigated removal of 62 different PPCPs and EDCs at concentrations 
ranging from 10-250 ng/L using alum (0-72% removal) and iron (0 - ~80%) coagulation, 
softening (0 - ~80%) , PAC (14-98%), hypochlorite oxidation (0-99%), and ozonation (2-
99%).  Removal efficiencies varied widely depending on the chemical structure and 
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properties of each individual PPCP or EDC; regardless, the highest individual removal 
efficiencies were observed for the ozone-based oxidation process. 
 
Other authors have investigated cumulative removal throughout an entire drinking 
water treatment process train.  Stackelburg et al. (2004) followed the concentrations of 
eleven PPCPs throughout a conventional drinking water treatment plant with coagulation, 
sedimentation, filtration (granular activated carbon; GAC), and disinfection 
(hypochlorite).  The concentrations of the eleven PPCPs in the raw water ranged from 6-
860 ng/L.  Of the eleven PPCPs followed through this drinking water treatment plant, 
only one compound, caffeine, showed significant removal.  Vieno et al. (2007) conducted 
a similar investigation, in which the authors documented changes in the concentrations of 
eleven pharmaceuticals (6-55 ng/L) through a pilot-scale drinking water treatment plant.  
The post-sedimentation and post-sand filtration concentrations were not statistically 
different from raw water concentrations.  The water was then ozonated, and the 
concentrations of all eleven pharmaceuticals were significantly reduced (16-99%).  The 
final units of the process train consisted of two granular activated carbon beds and UV-
disinfection.  Only three compounds were present above the detection limit after 
ozonation; two of those compounds, ibuprofen and naproxen, were removed below the 
detection limit after the first GAC bed.  The third compound, ciprofloxacin, did not 
demonstrate statistically significant removal after UV disinfection.  
 
  Other researchers (Xu et al., 2005; Kim et al., 2007; Snyder et al., 2007; Wang et 
al., 2009) have investigated the ability of membrane-based processes to remove 
pharmacologically active compounds from water and wastewater sources.  Xu et al. 
(2005) looked into the ability for reverse osmosis (RO) and nanofiltration (NF) 
membranes to remove seven pharmaceuticals at concentrations of 300 ng/L.  In that 
study, RO successfully removed over 90% of all seven compounds, but NF removal 
efficiencies varied from 10% to 70%.  Snyder et al. (2007) demonstrated the ability of 
ultrafiltration, membrane bioreactor (MBR), and RO processes to treat a cocktail of 36 
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pharmaceuticals.  In the ultrafiltration study, three compounds showed negative removal 
efficiencies; the other compounds demonstrated a wide range of removal (2.63 to greater 
than 98.85%).  Removal efficiencies in the MBR process ranged from 0% to greater than 
96.4%.  In the RO system, all compounds except caffeine (84.9% removal) and 
pentoxifylline (90.4% removal) were removed to below detection limits.  While reverse 
osmosis can effectively remove pharmaceuticals from water sources, the energy cost of 
using RO for low ionic strength water sources can be relatively high; for example, Lee et 
al. (2010) determined that the energy consumption of reverse osmosis was 1.1-1.5 
kWh/1000 gallons compared to 0.061-0.12 kWh/1000 gallons for ozone treatment. 
 
While the removal efficiencies for various PPCPs and EDCs in the drinking water 
treatment processes outlined in these studies (Adams et al., 2002; Stackelberg et al., 
2004; Westerhoff et al., 2005; Vieno et al., 2007) vary widely, the studies utilizing ozone 
processes always demonstrated the highest removal efficiencies with the possible 
exception of RO processes, which tend to be cost- and energy-intensive for water sources 
with low salt concentrations.  As a result, ozone-based treatment processes have emerged 
as the leading technology for removing trace concentrations of pharmacologically active 
compounds.  In this work, ozone and the peroxone process were employed in treating the 






OZONE AND PEROXONE CHEMISTRY 
 
Ozone can effectively oxidize trace concentrations of organic contaminants, 
including pharmaceuticals.  While all four of the selected compounds react with ozone to 
some degree, hydroxyl radicals, the principal ozone decomposition product, also 
contribute some oxidative capacity.  Peroxone, i.e., the combination of ozone and 
hydrogen peroxide, is an advanced oxidation process (AOP) that provides rapid 
generation of hydroxyl radicals by initiating ozone decomposition by hydrogen peroxide.  
For these reasons, it is important to consider ozone decomposition chemistry in the 
absence and presence of hydrogen peroxide.  Ozone decomposition reactions are 
presented below (Table 2-5).  These reactions essentially describe the rate of ozone 
decomposition in solution in pure water (Hoigné and Bader, 1976; Staehelin and Hoigné, 
1982; Buehler et al., 1984; Staehelin et al., 1984) and in water at alkaline conditions 
(Tomiyasu et al., 1985).  The reactions are split into three categories:  initiation, 
propagation, and termination reactions.  As the names suggest, initiation reactions trigger 
ozone decomposition, propagation reactions continue the ozone decomposition chain, and 
termination reactions end that chain of reactions.  In both scenarios, ozone decomposes 
into two radical species, which then undergo a complex set of propagation reactions to 
form hydroxyl radicals (HO·) and other reactive oxygen species (ROS), including the 
superoxide radical (O2
-·) and the peroxy radical (HO2·). 
 
  Below, two initiation reactions (Reactions 2-1, 2-2; Tomiyasu et al., 1985) and 
two propagation reactions (Reactions 2-3 (Westerhoff et al., 1997), 2-4 (Tomiyasu et al., 
1985)) are shown for pure water at alkaline conditions.  The major oxidizing agents 
formed via ozone decomposition include hydroxyl radicals (HO·) and superoxide radicals 
(O2
-·).  Both of these radicals are highly reactive and will attack almost all molecules 
present in solution.  In Reaction 2-5, a generic reaction for ROS attack on a 
pharmaceutical compound is shown.  Ozone, itself, will also attack organic molecules 







OHOHOO sM   

 Rxn. 2-1 






OHOHOO sM  Rxn. 2-2 






 Rxn. 2-3 






 Rxn. 2-4 
 ProductsROSProductsteIntermediaPhACPhACROS PhACROSk   ,  Rxn. 2-5  
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k
3
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Table 2-5. Ozone decomposition models. 
 
Ozone Decomposition in Pure Water 










  HOHO 22  7.9 × 10
5 s-1 
  22 HOHO  5 × 10
10 M-1s-1 
2323 OOOO 
  1.6 × 109 M-1s-1 
  33 HOHO  5.2 × 10
10 M-1s-1 
  HOHO 33  3.3 × 10
2 s-1 
23 OHOHO   1.1 × 10
5 s-1 
 43 HOHOO  2 × 10
9 M-1s-1 





32244 2 OOHHOHO   5 × 10
9 M-1s-1 




Ozone Decomposition in Pure Water at Alkaline Conditions 





  40 M-1s-1 * 





  HOHO 22  7.9 × 10
5 s-1 
  22 HOHO  5 × 10
10 M-1s-1 
2323 OOOO 
  1.6 × 109 M-1s-1 
  HOOHOOHO 223  20 - 30 M
-1s-1 
  223 OHOHOO  6 × 10
9 M-1s-1 
223 OHOHOO   3 × 10
9 M-1s-1 
222 OHHHO 
  5 × 1010 M-1s-1 









3 COHOCOHO  4.2 × 10
8 M-1s-1 
  22233 OCOOOCO  no data given 
* A value of 70 M-1s-1 is more widely employed for the ozone decomposition initiation reaction.
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 Reactions 2-2 to 2-5 also apply to the peroxone system as ozone is rapidly 
decomposed into a number of radical compounds that ultimately form ROS, including 
hydroxyl radicals and superoxide radicals, that are capable of transforming organic 
molecules.  Dissociation of hydrogen peroxide (Rxn. 2-7) leads to formation of peroxide 
(HO2
-), which can react with ozone as described above (Rxns. 2-2, 2-4).  The general 
reaction can be written as shown in Reaction 2-8 (Glaze and Kang, 1989; Alsheyab and 
Muñoz, 2006).  Ultimately, this reaction shows that, in the peroxone system, every mole 
of ozone is transformed into one mole of hydroxyl radicals; furthermore, the ideal molar 
ratio of hydrogen peroxide to ozone is 0.5 mol H2O2 / mol O3.  If the ratio is lower than 
0.5 mol H2O2 / mol O3, some ozone will not react, and lower hydroxyl radical exposures 
(∫[HO·]dt) will be attained.  On the other hand, if the molar ratio of H2O2 to ozone is 
greater than 0.5 mol/mol, the excess H2O2 will react with hydroxyl radicals (Rxns. 2-9, 2-
10; Beltran, 2003), effectively scavenging them and preventing their reaction with 
PhACs. 
 











OHOOHO sMk  
  Rxn. 2-8 





  Rxn. 2-9 






2  Rxn. 2-10 
 
Figure 2-2 illustrates the complexity of hydroxyl radical reactions, which are 
formed during ozonation and can be scavenged by carbonate (HCO3
-, CO3
2-), NOM, or t-
butanol (t-BuOH), among other compounds.  Hydroxyl radicals can also interact with 
NOM, methanol (MeOH), or formaldehyde, among other compounds, to generate the 
superoxide anion (O2
-), which promotes ozone decomposition.  Ozone decomposition to 
hydroxyl radicals is also facilitated by interaction with the hydroxide ion (HO-); 
therefore, ozone can be considered an AOP at high pH. 
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The left side of Figure 2-2 shows ozone decomposition in the peroxone system.  
In this scheme, carbonate actually promotes ozone decomposition through formation of 
superoxide.  As discussed in Reactions 2-2 and 2-8, hydrogen peroxide and peroxide also 
react with ozone to form hydroxyl radicals.  This reaction is extremely fast, i.e., the rate 
constant for ozone reaction with peroxide is 2.2×106 M-1s-1 (Tomiyasu et al., 1985). 
 
 





OZONE REACTOR SCHEMES 
 
Throughout the history of ozone in water treatment, a number of ozonation 
schemes have been utilized.  Some researchers have used gaseous ozonation (Andreozzi 
et al., 2003; Andreozzi et al., 2005; Snyder et al., 2006; DeWitte et al., 2008; Dodd et al., 
2008; DeWitte et al., 2009), while others have employed aqueous ozone (Acero et al., 
2000; Huber et al., 2003; McDowell et al., 2005; Dodd et al., 2006; Suarez et al., 2007; 
Dodd et al., 2009).   
  
Gaseous Ozonation 
Gaseous ozonation was the original ozone application method employed for water 
disinfection in the early 20th century.  In 1905, the experimental ozonation plant in 
Philadelphia (Vosmaer, 1916), employed a Vosmaer sterilizer (Figure 2-3).  Essentially, a 
gaseous stream containing some fraction of ozone, which was produced via electrolysis 
of water, was bubbled through the raw water.  The gaseous stream ran counter to the raw 
water stream to maximize contact time. 
 
While the technology has changed substantially over the last 100 years, the basic 
methodology of gaseous ozonation remains the same.  An ozone generator is employed to 
convert some fraction of an inlet oxygen gas stream into ozone (typically 8-12% O3 v/v); 
that ozone/oxygen gaseous stream is bubbled into a reactor containing the water of 
interest.  Typically, the amount of ozone adsorbed into solution is determined via mass 
balance (Eq. 2-2); this value represents the applied ozone dose. 
 
    















Figure 2-3. (a)  Vosmaer sterilizer in Philadelphia circa 1905 (Vosmaer, 1916);  
(b)  Schematic of Vosmaer sterilizer (Vosmaer, 1916). 
 
 
A multitude of research efforts have focused on application of gaseous ozone to 
remove organic contaminants of interest, from natural organic matter (Olson and Barbier, 
1994; Siddiqui et al., 1997; Volk et al., 1997; Westerhoff et al., 1999a) to trace organic 
compounds such as PPCPs and EDCs (Huber et al., 2003; Ternes et al., 2003; Westerhoff 
et al., 2005; Dodd et al., 2006; Hua et al., 2006; Snyder et al., 2006).  For laboratory 
studies, most of these endeavors have employed a gas-washing bottle containing the 
sample of interest; this scenario is represented schematically in Figure 2-4a.  Pilot- and 
full-scale studies employ ozone contactor tanks that are typically operated in a counter-
flow fashion (Huber et al., 2005; Snyder et al., 2006; Hollender et al., 2009).  For 
experimental studies, an ozone/oxygen gas is bubbled into the gas-washing bottle starting 
at time, t = 0.  Hence, at time, t = 0, the ozone and hydroxyl radical concentrations are 
both 0 M.  As the experiment progresses, ozone dissolves into solution, interacts with 
other dissolved compounds, and decomposes to form ROS, including hydroxyl radicals 
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(Table 2-5).  The ozone mass flow rate is dependent upon the oxygen gas flow rate and 
the ozone generator settings (Figure 2-4b). 
 
 
Figure 2-4. (a) Schematic of a gaseous ozone reactor.  (b) The ozone mass flow rate 
is a function of the oxygen gas flow rate and the ozone generator 
settings.  (The sample is placed into the gas washing bottle and ozone is 
introduced to the sample in the gaseous phase.  The gaseous ozone 
concentration is measured in the inlet/outlet lines to determine the amount of 
ozone dissolved in solution.) 
 
For the most part, researchers employing gaseous ozonation tend to use pseudo-
first order kinetics to describe the transformation of organic compounds via ozonation 
(Huber et al., 2003; DeWitte et al., 2008; DeWitte et al., 2009).  By analyzing PhAC 
concentrations throughout the batch experiment, and assuming that the ozone 
concentration is constant throughout experimentation, the pseudo-first order rate constant 
(k’pseudo,O3,PhAC) can be found (Eq. 2-3).  It should be noted that since [O3] and [HO·] are 
both 0 M at time, t = 0, pseudo-first order kinetics do not apply at early times.  












 Eq. 2-3 
 
The mass transfer involved with gaseous ozonation is quite complicated.  Dodd et 
al. (2008) investigated gaseous ozonation of EDCs in urine.  In that paper, the authors 
present a kinetic snapshot (Figure 2-5) of what occurs in a gaseous ozonation scenario.  
Accounting for all of the different terms in Figure 2-5 is a complex undertaking and 
complicates experimentation; therefore, many researchers have moved to using 
concentrated aqueous ozone stock solutions (Acero et al., 2000; Huber et al., 2003; 
McDowell et al., 2005; Dodd et al., 2006; Suarez et al., 2007; Dodd et al., 2009). 
 
 
Figure 2-5. Representation of the interfacial film for a pseudo-first order kinetic 
regime with respect to ozone consumption (Dodd et al., 2008). 
 
Aqueous Ozone Addition 
The use of concentrated ozone stock solutions dates back to the early work of 
Hoigné and Bader (Hoigné and Bader, 1975; 1976; Bader and Hoigné, 1981).  That work 
employed aqueous ozone stocks to measure ozone decomposition kinetics; regardless, the 
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bulk of water treatment applications and studies employed gaseous ozone.  Recently, 
several researchers have returned to aqueous ozone for treatment of trace organic 
contaminants (Elovitz and von Gunten, 1999; Acero et al., 2000; Huber et al., 2003; 
McDowell et al., 2005; Dodd et al., 2006; Suarez et al., 2007) especially in experimental 
scenarios.  Given the complicated mass transfer picture associated with gaseous 
ozonation (Figure 2-5), the use of aqueous ozone presents a unique advantage to studying 
transformation reactions between ozone (and other ROS, including hydroxyl radicals) 
and PhACs. 
 
This ozonation scenario involves generating a concentrated ozone stock solution 
by bubbling gaseous ozone into deionized water (DI) for several hours.  Figure 2-6 shows 
a schematic representation of this setup.  The solution is placed in an ice bath to increase 
the ozone saturation concentration; some researchers also acidify the stock solution to 
increase ozone stability in solution (recall, HO- initiates O3 decomposition; Table 2-5).  
After 5-6 hours of ozonation, the ozone concentration of a stock solution at 0.5°C and 
near neutral pH can reach 60-70 mg O3/L; however, this concentration is dependent on 
the ozone generator, the gas diffuser, and the ozone solution vessel. 
 
The ozone stock solution can then be dosed into other reaction vessels at the 
desired concentration.  It is important to note that, at time t = 0, the ozone concentration 
is the applied dose (Eq. 2-4). 
 







 33  Eq. 2-4 
 
As ozone decomposition products, including hydroxyl radicals, are present in the 
stock solution, some concentration of those decomposition products are introduced into 
the reaction vessel.  For this reason, the initial conditions are different with liquid ozone 
addition than with the gaseous addition counterpart; recall that for gaseous ozonation, 
[O3] and [HO·] were both zero at time, t = 0.  More importantly, since differences may 
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exist between ozone generators, warm-up time, diffuser size, and the temperature and pH 




Figure 2-6. Aqueous ozone experimental setup for batch experimentation. 
 
 
At time, t = 0, a volume of ozone stock solution, corresponding to a specific 
ozone dose, is added to a water sample containing the PhAC and background matrix of 
interest.  The concentrations of ozone and PhAC are followed throughout the duration of 
the experiment.  As the experiment progresses, the ozone concentration goes to zero 
because of reaction with organic compounds, interaction with the background matrix, and 
decomposition.  Therefore, at some point, ozone is no longer present.  More information 




Measuring Ozone and Hydroxyl Radical Kinetics 
As discussed above, two dominant oxidants are present in ozonation applications:  
ozone (O3) and hydroxyl radicals (HO·).  Typically, second order kinetics are used to 
describe the transformation of organic compounds with aqueous ozone and hydroxyl 
radicals (Yao and Haag, 1991; Dodd et al., 2006).  The transformation of a PhAC by 
ozone and hydroxyl radicals in a batch experiment is described by Eq. 2-5.  By running 
two batch experiments (described below), the second order rate constants for PhAC 
transformation by ozone (k”O3,app,PhAC) and hydroxyl radicals (k
”




         PhACHOkPhACOk
dt
PhACd








Isolating Ozone Kinetics 
To isolate the contribution of ozone to the transformation of a PhAC, hydroxyl 
radicals need to be scavenged.  Ideally, hydroxyl radical scavengers should react 
minimally with ozone and rapidly with hydroxyl radicals.  Most researchers use t-BuOH 
for this purpose; however, a number of other compounds, including 2-propanol (Ho and 
Ho, 1976), octanol (von Gunten and Hoigne, 1994), and others, have been employed.  In 
this study we employed t-BuOH.  The second order rate constants for t-BuOH 
transformation by ozone and hydroxyl radicals are provided in Table 2-6.  Clearly, t-




Table 2-6. Properties of t-BuOH and pCBA. 
Property t-BuOH pCBA 
Chemical formula C4H10O C7H5ClO2 







(Hoigné and Bader, 1983a) 
0.15 




(Buxton et al., 1988) 
5.9×109 
(Neta and Dorfman, 1968) 
 
 Assuming that t-BuOH scavenges the hydroxyl radicals in solution, the change in 
[PhAC] caused by hydroxyl radicals (the last term in Eq. 2-5) goes to zero.  Therefore, by 
plotting the change in PhAC concentration vs. ozone exposure (∫[O3]dt), the second order 
rate constant for PhAC transformation by ozone can be deduced.  Several authors have 
employed this protocol to determine the rate constants for transformation of various 
organic contaminants with ozone (McDowell et al., 2005; Dodd et al., 2006; Suarez et 
al., 2007).  More information regarding experimental conditions and the mathematics of 
solving for the second order rate constant are provided in Chapter 3. 
 
Determining Hydroxyl Radical Kinetics 
A number of hydroxyl radical probe compounds have been used to determine 
hydroxyl radical exposure; however, the most frequently employed compound is para-
chlorobenzoic acid (pCBA; Table 2-6).  The second order rate constants for pCBA 
reaction with O3 and HO· are listed in Table 2-6.  Like t-BuOH, pCBA reacts negligibly 
with ozone; hence, any change in pCBA concentration is mainly due to reaction with 
hydroxyl radicals.  Given that relationship, the change in pCBA concentration can be 








reaction between hydroxyl radicals and pharmaceuticals can be found once the second 
order rate constant for PhAC transformation by ozone, measured values of ozone 
exposure, measured values of pharmaceutical concentration, and the hydroxyl radical 
exposure are known.  Again, the experimental conditions and mathematics of these 
calculations are provided in Chapter 3.  Ultimately, determination of the rate constants 
for PhAC transformation by ozone and hydroxyl radicals allows for calculation of the 




OXIDATION AND ADVANCED OXIDATION PROCESSES (AOPS) 
 
Ternes and coworkers (2002; 2003) investigated the abilities of ozone processes 
to treat 22 PPCPs and EDCs.  In the earlier work, Ternes et al. (2002) demonstrated 
removals of approximately 80% for carbamazepine, diclofenac, bezafibrate, and 
primidone at an applied ozone dose of 3 mg/L; however, clofibric acid (a metabolic 
product of the cholesterol-lowering drug, clofibrate) only achieved ~40% removal for the 
same applied ozone dose.  In the later paper, Ternes et al. (2003) investigated the ability 
of two different applied ozone doses to successfully transform 22 different PPCPs and 
EDCs (with concentrations ranging from 15-2100 ng/L) in municipal wastewater.  At an 
applied ozone dose of 5 mg/L, fourteen compounds were treated to below the limit of 
quantification (LOQ).  With an applied ozone dose of 10 mg/L, all compounds were 
successfully treated below their LOQs; these removals corresponded to greater than 50% 
to greater than 98% for individual compounds. 
 
Huber et al. (2003) studied the removal of five pharmaceuticals in lake water 
from Finland ([DOC] = 3.7 mg/L, alkalinity = 0.7 mM) and bank filtrate from the River 
Seine ([DOC] = 1.3 mg/L, alkalinity = 4.1 mM) at pH 8.  Overall, higher removal 
efficiencies were found in the bank filtrate matrix, presumably due to the lower DOC 
concentration, which acts as the primary ozone scavenger in water treatment processes.  
Subsequently, Huber et al. (2004) investigated ozonation of 17α-ethinylestradiol, 
removal of estrogenic activity, and identification of the intermediate oxidation products.  
The reaction kinetics of eleven PPCPs and EDCs were determined by Huber et al. 
(2005); at pH 7, the apparent second order rate constants for PhAC transformation by 
ozone varied from 0.75 M-1s-1 (diazepam) to 3×106 M-1s-1 (17α-ethinylestradiol) and the 
second order rate constants for PhAC transformation with hydroxyl radicals varied in the 
narrow range of 3.3×109 M-1s-1 (iopromide) to 9.8×109 M-1s-1 (17α-ethinylestradiol).  In 
batch transformation studies, most compounds demonstrated high transformation (>95%) 
for an applied ozone dose of 3.5 mg/L; iopromide, the compound exhibiting the lowest 
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second order rate constant, did not achieve high removal efficiencies even at applied 
ozone doses up to 5 mg/L. 
 
Other researchers have identified the reaction kinetics of various PPCPs and 
EDCs with ozone and hydroxyl radicals (Andreozzi et al., 2003; Lopez et al., 2003; 
Andreozzi et al., 2005; McDowell et al., 2005; Dodd et al., 2006; Suarez et al., 2007; 
Rosal et al., 2008; An et al., 2010; Garcia-Ac et al., 2010).  Based on the work of these 
investigators, as well as that of earlier authors, especially Hoigné and coworkers (Hoigné 
and Bader, 1983a; b; Hoigné et al., 1985) and Yao and Haag (Yao and Haag, 1991; Haag 
and Yao, 1992), kinetic regimes for ozone and hydroxyl radicals have been established.  
For this work, we define the fast and slow regimes of transformation by ozone as greater 
than and less than 103 M-1s-1, respectively.  The rate constant is a function of the 
molecular structure of the target compound.  Ozone preferentially oxidizes electron-rich 
molecules like alkenes and aromatic alcohols (Hoigné and Bader, 1983a; b); therefore, 
compounds with double bonds, free amines, and other electron-rich areas will 
demonstrate high reactivity with ozone.  Most organic molecules interact with hydroxyl 
radicals on the order of 108‒1010 M-1s-1; given the magnitude of these rate constants, the 
“slowness” or “fastness” of the reaction is dependent upon hydroxyl radical exposure.  
Furthermore, as a result of the high reactivity and instability of hydroxyl radicals in 
solution, hydroxyl radicals essentially react randomly with adjacent molecules; the 
relatively narrow range of rate constants observed for hydroxyl radical reaction with 
PhACs corroborates this statement.   
 
From the results described above, it is clear that ozone-based water treatment 
processes offer a great deal of potential for effectively treating trace organic 
contaminants.  This potential is based on the reactivity of PPCPs with not only ozone, but 
also with ozone decomposition products, particularly hydroxyl radicals.  Some 
investigators have encouraged the implementation of advanced oxidation processes 
(AOPs) to treat PhACs.  Recall that AOPs are oxidation processes that are engineered to 
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rapidly produce hydroxyl radicals.  Many authors have reported on the peroxone process 
(Acero and von Gunten, 2001; Venta et al., 2005; Rosal et al., 2008; DeWitte et al., 
2009; Lin et al., 2009; Vasconcelos et al., 2009), which uses the reaction between ozone 
and hydrogen peroxide to generate hydroxyl radicals.  Depending on the specific 
contaminants present in a water source, the user can determine whether ozone or 
peroxone processes would be ideal.  This decision would be based on two pieces of 
information:  the rate constants for the specific PhACs of concern and the background 
water quality matrix, which controls the ratio of hydroxyl radical exposure to ozone 
exposure.   
 
Impact of Natural Organic Matter on Oxidation Processes 
  Huber et al. (2003) investigated the ability of ozone (O3) and peroxone (O3/H2O2) 
to treat nine pharmaceuticals in four different water matrices; the results indicated that 
pharmaceutical structure and the alkalinity and dissolved organic carbon (DOC) 
concentration of the water source are the most important variables in determining 
treatment efficiency.  In that research, the peroxone process demonstrated better overall 
performance than ozone treatment.  Other researchers have documented the impacts of 
DOC on O3 and O3/H2O2 processes (Westerhoff et al., 1999a) and UV/H2O2 processes 
(Baeza, 2008).  Ultimately, these impacts are likely to govern the oxidant dose required 
to treat a given water containing PhACs.  Furthermore, it is likely that the organic matter 
composition, particularly the relative amounts of terrestrially-, microbially-, and 
anthropogenically-derived organic matter, will exert an impact on treatment efficiency, 
mainly through the different rate constants for different DOC sources with ozone and 
hydroxyl radicals. 
 
Throughout the past few decades, water treatment engineers have discovered that 
organic matter affects virtually every treatment process.  Since composition of the 
organic matter matrix differs from location to location, we can expect the organic matter 
impact on PhAC treatment to be source dependent.  Traditionally, the term natural 
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organic matter (NOM) was used to refer to organic matter present in surface waters; 
however, the increased use of indirect and direct potable water reuse has changed the 
organic matter matrix.  For this reason, the composition of organic matter in surface 
waters consists of both NOM and wastewater effluent-derived organic matter, or EfOM.  
Ma et al. (2001) compiled an extensive summary of the organic matter differences 
between several NOM-dominated waters and a wastewater effluent.  Sirivedhin and Gray 
(2005a; 2005b) showed the differences between the organic matter present in WWTP 
effluent (EfOM) and NOM; the authors went on to demonstrate that these structural 
differences impact the formation of disinfection byproducts.  For that reason, it seems 
plausible that the compositional differences should also affect the behavior of organic 
matter in oxidation and advanced oxidation processes. 
 
  For advanced oxidation, organic matter affects treatment via the following means:  
direct oxidant consumption, initiator for oxidant consumption, promoter of oxidant 
consumption, or inhibitor of oxidant consumption (Westerhoff et al., 1999a).  The most 
important mechanism is direct oxidant consumption, which essentially causes organic 
matter to compete with PhACs for the oxidant.  Westerhoff et al. (1999a) showed that 
ozone consumption by organic matter varied with SUVA254 and organic matter structure 
(Figure 2-7); that paper also showed that hydroxyl radical consumption varies with 
SUVA254 (Figure 2-7).  In a second paper, Westerhoff et al. (1999b) described the 
changes in NOM structure caused by reaction with ozone.  Ozone specifically reacted 
with aromatic carbon and this reaction resulted in the insertion of an oxygen atom at the 
carbon-carbon double bond; furthermore, the authors postulated that increased oxygen 






Figure 2-7. Impact of SUVA on NOM reactivity with ozone (Westerhoff et al., 
1999a). 
 
Intermediate Oxidation Products 
  Oxidative treatment, unlike ion exchange, PAC, or RO, is a transformative 
process.  Parent compounds (i.e., pharmaceuticals) are attacked by the oxidant and a 
complex oxidative transformation pathway follows.  Several researchers (Acero et al., 
2000; Huber et al., 2004; Andreozzi et al., 2005; McDowell et al., 2005; DeWitte et al., 
2008) have characterized the oxidation products formed through ozone reaction with 
PPCPs and EDCs.  These investigators identified transformation products of 17α-
ethinylestradiol, amoxicillin, atrazine, carbamazepine, and ciprofloxacin after exposure to 
ozone and hydroxyl radicals.  McDowell et al. (2005) proposed a classical ozone attack 
on the double bond present in carbamazepine’s central ring, resulting in the addition of 
oxygen atoms to the chemical structure.  The ozonation products of 17α-ethinylestradiol 
were investigated by Huber et al. (2004); the initial transformation mechanism occurs at 
aromatic rings and effectively open the ring forming carboxylic acid functional groups.  
These results are consistent with Westerhoff et al.’s (1999b) findings regarding the 
structural changes induced in NOM via ozonation. 
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  Recent work by DeWitte et al. (2008) suggested twelve structures for 
intermediate oxidation products formed during gaseous ozonation of ciprofloxacin.  
These compounds are structurally similar to ciprofloxacin.  Lemke and Williams (2008) 
delineated the structure-activity relationship for quinolonic compounds, as seen in Figure 
2-8.  The pharmacophore is the core structure required for the compound to exert 
pharmacological activity; furthermore, three functional groups determine the 
pharmacological capabilities of the compound.  The R6 group contributes to the ability of 
the compound to penetrate cell walls; fluoroquinolones, such as ciprofloxacin, have a 
fluoro group at R6.  The R7 group relates to the compound’s spectrum of activity, i.e., this 
functional group establishes what microorganisms will be affected by the compound.  
The R group determines the relative potency of the compound.  Of the twelve 
intermediate oxidation products determined by DeWitte et al. (2008), all twelve 
structures retained the fluoro group on R6, all twelve compounds retained the same 
potency group as ciprofloxacin, and six intermediate oxidation products retained the 
pharmacophore.  The majority of oxidative transformations target the piperazinyl group 
(R7; DeWitte et al., 2008), which may change the spectrum of microorganisms affected 
by the compound but does not necessarily remove pharmacological activity.  Therefore, 
the potential for oxidative intermediate products to exhibit residual pharmacological 
activity is high. 
 
 





Residual Pharmacological Activity 
In the past few years, a few researchers (Suarez et al., 2007; Baeza, 2008; Dodd et 
al., 2009; Paul et al., 2010) have used an antimicrobial susceptibility assay (NCCLS, 
2004) to describe treatment efficacy in terms of pharmacological activity.  Suarez et al. 
(2007) treated triclosan with aqueous ozone and showed that antibacterial activity closely 
followed triclosan concentration.  Baeza (2008) used this assay in combination with UV 
photolysis and photochemical UV/H2O2 treatment of four antimicrobials to demonstrate 
that the impact of the background water matrix varied depending on the treatment 
conditions.  Dodd et al. (2009) employed an antimicrobial susceptibility assay to track 
the pharmacological activity of 14 antimicrobial compounds from various pharmaceutical 
classes, including macrolides, fluoroquinolones, and β-lactams, among others.  The 
findings from the Dodd et al. (2009) study suggest that intermediate oxidation products 
generated through ozonation of roxithromycin, penicillin G, and cephalexin retain some 
residual antibacterial activity; furthermore, no apparent contribution of ciprofloxacin’s 
intermediate oxidation products to the residual antimicrobial activity was detected.  A 
recent paper by Paul et al. (2010) indicates that ciprofloxacin degradation products from 
photolytic (UV) and photocatalytic (UV-TiO2) processes exert some antimicrobial 
activity.  In summary, many questions remain unresolved regarding the pharmacological 
activity of intermediate oxidation products resulting from transformations of 






CHAPTER 3:  MATERIALS AND METHODS 
 
The research approach used in this work was employed to meet the primary 
research objectives discussed in Chapter 1.  These objectives include investigating the 
transformation of four model PhACs in ozone-based treatment processes, characterizing 
the impact of NOM on PhAC removal efficiency, and description of the residual 
antimicrobial activity of water sources containing antimicrobial PhACs.  In this chapter, 
the properties of the chemicals, pharmaceuticals of concern, and natural organic matter 
(NOM) isolates are presented.  Furthermore, the analytical methods employed to measure 
ozone, the pharmaceuticals of concern, intermediate oxidation products, para-
chlorobenzoic acid, NOM, hydrogen peroxide, and pH are described.   
 
Several different ozone reactors were employed to meet the research objectives.  
In particular, batch ozonation experiments were conducted to demonstrate the impact of 
NOM on the transformation of cyclophosphamide, erythromycin, and ifosfamide, to 
characterize the intermediate oxidation products formed via ozonation and peroxonation 
of cyclophosphamide, erythromycin, and ifosfamide, and to monitor the residual 
antimicrobial activity of ozone-treated solutions containing erythromycin.  Continuous 
aqueous ozone addition experiments were employed to demonstrate the impact of NOM 
on ciprofloxacin transformation and elimination of ciprofloxacin-associated antimicrobial 
activity and to determine the transformation kinetics of cyclophosphamide and ifosfamide 
with ozone and hydroxyl radicals.  The continuous peroxone addition reactor was used to 
verify the rate constants for the reaction of cyclophosphamide and ifosfamide with 
hydroxyl radicals.  These reactor setups are described in detail below; furthermore, the 
data analysis procedures for the different types of experiments are also explained.  The 
antimicrobial activity assay, which is used to measure the residual antimicrobial activity 
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of samples, is also presented in this chapter; analysis of data resulting from the 
antimicrobial activity assay is demonstrated in Appendix C. 
 
CHEMICALS 
All chemicals were purchased through VWR.  The pharmaceuticals employed in 
this work are discussed in the following section.  Certain chemicals (pCBA (99%), t-
BuOH, and indigotrisulfonate) were employed for various reasons as documented 
throughout this Chapter.  Hydrogen peroxide was purchased as 30% H2O2; stock 
solutions of 0.105 M were created and stored in amber bottles in a dark, 4°C 
environment; the stock solution was stable for at least 6 months.  Several inorganic salts, 
including NaCl, NaHCO3, NaH2PO4, Na2HPO4, and BaCl were employed in 
experimentation; these chemicals were ACS grade.  Hydrochloric (trace metal grade), 
sulfuric (trace metal grade), and phosphoric acids (ACS grade) were employed for 
various uses.  Sodium hydroxide (10 N) was diluted to 1N and 0.1N solutions that were 
employed for pH adjustment purposes.  A 0.1 N potassium permanganate solution (ACS 
grade) was employed for H2O2 titrations.  ACS grade pH buffers (4.01, 7.01, and 10.01) 
were employed for calibration of pH probes. 
 
Several different solutions were employed in the analytical methods relevant to 
this research.  HPLC analysis of ciprofloxacin employed HPLC grade acetonitrile and a 
25 mM phosphate buffer, which was made by adding H3PO4 to deionized water (DI).  
LC-MS grade methanol and LC-MS grade water were employed in measurement of 
cyclophosphamide and ifosfamide via LC-MS and LC-MS/MS.  LC-MS grade 
acetonitrile was employed for measurement of erythromycin using LC-MS and LC-
MS/MS methods.  The erythromycin LC-MS and LC-MS/MS methods also employed a 
0.1% formic acid eluent, which was generated by adding ACS grade formic acid (88%) to 
DI.  LC-MS grade methanol and the 25 mM phosphate buffer, discussed above for 
ciprofloxacin analysis, were employed for HPLC analysis of para-chlorobenzoic acid 
(pCBA).   
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All glassware was meticulously washed using the washing procedure described in 
Appendix A, which also contains information regarding autoclave protocols. 
 
Pharmacologically Active Compounds 
The four pharmacologically active compounds (ciprofloxacin, cyclophosphamide, 
erythromycin, and ifosfamide) employed in these studies were purchased from VWR.  
Ciprofloxacin, cyclophosphamide monohydrate, and ifosfamide were all purchased in the 
powder form, while erythromycin was purchased as a 50 mg/mL solution in ethanol. 
 
Working stock solutions of ciprofloxacin (10 mg/L), cyclophosphamide (1000 
mg/L), and ifosfamide (1000 mg/L) were created by dissolving the appropriate mass of 
the compounds into DI water.  A working stock solution of erythromycin (1000 mg/L) 
was produced by diluting the purchased solution (50 mg/mL) with DI.  Working solutions 
were kept in amber bottles, and these solutions were stored in a dark, 4°C environment.  
New stock solutions were made every three months; ciprofloxacin and erythromycin 
concentrations were periodically confirmed using the antimicrobial activity assay 
described below.  Detailed description of these compounds and their presence in 
environmental waters is provided in Chapter 2 and is not repeated here. 
 
Natural Organic Matter 
  Organic matter was extracted from two sources:  Lake Austin (LA; Austin, TX) 
and Claremore Lake (CL; Claremore, OK).  The extractions followed the method 
developed by Thurman and Malcolm (1981) and later refined by Aiken et al. (1992).  The 
details of these extraction materials and methods are presented in Marron (2010) and are 
not described in extensive detail here.  After isolation, the concentrated NOM solutions 
were freeze-dried at the USGS to yield a solid product. 
 
  Claremore Lake water was collected near the Ranger Station on D4168 Road 
(Latitude = +36.329864°, Longitude = -95.581356°) in Claremore, OK.  Approximately 
53 
 
200 L of raw Claremore Lake water was collected.  Extractions of Claremore Lake 
hydrophobic organic acids (HPOA) and transphilic organic acids (TPIA) were conducted 
at the USGS (Boulder, CO) under the direction of George Aiken and Kenna Butler.  
Knowing the volume of water passed through the XAD-8 and XAD-4 resins, as well as 
the dissolved organic carbon (DOC) concentration of the raw water, the percent recovery 
of DOC for the HPOA and TPIA isolates could be calculated (Table 3-1).  
Approximately 95% and 89% DOC recovery was experienced for the Claremore Lake 
HPOA and TPIA, respectively.  
 
  Approximately 400 L of Lake Austin water was collected from the raw water 
pump station on Forest View Drive at the Ullrich Drinking Water Treatment Plant 
(Austin, TX).  The HPOA fraction of the Lake Austin NOM was isolated at the 
University of Texas.  Approximately 89% of the HPOA present in the raw Lake Austin 
water was recovered during the organic matter extraction. 
 








Volume of sample loaded onto columns (L) 201.6 201.6 423.3 
Expected mass recovery (mg) 490 1161 1037 
Mass recovered (mg) 436 1100 923 
Percent recovered 89% 95% 89% 
 
The raw water quality of the Claremore Lake and Lake Austin sources is 
presented in Table 3-2.  While pH, alkalinity, and turbidity are important water quality 
parameters for ozone-based processes, these characteristics are for the whole waters, not 
the NOM isolates.  In most of the experimentation discussed in this dissertation, organic 
matter was added to solution in extract form; furthermore, pH and alkalinity were 
controllable parameters.  While the turbidity of experimental samples was not tested, no 
significant turbidity should have been present in any experimental samples.  On the 
contrary, the UV254 nm, DOC concentration, specific ultraviolet absorbance at 254 nm 
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(SUVA254 nm), percent of HPOA, and percent of TPIA are important raw water 
characteristics because these parameters describe the makeup of the HPOA and TPIA 
isolates, which impact the reactivity of these fractions with ozone and hydroxyl radicals.  
The distinction between the absorbance at 254 nm for the Claremore Lake (UV254 nm,CL = 
0.185 cm-1) and Lake Austin (UV254 nm,LA = 0.059 cm
-1) waters indicates that the 
Claremore Lake water contains more aromatic substances, which are highly reactive with 
ozone as discussed in Chapter 2.  That difference is somewhat due to the higher DOC 
concentration of the Claremore Lake ([DOC] = 6.4 mg/L) water as compared to the Lake 
Austin water ([DOC] = 3.5 mg/L).  Since the organic matter isolates are available in 
extract form, we can control the [DOC] of experimental solutions.  The SUVA254 nm 
value, which is an inherent characteristic of individual organic matter isolates, provides 
one way to compare the impact of these three organic matter isolates on ozone-based 
processes for treatment of pharmacologically active compounds.  In this case, the higher 
SUVA254 nm of the Claremore Lake raw water (SUVA254 nm,CL = 2.9 L/mg-m) as 
compared to the Lake Austin raw water (SUVA254 nm,LA = 1.7 L/mg-m) suggests that the 
Claremore Lake organic matter matrix is more reactive with ozone and hydroxyl radicals 
(Westerhoff et al., 1999a). 
 
Table 3-2. Raw water quality of Claremore Lake and Lake Austin water sources. 
Parameter Claremore Lake Lake Austin 
Collection Date 6/18/09 7/22/09 
pH 7.5 8.0 
Alkalinity (mg CaCO3/L) 57 164.5 
UV254 nm (cm
-1) 0.185 0.059 
[DOC] (mg/L) 6.4 3.5 
Turbidity (NTU) 8.5 4.5 
SUVA254 nm (L/mg-m) 2.9 1.7 
HPOA (%) 45 35 





ANALYTICAL METHODS  
 
Ozone Analysis 
Dissolved ozone concentrations of stock solutions were measured directly at 258 
nm on a UV-VIS spectrophotometer (Agilent).  This method was only used for stock 
ozone solutions with aqueous ozone concentrations greater than 10 mg/L.  Typically, 0.5 
mL of the ozone stock solution was mixed into 3.5 mL of 5 mM phosphate buffer in a 1 
cm quartz cuvette with Teflon cap.  These samples were measured immediately after 
addition of the ozone stock solution.  Using the absorbance at 258 nm and the molar 






















































 Eq. 3-1 
 
where, UV258 nm is the absorbance at 258 nm, MW is the molecular weight of ozone (48 
mg/mmol), dil is the dilution factor (typically, 8), and εO3 is the molar absorptivity of 
ozone (3000 M-1cm-1; Acero and von Gunten, 2000).  Typical absorbance scans are 
shown in Figure 3-1; the corresponding aqueous ozone concentration is listed next to 





Figure 3-1. Examples of direct ozone measurement at 258 nm and the 
corresponding ozone concentrations found using Eq. 3-1. 
 
Aqueous ozone concentrations in the 2-L continuous aqueous ozone addition 
reactor were measured using the indigo blue method (Bader and Hoigné, 1981).  In this 
method, indigotrisulfonate (Figure 3-2) is cleaved by ozone at the double bond in the 
center of the molecule to form the products shown.  Indigotrisulfonate has a significant 
molar absorptivity at 600 nm, whereas the products do not demonstrate any absorbance at 
600 nm; this difference allows the use of indigotrisulfonate for quantification of aqueous 
ozone concentrations.  Indigotrisulfonate reacts very quickly with ozone 
(k”O3,indigotrisulfonate = 9.4×10
7 M-1s-1; Munoz and von Sonntag, 2000).  Hence, addition of 
indigotrisulfonate allows measurement of the aqueous ozone concentration while also 
quenching aqueous ozone concentrations, thereby stopping both the generation of 




Figure 3-2. Ozone reaction with indigotrisulfonate, and the resulting ozonation 
products (adapted from Bader and Hoigné, 1981). 
 
Indigo Reagent I and Indigo Reagent II solutions (Standard Method 4500-O3 B.  
Indigo Colorimetric Method; APHA et al., 2006) were employed in this research.  Indigo 
stock solution was created by dissolving 770 mg of indigotrisulfonic acid 
(C16H10N2O11S3), 1 mL phosphoric acid, and 12 mg Na2HPO4 in 100 mL of DI.  Indigo 
reagent I was made by adding 1000 mg of Na2HPO4, 0.7 mL of phosphoric acid, and 2 
mL of indigo stock solution to 100 mL of DI; indigo reagent II was made in the same 
manner, albeit with 10 mL of indigo stock solution.  Indigo Reagent I was employed for 
lower aqueous ozone concentrations (6×10-8 – 2×10-6 M with a 4-cm quartz cuvette); 
however, Indigo Reagent II offered a larger range of ozone measurement (6×10-8 – 
10×10-6 M with a 4-cm quartz cuvette), and so was used more often than Indigo Reagent 
I.  In select cases, a 10-cm quartz cuvette was employed to provide higher sensitivity and 
lower aqueous ozone detection (2.5×10-8 – 10×10-6 M).  It should be noted that samples 
were often diluted to ensure incomplete indigo transformation, which is required for 
calculation of aqueous ozone calculations.  For example, as the aqueous ozone 
concentration increases during continuous ozonation experimentation, samples were 
diluted 1:1 or 1:3 with DI.  Indigo was measured at 600 nm on the UV-VIS 





















































 Eq. 3-2 
 
where [O3] is the aqueous ozone concentration, ABS600 nm,initial is the absorbance at 600 
nm of the initial solution (pre-ozonation), ABS600 nm,sample is the absorbance at 600 nm of 
the sample, VT is the total volume of the solution (indigo reagent, sample, and DI) being 
measured, f is a constant based on the molar absorptivity of indigo (20,000 M-1cm-1; 
Bader and Hoigné, 1981) and is equal to 0.42 L-cm/mg, l is the path length (in cm, the 
units are incorporated into the ABS600 nm values), and Vsample is the volume of the sample 
added to the total solution. 
 
 
Figure 3-3. Example of indirect ozone measurement using indigotrisulfonate, which 
absorbs light at 600 nm.  (The different spectra correspond to different 
aqueous ozone concentrations.  As the UV600 decreases, less 
indigotrisulfonate is remaining in solution; therefore, more aqueous ozone 






Ciprofloxacin was measured by high performance liquid chromatography (HPLC; 
Waters 2795, Waters Corporation, Milford, MA) equipped with a fluorescence detector 
(FLD); a Phenomenex (Torrence, CA) Luna 5u C18(2) (250×4.6mm, 5µm) column was 
utilized for analyte separation.  Fifty microliter aliquots were directly injected into the 
HPLC.  The analytical method is based on the procedure developed by Golet et al. (2001) 
but several changes were made to optimize the response on the instrument.  The eluent 
gradient was 7% acetonitrile (ACN), 93% 25-mM H3PO4 for 2 min; 3 min ramp to 12% 
ACN, 88% 25-mM H3PO4; 2 min ramp to 15% ACN, 85% 25-mM H3PO4; 3 min ramp to 
20% ACN, 80% 25-mM H3PO4; 10 min isocratic.  The flow rate was 0.70 mL/min, and 
the column temperature was set at 40°C.  Excitation and emission wavelengths were set 




Figure 3-4. Representative chromatogram of ciprofloxacin analysis using HPLC 






Cyclophosphamide was measured with LC-MS/MS (TSQ Quantum, Thermo 
Finnigan, Waltham, MA).  The injection volume was 10 μL and the flow rate was 700 
μL/min.  HPLC separation was achieved with a C18 (Shimadzu 150×4.6 mm; particle 
size, 5 µm) column; the eluent gradient was 5% MeOH, 95% H2O (0-3 min); ramp to 
80% MeOH, 20% H2O (3-10 min); 80% MeOH, 20% H2O (10-12 min); ramp to 100% 
MeOH, 0% H2O (12-12.1 min); 100% MeOH, 0% H2O (12.1-16 min); ramp to 5% 
MeOH, 95% H2O (16-16.1 min); 5% MeOH, 95% H2O (16.1-18 min).  The electrospray 
ionization tandem mass spectrometer was operated in positive ion mode.  Method 
parameters include the following:  parent mass, 261.0 mg; product mass, 139.8 mg; 
collision gas pressure, 1.5 mTorr; collision energy, 20 V; spray voltage, 4000 V; 
vaporizer temperature, 400 °C; sheath gas pressure, 50 psi; and auxiliary gas pressure, 30 
psi.  Cyclophosphamide was eluted at 12.0 minutes as shown in Figure 3-5. 
 
 
Figure 3-5. Cyclophosphamide (100 µg/L) peak using LC-MS/MS. 
 
 
Cyclophosphamide intermediate products were analyzed using LC-MS; the 
measured m/z range was 30–1500.  The injection volume was 20 μL and the flow rate 
was 350 μL/min.  The eluent gradient was 5% MeOH, 95% H2O (0-15 min); ramp to 
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80% MeOH, 20% H2O (15-22 min); 80% MeOH, 20% H2O (22-29 min); ramp to 100% 
MeOH, 0% H2O (29-29.1 min); 100% MeOH, 0% H2O (29.1-33 min); ramp to 5% 
MeOH, 95% H2O (33-33.1 min); 5% MeOH, 95% H2O (33.1-35 min).  The electrospray 
ionization tandem mass spectrometer was operated in positive ion mode.  Method 
parameters include the following:  parent mass, 261.0 mg; collision gas pressure, 1.5 
mTorr; collision energy, 20 V; spray voltage, 4000 V; vaporizer temperature, 400 °C; 
sheath gas pressure, 25 psi; and auxiliary gas pressure, 15 psi.  Example LC-MS peaks 
for cyclophosphamide and cyclophosphamide intermediate oxidation products are shown 
in Figure 3-6.  These compounds were eluted in the 26-29 minutes range. 
 
 
Figure 3-6. Typical peaks for cyclophosphamide and intermediate oxidation 
products generated by ozone and hydroxyl radical reaction with 
cyclophosphamide.  (Intermediate oxidation products were detected by 
peak presence in the total ion current; those peaks were then extracted and 
plotted individually.  In this case, the m/z window was ±0.5 m/z units to 






Erythromycin was analyzed using LC-MS/MS (Thermo Finnigan, TSQ 
Quantum).  The injection volume was 10 µL and the flow rate was 700 µL/min.  LC 
separation was achieved with a C18 column (Shimadzu Premier C18 5µ 150×4.6-mm); 
the eluent gradient was 100% 0.1% Formic acid (FA), 0% Acetonitrile (ACN) (0-3 min); 
ramp to 88% 0.1% FA, 12% ACN (3-10 min); 75% 0.1% FA, 25% ACN (10-12 min); 
ramp to 50% 0.1% FA, 50% ACN (12-12.1 min); 50% 0.1% FA, 50% ACN (12.1-16 
min); ramp to 50% 0.1% FA, 50% ACN (16-16.1 min); 88% 0.1% FA, 12% ACN (16.1-
18 min).  The electrospray ionization tandem mass spectrometer was operated in positive 
ion mode.  Method parameters include the following:  parent mass, 734.4 mg; product 
mass, 576.2 mg; collision gas pressure, 1.5 mTorr; collision energy, 24 V; spray voltage, 
4000 V; vaporizer temperature, 400 °C; sheath gas pressure, 25 psi; and auxiliary gas 
pressure, 20 psi.  Erythromycin was eluted at 15.2 minutes (Figure 3-7).  A similar 
method was employed by Huang (2011) to measure anhydroerythromycin A, an 
erythromycin degradation product. 
 
 
Figure 3-7.  A representative erythromycin peak using the LC-MS/MS analytical 
method described above.  (The erythromycin concentration of this sample 
was 100 mg/L.) 
 
Samples were also analyzed using LC-MS to detect erythromycin’s intermediate 
oxidation products; the measured m/z range was 150–1500.  The injection volume was 20 
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µL and the flow rate was 350 µL/min.  The eluent gradient was 100% 0.1% FA, 0% ACN 
(0-2 min); ramp to 88% 0.1% FA, 12% ACN (2-12 min); 75% 0.1% FA, 25% ACN (12-
16 min); ramp to 50% 0.1% FA, 50% ACN (16-21 min); 50% 0.1% FA, 50% ACN (21-
28 min); ramp to 50% 0.1% FA, 50% ACN (28-30 min); 88% 0.1% FA, 12% ACN (30-
35).  The electrospray ionization tandem mass spectrometer was operated in positive ion 
mode.  Method parameters include the following:  parent mass, 734.4 mg; collision gas 
pressure, 1.5 mTorr; collision energy, 24 V; spray voltage, 4000 V; vaporizer 
temperature, 400 °C; sheath gas pressure, 25 psi; and auxiliary gas pressure, 20 psi.  
Example LC-MS peaks for erythromycin and erythromycin intermediate oxidation 




Figure 3-8. Examples of erythromycin and erythromycin intermediate oxidation 
products generated by erythromycin reaction with aqueous ozone.  (In 
this case, erythromycin and erythromycin intermediate oxidation products 
were detected from the total ion current of the sample.  The individual peaks 
were separated and are plotted according to the major m/z values found in 





Ifosfamide was measured with LC-MS/MS (Thermo Finnigan, TSQ Quantum).  
The injection volume was 10 μL and the flow rate was 700 μL/min.  HPLC separation 
was achieved with a C18 (Shimadzu 150×4.6 mm; particle size, 5 µm) column; the eluent 
gradient was the same as that employed in the LC-MS/MS method used for 
cyclophosphamide analysis.  The electrospray ionization tandem mass spectrometer was 
operated in positive ion mode.  Method parameters include the following:  parent mass, 
261.0 mg; product mass, 153.9; collision gas pressure, 1.5 mTorr; collision energy, 20 V; 
spray voltage, 4000 V; vaporizer temperature, 400 °C; sheath gas pressure, 30 psi; and 
auxiliary gas pressure, 10 psi.  Ifosfamide was eluted at 11.7 minutes (Figure 3-9). 
 
 
Figure 3-9. A typical ifosfamide peak using the LC-MS/MS method described 
above.  (In this sample, the ifosfamide concentration was 100 µg/L.) 
 
In kinetics experiments, cyclophosphamide and ifosfamide were typically both 
present in solution.  For that reason, these two compounds were often both analyzed in 
LC-MS/MS mode using a combined method.  That method essentially combined the 
ifosfamide method described above from minutes 0 to 11.85, and then the detection 
method was switched to the cyclophosphamide LC-MS/MS method described earlier.  An 





Figure 3-10. Example of combined method allowing concomitant analysis of 
cyclophosphamide and ifosfamide for the same injection volume.  (For 
this sample, the concentration of both PhACs was 100 µg/L.) 
 
 
Ifosfamide intermediate products were analyzed using LC-MS; the measured m/z 
range was 30–1500.  The injection volume was 20 μL and the flow rate was 350 μL/min.  
The eluent gradient was the same employed in LC-MS analysis of cyclophosphamide and 
cyclophosphamide intermediate oxidation products.  The electrospray ionization tandem 
mass spectrometer was operated in positive ion mode.  Method parameters include the 
following:  parent mass, 261.0 mg; collision gas pressure, 1.5 mTorr; collision energy, 20 
V; spray voltage, 4000 V; vaporizer temperature, 400 °C; sheath gas pressure, 15 psi; and 
auxiliary gas pressure, 5 psi.  Example LC-MS peaks for ifosfamide and ifosfamide 
intermediate oxidation products are shown in Figure 3-11.  These peaks are eluted in the 





Figure 3-11. Ifosfamide and ifosfamide intermediate peaks detected using LC-MS.  
Ifosfamide and ifosfamide intermediate oxidation products were 
detected by their distinctive m/z values and separated from the total ion 
current.  (In the figure, all compounds are plotted across a window of m/z 
values (central m/z ± 0.5) as described above.) 
 
 
para-Chlorobenzoic Acid (pCBA) Analysis 
The hydroxyl radical probe compound, pCBA, was measured at 234 nm using an 
HPLC (Waters Corporation) with PDA.  HPLC separation was achieved with a C18 
column (Sonoma C18(2), 3µ 100 Å).  The eluent, 60% MeOH, 40% 25 mM H3PO4, was 
pumped at a constant flow rate (0.5 mL/min).  pCBA was eluted after 5.35 minutes as 









Preliminary analysis of the NOM source waters and the NOM isolates was 
conducted at the USGS laboratories in Boulder, CO (Marron, 2010).  As discussed in 
Marron’s thesis (2010), the NOM isolates were freeze-dried to provide a solid NOM 
powder.  NOM working solutions were prepared by dissolving 100 mg of the dried NOM 
extract in 100 mL of DI; the pH of the NOM solutions was dropped to pH ~1.9 through 
the addition of concentrated phosphoric acid.  After dissolution of the NOM extract in the 
acidified working solution, several water quality parameters, namely, pH, total organic 
carbon (TOC), and the absorbance at 254 nm (UV254), were measured to characterize the 
strength of the NOM working solution.  The pH was measured using a Thermo Electron 




The TOC of working solutions was measured using a TOC Analyzer (O.I. 
Corporation, College Station, TX).  Standard organic carbon solutions were prepared 
using potassium hydrogen phthalate according to Standard Methods (5310 B. 
Combustion-Infrared Method; APHA et al., 2006).  Due to the high concentration of the 
working solutions (1 g NOM / L), these solutions were diluted 100× before analysis on 
the TOC Analyzer.  While the TOC concentration of the different NOM working 
solutions varied, the TOC was typically 380-420 mg C / L; therefore, the percentage of 
organic carbon in the NOM isolates was approximately 38-42%. 
 
The UV254 was measured using a UV-VIS spectrophotometer (Agilent 
Technologies).  Approximately 12 mL of the 100× dilution used for TOC analysis was 
placed into a 10-cm quartz cuvette, and the absorbance was measured at 254 nm.  The 
resultant absorbance at 254 nm and the TOC concentration can be used to calculate the 

































254  Eq. 3-3 
 
The NOM isolates were also analyzed using Excitation-Emission Matrix (EEM) 
fluorescence spectroscopy.  As the results of that analysis are not discussed in the body of 
this document, the fluorescence EEM characterization of all three organic matter isolates 
as well as the Lake Austin whole water used in the NOM extractions are provided in 
Appendix B. 
 
Hydrogen Peroxide Titration 
For peroxone experiments, a hydrogen peroxide solution was employed.  A 
hydrogen peroxide stock solution (30% H2O2) was purchased from VWR.  A hydrogen 
peroxide working solution (0.105 M) was made by diluting the stock solution (30% 
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H2O2) with DI.  The working solution was kept in an amber bottle at 4°C in a dark 
environment to prevent hydrogen peroxide decomposition.  Hydrogen peroxide 





  Rxn. 3-1 
 
For experimental titrations, 1 mL of the H2O2 working solution, 0.4 mL of H2SO4, and 
8.6 mL of DI were mixed together to constitute the sample.  The titrant was 0.1 N 
KMnO4 (0.02 M MnO4
-).  The titration endpoint was reached when the sample solution 
changed color from clear to pink.  The hydrogen peroxide concentration (Eq. 3-4) was 
calculated using the volume of titrant (Vtitrant), the volume of the sample (Vsample = 1 mL), 
and the stoichiometry of Rxn. 3-1.   
 



















 Eq. 3-4 
 
Over the course of six months, the hydrogen peroxide concentration of the 
working solution (0.105 M) did not change; regardless, new working solutions were 
prepared every six months. 
 
pH 
The pH was measured and recorded during continuous ozone and peroxone 
addition experiments, as well as in other solutions throughout this research.  A Thermo 
Electron Corporation pH meter (Orion 720 A+) was employed for these purposes; the 
probe was a Thermo Fisher Scientific Orion ROSS Sure-Flow pH electrode.  The pH 







A schematic of the ozone supply system and reactor is shown in Figure 3-13.  
Oxygen gas flowed into the ozone generator at 30 cm3/min; a fraction of that oxygen was 
converted to ozone.  This combined gas stream was directed into a gas-washing bottle, 
which served as a stock ozone solution.  The ozone stock solution was kept on ice 
(Tsolution ~ 0.5°C) to increase the solubility of ozone (Sotelo et al., 1989).  After 4-6 hours, 
the ozone concentration in the stock solution reached a plateau at 50-60 mg O3/L.  These 
concentrations are comparable to ozone concentrations in stock solutions used by other 
researchers (Buffle et al., 2004; Buffle et al., 2006; Suarez et al., 2007).  For all 
experiments discussed in this dissertation, the aqueous ozone stock solution was 
employed as the primary supply of ozone. 
 
 
Figure 3-13. Schematic of the ozone reactor showing gaseous generation of ozone 





Determination of PhAC Transformation in Batch Reactors with Aqueous Ozone 
Small aliquots of the ozone stock solution were added to culture tubes containing 
the solution of interest (Figure 3-14) for a variety of reasons, including the following:  to 
demonstrate the impact of NOM on the transformation of cyclophosphamide, 
erythromycin, and ifosfamide; to characterize the intermediate oxidation products formed 
via ozonation and peroxonation of cyclophosphamide, erythromycin, and ifosfamide; and 
to monitor the residual antimicrobial activity of ozone-treated solutions containing 
erythromycin.  The water quality matrix varied depending on the type of experiment; for 
instance, lower PhAC concentrations were employed in experiments documenting the 
transformation of the parent pharmaceutical, but higher PhAC concentrations were 
employed for experiments aimed at characterization of intermediate oxidation products,.  
The background water quality matrix (e.g., pH, NOM, [DOC], t-BuOH, pCBA, and 
alkalinity, among others) also changed between experiments.  For batch experiments, all 
solutions were immediately capped, shaken, and placed into a dark environment (at room 
temperature) for at least 24 hours before analysis; before analysis, samples were 
quenched using indigotrisulfonate.  Details on specific ozone doses added to samples 
containing the PhACs of interest are provided in Chapters 4 and 6.   
 
An essentially identical protocol was employed for batch peroxone experiments.  
Hydrogen peroxide was added to the individual batch solutions in concentrations that 
were calculated to yield specific H2O2 to O3 molar ratios after application of aqueous 
ozone.  Besides inclusion of hydrogen peroxide in the water quality matrix, no 





Figure 3-14. Schematic of experimental setup for batch transformation studies.  
 
 
Continuous Aqueous Ozone Addition Reactor 
The continuous aqueous ozone addition reactor (Figure 3-15) is a novel method 
for investigating the transformation of organic compounds.  Teflon tubing and stainless 
steel connections were employed to reduce ozone loss from the stock reservoir and into 
the 2-L reactor.  Prior to all experiments, the ozone stock solution was continuously 
cycled through the tubing; hence any ozone demand from the tubing would have been 
sated.  In addition, quality control experiments were run to ascertain whether any 
significant ozone loss occurred between the stock reservoir and the reactor; the results 
show that for a stock ozone solution containing 36.96 (±0.41) mg/L O3, the ozone 
concentration measured at the effluent of the tubing (i.e., the influent line to the reactor) 
was 36.89 (±0.44) mg/L O3.  Given these results, no appreciable changes in ozone 





Figure 3-15. Schematic of the experimental setup for continuous ozone addition 
experiments. 
 
In this research, the continuous ozone reactor was employed to demonstrate the 
impact of NOM on ciprofloxacin transformation and elimination of ciprofloxacin-
associated antimicrobial activity and to determine the transformation kinetics of 
cyclophosphamide and ifosfamide with ozone and hydroxyl radicals.  Two experimental 
protocols were utilized.  In the first scenario (Method 1), concentrated ozone stock 
solution was continuously pumped into the separate 2-L reactor, which contained the 
water matrix of interest, to determine the impact of NOM on transformation of 
ciprofloxacin and elimination of the associated antimicrobial activity.  Samples were 
taken at set time intervals.  This reactor setup is discussed in more detail in Chapter 5, 
which shows how this process is utilized for removal of ciprofloxacin, and its associated 
antimicrobial activity, from various water sources.  The second operational scenario 
(Method 2) was utilized to elucidate the reaction kinetics of cyclophosphamide and 
ifosfamide reaction with aqueous ozone and hydroxyl radicals.  In this method, the ozone 
stock solution was pumped into the 2-L reactor for a set period of time (typically, 30 
minutes) before dosing in the organic compounds of interest.  During this period, the 
aqueous ozone concentration in the reactor builds up to a controllable concentration.  
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This concentration is a function of several variables, including the ozone stock solution 
concentration, the pumping rate, and the composition of the background matrix, 
specifically the carbonate species and other compounds that affect ozone decomposition.  
As ozone is being continually introduced into the reactor, the ozone concentration can be 
controlled throughout experimentation; therefore, at time, t = 0, defined as the time at 
which the pharmaceuticals and the background water matrix are dosed into the reactor, an 
excess of ozone and hydroxyl radicals are present in solution.  This process is explained 
in more detail in Chapter 4, which details the investigation of cyclophosphamide and 
ifosfamide kinetics with ozone and hydroxyl radicals. 
 
The ozone profile for a continuous ozone addition experiment with pre-ozonation 
(Method 2) is shown in Figure 3-16.  The initial solution contained 100 mg/L NaCl, 200 
mg/L NaHCO3, and 10 mM t-BuOH at a pH of 8.3.  At time, t = 0, 100 µg/L of 
cyclophosphamide and 100 µg/L of ifosfamide was dosed into the reactor.  Figure 3-16 
also shows the ozone exposure (integration of [O3] with respect to time) for the duration 
of the experiment.  Clearly, the ozone exposure in the continuous liquid addition reactor 
increases in a linear fashion throughout experimentation due to the relatively steady 
aqueous ozone concentrations; in contrast, for a batch ozonation experiment, the ozone 
exposure approaches an asymptote as the aqueous ozone concentration decreases to zero.  
As the ozone exposure is controllable (through maintenance of a desired ozone 
concentration), the continuous ozone reactor provides a unique advantage over more 
traditional methods for determining the kinetics of compounds that react slowly with 
ozone.  It should be noted that this process is novel, that is, this research is the first time 
that a continuous liquid ozone addition reactor was employed for determination of the 
reaction kinetics of compounds with ozone and hydroxyl radicals.  In Chapter 4, the rate 
constants for cyclophosphamide reaction with ozone and hydroxyl radicals are 





Figure 3-16. Typical ozone concentration and ozone exposure profiles during 
experimentation.  (100 mg/L NaCl, 200 mg/L NaHCO3, and 10 mm t-
BuOH at pH 8.3.  At time, t = 0 minutes, 100 µg/L cyclophosphamide and 
100 µg/L ifosfamide were introduced to the reactor.) 
 
Upon dosing of organic compounds, an immediate loss in ozone and hydroxyl 
radical concentration occurs due to “instantaneous” reaction with the organic matrix.  In 
this case, the loss in ozone concentration is minimal because of the low reactivity of 
cyclophosphamide/ifosfamide with ozone (see Chapter 4).  For this experiment, hydroxyl 
radicals were scavenged using t-BuOH; therefore, no effect of ifosfamide addition on 
hydroxyl radical exposure is expected.  More details about the use of t-BuOH are 
presented below.  For other cases, the initial drop in pharmaceutical and ozone 
concentrations is more drastic (Marron, 2010).  One example of a more drastic initial 
drop in ozone concentration upon dosing of the chemicals of interest in illustrated in 
Figure 3-17.  In this experiment, a 2-L reactor containing 100 mg/L NaCl and 200 mg/L 
NaHCO3 at pH 8.3; at time, t = 0, 1 mg/L DOC from Lake Austin HPOA was applied to 
the reactor.  As Figure 3-17 demonstrates, the aqueous ozone concentration in the reactor 
quickly drops and then begins to recover as the more reactive fractions of the NOM are 
exhausted.  The recovery of ozone in this scenario demonstrates that the continuous 
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aqueous ozone addition reactor can maintain ozone exposure even in the presence of 
background NOM; therefore, PhACS can be effectively treated even in the presence of 
relatively high concentrations of NOM. 
 
 
Figure 3-17. Demonstration of the impact that dosing 1 mg/L DOC from Lake 
Austin HPOA on the aqueous ozone concentration in continuous ozone 
reactor. 
 
Continuous Peroxone Addition Reactor 
Continuous peroxone addition was achieved by concomitantly pumping the ozone 
stock solution and a hydrogen peroxide stock solution into a separate 2-L reactor (Figure 
3-18).  This reactor was used to verify the rate constants for the reaction of 
cyclophosphamide and ifosfamide with hydroxyl radicals.  The 2-L reactor contained the 
water composition of interest, which included PhACs, 100 mg/L NaCl, 200 mg/L 
NaHCO3, and 10 µM pCBA at a particular pH.  At time, t = 0, both pumps (the one 
connected to the ozone stock solution and the one connected to the hydrogen peroxide 
working solution) were switched on.  The ozone and hydrogen peroxide concentrations 
(of the ozone stock solution and the hydrogen peroxide working solution) were used to 
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determine what ozone and hydrogen peroxide pumping rates were required to achieve the 
desired H2O2 to O3 molar ratio. 
 
As discussed in Chapters 2 and 4, hydrogen peroxide reacts quickly with ozone to 
promote ozone decomposition and, ultimately, to form hydroxyl radicals.  Therefore, in 
this reactor setup, very low concentrations of aqueous ozone are expected; furthermore, 
hydroxyl radical exposure should continually increase.  Figure 3-19a shows the measured 
ozone concentrations (via the indigo method) and the hydroxyl radical exposure 
(determined by the change in [pCBA]).  These data were obtained from an experiment in 
which ozone (9.77×10-4 M) and hydrogen peroxide (1.05×10-3 M) were continuously 
pumped into a 2-L reactor containing 200 mg/L NaHCO3, 100 mg/L NaCl, 100 µg/L 
ifosfamide, and 10 µM pCBA at pH 8.3.  The pumping rate of the ozone and hydrogen 
peroxide solutions were 3.1 mL/min and 2.53 mL/min, respectively.  Therefore, the 
molar ratio of hydrogen peroxide to ozone was 0.88 mol/mol.  This ratio is higher than 
the ideal molar ratio of 0.5 mol H2O2 / mol O3, indicating that the excess hydrogen 
peroxide may have scavenged some of the hydroxyl radicals, which would lower the 
achievable hydroxyl radical exposure.  In Figure 3-19b, the hydroxyl radical exposure is 
plotted as a function of the applied ozone exposure, that is, the integration of the 
cumulative ozone dose with respect to time.  Clearly, the attainable hydroxyl radical 
exposure is a function of the applied ozone exposure; this relationship makes sense as 
hydroxyl radicals are a product of ozone decomposition.  These relationships were typical 
of all of the continuous peroxone addition experiments.  The hydroxyl radical exposure 
was used in combination with changes in PhAC concentration throughout treatment to 





Figure 3-18. Schematic of the continuous peroxone addition reactor. 
 
 
Figure 3-19. (a) Ozone concentration and hydroxyl radical exposure history 
throughout a typical continuous peroxone addition experiment; (b) 




MEASUREMENT OF OZONE AND HYDROXYL RADICAL KINETICS 
As discussed in Chapter 2, in ozone-based oxidation processes, organic molecules 
interact not only with ozone but also with hydroxyl radicals (Eq. 3-5).   
 
 
       PhACHOkPhACOk
dt
PhACd








where [PhAC] is the concentration of the pharmacologically active compound at time t in 
a batch reactor, kO3,app,PhAC is the apparent rate constant for the reaction between ozone 
and the PhAC, [O3] is the ozone concentration at time t, [HO·] is the hydroxyl radical 
concentration at time t, and kHO·,app, PhAC is the rate constant for the reaction between 
ozone and the PhAC.  In this work, the rate constants for PhAC transformation by ozone 
and hydroxyl radicals were determined using three different means.  Cyclophosphamide 
and ifosfamide kinetics with ozone and hydroxyl radicals were determined using the 
continuous addition ozone reactor.  The rate constants for ciprofloxacin and erythromycin 
transformation by ozone were found using a conventional batch ozone reactor; however, 
these tasks were primarily completed by Marron (2010) for ciprofloxacin and Huang 
(2011) for erythromycin and so are not described in detail here.  The rate constant for 
erythromycin was used in batch tests to calculate the rate constant for 
anhydroerythromycin transformation by ozone.  This section focuses on the use of the 
continuous aqueous ozone addition reactor to determine rate constants for 
cyclophosphamide and ifosfamide transformation by ozone and hydroxyl radicals.   
 
After continuous ozonation for 6-8 hours, a highly concentrated ozone stock 
solution (50-60 mg/L O3) was generated.  That solution was continuously pumped into a 
2-L reactor containing the background matrix of interest for at least 30 minutes.  During 
the course of these 30 minutes, an excess of aqueous ozone was built up in the reactor as 
shown in Figure 3-16a.  Note that the pre-ozonation time is listed as negative time in 
Figure 3-16a.  At time, t = 0 min, a small volume of cyclophosphamide and/or ifosfamide 
stock solution was added to the reactor to achieve an initial concentration of 
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approximately 100 µg/L.  These details were the same for all experiments; however, two 
separate background matrices were employed to determine the rate constants for the 
PhACs with ozone and hydroxyl radicals.  The two experiments were run with the 
following background matrices:  (1) 10 mM t-BuOH was added to scavenge hydroxyl 
radicals and (2) 1-10 µM pCBA was included as a hydroxyl radical probe compound.  
The strategy for using the results of experiments with these chemicals to elucidate the 
rate constants for PhAC transformation by ozone and hydroxyl radicals is presented 
below. 
 
Isolating Ozone Kinetics 
As discussed above and earlier in Chapter 2, t-BuOH is an excellent hydroxyl 
radical scavenger.  Recall, t-BuOH reacts slowly with ozone (k”app,O3,t-BuOH = 0.003 
M-1s-1; Hoigné and Bader, 1983a) but quickly with hydroxyl radicals (k”app,HO·,t-BuOH = 
6×108 M-1s-1; Buxton et al., 1988).  For this reason, t-BuOH is not expected to 
significantly affect aqueous ozone concentrations, and therefore, should not greatly 
impact the aqueous ozone exposure.  However, due to the relatively high concentration of 
t-BuOH in solution and the high rate constant for t-BuOH transformation with hydroxyl 
radicals, t-BuOH will scavenge virtually all of the hydroxyl radicals in solution; 
therefore, any changes in PhAC concentration can be attributed to reaction with ozone 
(Eq. 3-6).   
 
 









It should be noted that the reactor volume varies with time in these experiments 
due to the continuous flow of ozone stock solution into the reactor and sample 
withdrawal.  Here, a modified constant volume equation was employed; in this case, the 
effects of dilution on PhAC concentrations were accounted for in the data analysis by 
multiplying the pharmaceutical concentration by the ratio of the initial reactor volume to 
the reactor volume at time, t.  Appendix E demonstrates that this assumption has a 
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negligible impact on calculation of the rate constant for pharmaceutical transformation by 
ozone; therefore, the modified constant volume model was used here. 
 
At a concentration of 10mM t-BuOH, the molar ratio of t-BuOH to ifosfamide 
(100 µg/L or 0.38 µM) is over 26,000.  Assuming that hydroxyl radicals react with t-
BuOH at the same rate as ifosfamide, then t-BuOH will scavenge 99.996% of the 
hydroxyl radicals in solution.  During experimentation, t-BuOH is transformed through 
reaction with hydroxyl radicals.  In these experiments, the maximum hydroxyl radical 
exposure observed is approximately 10-9 M-s, which would transform 45% of the t-
BuOH in solution; even then, the residual t-BuOH would still scavenge 99.993% of the 
hydroxyl radicals formed.  
 















0  Eq. 3-7
 
 
By carrying out the integrations shown in Eq. 3-7, a direct relationship between changes 


















By plotting ln [PhAC]/[PhAC]o vs. the ozone exposure (∫[O3]dt), the second order rate 
constant for PhAC transformation with ozone (k”app,O3,PhAC) can be measured.  Figure 3-
20 demonstrates such a plot; in this case, the rate constant for ifosfamide reaction with 
ozone was determined to be k”app,O3,IFO = 6.07 M
-1s-1.  This model (Eq. 8) has been 
extensively employed by previous authors (McDowell et al., 2005; Dodd et al., 2006; 
Suarez et al., 2007) to determine the second order rate constant for ozone with various 
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trace organic contaminants.  It should be noted that, if a significant fraction of the t-
BuOH added into solution is transformed, the data in this plot would exhibit a steepening 
slope due to PhAC transformation through reaction with hydroxyl radicals.  This issue 
was never observed; therefore, it can be concluded that the original t-BuOH 
concentration was sufficient to allow effective scavenging of hydroxyl radicals 
throughout experimentation.  More details on these experiments and the meaning of the 
results are presented in Chapter 4. 
 
 
Figure 3-20. Determination of the second-order rate constant for ozone reaction with 
ifosfamide.  (The slope of the curve represents k”app,O3,IFO.  The data in this 
figure correspond to a background solution containing 100 mg/L NaCl, 200 
mg/L NaHCO3, 10 mM t-BuOH, 100 µg/L cyclophosphamide, and 100 
µg/L ifosfamide at pH 8.3.) 
 
 
Determination of Hydroxyl Radical Kinetics 
The second type of experiment involved using a hydroxyl radical probe 
compound.  In this work, para-chlorobenzoic acid (pCBA) was employed.  The second-
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order rate constants for pCBA with ozone and hydroxyl radical are known from the 
literature:  k”app,O3,pCBA = 0.15 M
-1s-1 (Yao and Haag, 1991) and k”app,HO·,pCBA = 5.2×10
9 
M-1s-1 (Buxton et al., 1988).  Because of the low reactivity with ozone, we can consider 
changes in pCBA concentration in a batch reactor to be due solely to reaction with 
hydroxyl radicals (Eq. 3-9). 
 
 


























By plotting ln [pCBA]/[pCBA]o versus ozone exposure (Eq. 3-11), we can solve for 
Elovitz and von Gunten’s (1999) Rct term (Eq. 3-12) as shown in Figure 3-21.  Rct is the 
ratio of hydroxyl radical exposure to ozone exposure.  In this case, the value of Rct was 





































Figure 3-21. Determination of Rct using the relationship described in Eq. 3-11.  (The 
slope of the data corresponds to the Rct for this particular experiment.  The 
data in this figure correspond to a solution containing 100 mg/L NaCl, 200 
mg/L NaHCO3, 10 µM pCBA, 100 µg/L cyclophosphamide, and 100 µg/L 
ifosfamide at pH 8.3.) 
 
 
In batch ozonation tests (i.e., experiments with one dose of ozone stock solution at 
time, t = 0), most real waters demonstrate an Rct in the range of 4.9×10
-7 to 7.0×10-10 mol 
HO· / mol O3 (Elovitz et al., 2000).  In synthetic matrices containing acetate, t-BuOH, 
carbonate, and phosphate buffer (pH 8.0), Elovitz and von Gunten (Elovitz and von 
Gunten, 1999) found Rct values on the order of 1.4×10
-10 mol HO· / mol O3.  While the 
value found in Figure 3-21 is on the higher end of the range observed by Elovitz et al. 
(2000), the water matrix is relatively clean, which means that fewer hydroxyl radical 
scavengers are present in solution.  With fewer hydroxyl radical scavengers in solution, 
hydroxyl radical exposure and Rct will both be higher.  Thus, it appears that continuous 
aqueous ozone addition scenarios yield Rct values that are consistent with those observed 
in batch ozone experiments.   
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The ozone and hydroxyl radical exposures for this scenario are shown in Figure 3-
22.  Unlike the t-BuOH experiments (Figure 3-20) where hydroxyl radicals are 
scavenged, the pCBA experiment does exhibit hydroxyl radical exposure (Figure 3-22).  
Furthermore, the pCBA experiment also demonstrates significant ozone exposure (Figure 
3-22).  For that reason, it is clear that PhACs can interact with both ozone and hydroxyl 
radicals (Eq. 3-5), and both terms must be incorporated into the rate expression.  
Integration of the overall rate expression for PhAC degradation (Eq. 3-5) with respect to 
















 Eq. 3-13 
 
 
Figure 3-22. Ozone and hydroxyl radical exposure throughout an experiment 
employing 10 µM pCBA.  (The magnitudes of ozone and hydroxyl radical 
exposure are sufficient for transformation of ifosfamide according to both 
mechanisms.  The data in this figure correspond to the same experiment 




The slope of a plot of ln [PhAC]/[PhAC]o vs. ozone exposure is represented by Eq. 3-14. 
 
 
 ctPhACHOappPhACOapp Rkk  " ,," ,3,    slope
 Eq. 3-14 
 
The second-order rate constant for PhAC transformation with ozone was determined 
using Eq. 3-8 and Rct was calculated from Eq. 3-11; therefore, Eq. 3-14 can be solved for 
the second-order rate constant for the PhAC with hydroxyl radicals.  Example plots of 
Eq. 3-13 for cyclophosphamide and ifosfamide are shown in Figure 3-23.  In this case, 
the slope (Eq. 3-14) is equal to 121 M-1s-1. 
 
 
Figure 3-23. Determination of the second-order rate constant for hydroxyl radical 
reaction with ifosfamide.  (The slope was used to solve for the second-
order rate constant of ifosfamide PhAC with hydroxyl radicals (Eq. 3-14).  
The data in this figure correspond to the same experimental conditions 
described in Figure 3-21 and Figure 3-22.) 
 
In the continuous peroxone reactor, the rate constant for PhAC transformation by 
hydroxyl radicals was determined using only the experiment with pCBA because 
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hydroxyl radicals are the dominant oxidant present in the system.  Indeed, as shown in 
Figure 3-19a, the aqueous ozone concentration in continuous peroxone experiments was 
negligible; therefore, the ozone component of Eq. 3-5 goes to zero.  Then, transformation 
of PhACs can be described by Eq. 3-15. 
 
 






 Eq. 3-15 
 














 Eq. 3-16 
 
The change in pCBA concentration can be used to obtain the hydroxyl radical exposure; 
therefore, the change in pCBA concentration and the rate constant for pCBA reaction 





















 Eq. 3-17 
 
Eq. 3-17 is a competition kinetics model that relates the hydroxyl radical exposure found 
through manipulation of the [pCBA] data with the hydroxyl radical exposure determined 
from the [PhAC] data.  An example of the use of Eq. 3-17 to determine the second order 
rate constant for ifosfamide reaction with hydroxyl radicals is shown in Figure 3-24.  In 
this case, the second-order rate constant for ifosfamide transformation by hydroxyl 





Figure 3-24. Ifosfamide transformation in the peroxone system as described by Eq. 
3-17.  (The slope of the plot represents the second order rate constant for 
ifosfamide reaction with hydroxyl radicals.  The data correspond to an 
experiment run at a molar ratio of 0.88 mol H2O2 / mol O3; the reactor 
solution contained 100 mg/L NaCl, 200 mg/L NaHCO3, 100 µg/L 
ifosfamide, and 10 µM pCBA at pH 8.3.) 
 
As shown in Chapter 6, a competition kinetics model (Dodd et al., 2006) is used 
to determine the kinetics of an erythromycin degradation product, anhydroerythromycin 
A, with ozone.  In that situation, the hydroxyl radical exposure is negligible; therefore, 
the known rate constant for erythromycin transformation by ozone, the ozone exposure 
calculated from erythromycin data, and the ozone exposure from anhydroerythromycin 
data were used to calculate the rate constant for anhydroerythromycin reaction with 
ozone.  This relationship (Eq. 3-18) is similar to that shown in Eq. 3-17.  In Eq. 3-18, a 



























ANTI-MICROBIAL SUSCEPTIBILITY ASSAY 
To determine the antimicrobial activity of the pharmaceuticals of concern and the 
residual antimicrobial activity throughout treatment, the Clinical Laboratory Standards 
Institute (CLSI) standard, Methods for Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically (NCCLS, 2004), was employed.  This assay was 
developed to test the ability of antimicrobial pharmaceuticals (i.e., ciprofloxacin and 
erythromycin, in this case) to inhibit the growth of various microorganisms.  A standard 
microorganism, Escherichia coli (ATCC #25922), was employed to describe the 
inhibition profile of individual pharmaceuticals and to determine how ozone treatment 
affects the residual antimicrobial activity of a water containing the PhACs of concern, 
PhAC intermediate oxidation products, and other compounds, including background 
electrolytes and NOM, among others.  The protocol for using the antimicrobial activity 
assay is described below, and more detail on the data analysis is presented in Appendix 
C.  All glassware, disposables, and solutions employed in antimicrobial activity studies 
were sterilized using the autoclave protocol available in Appendix A. 
 
  E. coli was purchased from the American Type Culture Collection (ATCC).  
Upon arrival, a small aliquot of the E. coli stock was scraped into 10-mL of Mueller-
Hinton Broth (MHB).  The suspension was incubated in an ambient air environment at 
37°C for 48 hours.  After the incubation time, the E. coli suspension was quite dense.  
Using a sterile inoculation loop, a streak plate was made on Trypticase Soy Agar.  One 
distinct colony forming unit was selected and mixed into a solution of 10-mL MHB.  
That suspension was incubated for three days at 37°C in ambient air.  The resulting E. 
coli suspension was mixed 1:1 with a 50% glycerol solution; aliquots of 1-mL were 
placed into 5 separate sterile cryotubes.  These E. coli stock suspensions were then placed 
into a dark, -80°C freezer for storage. 
 
  Every month, an E. coli working solution was generated by scraping a small 
amount of frozen (-80°C) E. coli suspension into 10-mL of Mueller-Hinton broth (MHB) 
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and incubating the mixture in ambient air at 37°C overnight (12-18 hours).  Throughout 
the month, the E. coli working solution was split 1:10 at least every three days.  The 
purity of the E. coli working solutions were confirmed throughout the month by 
comparing the inhibition profiles of ciprofloxacin/erythromycin standards. 
 
  The inoculum for antimicrobial activity assays was prepared by diluting the E. 
coli working solution with sterile MHB to obtain the same absorbance at 625 nm as a 
BaSO4 turbidity standard equivalent to a 0.5 McFarland standard.  The BaSO4 standard 
was produced by mixing 0.5-mL of a 0.048 M BaCl solution with 99.5-mL of 0.36 N 
H2SO4 (NCCLS, 2004).  The antimicrobial susceptibility assays were run in 96-well 
microplates.  Assays were run according to two different protocols, as described below. 
 
Inhibition Profile Protocol.  Wells were partially filled with 100 μL of either a standard 
containing a known concentration of an antimicrobial PhAC in the background matrix of 
choice or a sample from experimentation; then, 100 μL of the E. coli inoculum was added 
to the well.  Positive growth controls consisted of 100 μL of the background matrix 
without the drug and 100 μL of inoculum; negative growth controls were made up of 100 
μL of the background matrix and 100 μL of MHB.  Triplicate analyses were run for all 
standards, samples, and controls. 
 
Potency Equivalent Protocol.  In the first row (“A”) of the microplate, the wells (A2-
A11) are filled with 250 μL of either a standard containing a known concentration of an 
antimicrobial PhAC in the background matrix of choice or a sample from 
experimentation.  All other wells (i.e., rows “B” through “H”) are filled with 100 μL of 
sterile DI water.  Each sample/standard from row “A” is serially diluted into the 
subsequent rows.  In most cases, a dilution factor of 0.6 was used, i.e., the concentration 
in row “B” was 60% of the concentration in row “A.”  Therefore, 150 μL of the 
sample/standard in row “A” was added to the 100 μL in row “B.”  Next, 150 μL of the 
solution now in row “B” was added to the 100 μL in row “C,” and so on.  After all 
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samples/standards are serially diluted, 100 μL of the E. coli inoculum is added to each 
well.  The resultant wells contain 100 μL of the sample/standard and 100 μL of the E. coli 
inoculum.  Columns 1 and 12 contained positive and negative growth controls, 
respectively. 
 
  After each plate was prepared, microplates were covered in Parafilm to prevent 
evaporative water loss and incubated in ambient air at 37°C for 20 hours.  After the 20 
hour incubation period, plates were read on a microplate reader (BioTek) at 600 nm.  No 
condensation was observable on the Parafilm covers.  This wavelength is routinely used 
to correlate absorbance with microbial growth (or optical density).  Therefore, low 
absorbance values correspond to high inhibition, whereas high absorbance values indicate 
E. coli growth and, therefore, low inhibition.  The percent inhibition can be calculated 





















Inhibition  Eq. 3-19 
 
 After calculation of the percent inhibition, GraphPad Prism (GraphPad Software, 
Inc.) was used to fit the data to the Hill curve.  This software was used to determine the 
half maximal inhibitory concentration (IC50) and the Hill slope, H, and also to calculate 
95% confidence intervals on the resultant Hill curve.  When the inhibition profile 
protocol was employed, all data were modeled together in GraphPad Prism, that is, one 
curve was fit to each set of samples or standards.  With the potency equivalents method, 
“inhibition profiles” were generated for each set of serial dilutions by plotting the percent 
inhibition against LOG(CPhAC,i/CPhAC,o), where CPhAC,i and CPhAC,o are the PhAC 
concentration in the “i”th dilution and the PhAC concentration in the original 
sample/standard.  The equivalent of IC50 (i.e., the value of LOG(CPhAC,i/CPhAC,o) that 
corresponds to 50% inhibition) for these curves was calculated by GraphPad Prism.  
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Using those values, the potency equivalents (PEQ) were calculated according to Equation 
























  Eq. 3-20 
 
In Eq. 3-20, the numerator refers to the antilog of the value of LOG(CPhAC,i/CPhAC,o) that 
corresponds to 50% inhibition for the serial diluted data derived from the initial (highest 
concentration) sample; the term in the denominator corresponds to the same value for 
treated samples or standards at concentrations lower than the initial sample. 
 
 Potency equivalents are a tool designed to provide quantitative measurement of 
antimicrobial activity at drug concentrations that demonstrate high inhibition.  With 
solutions containing only standards, every step down in concentration results in an 
equivalent drop in potency equivalents.  While more details are presented in Appendix C, 
a graphical description of these different data analysis mechanisms is shown in Figure 3-
25.  Figure 3-25a presents the inhibition profile of ciprofloxacin against E. coli ATCC 
25922.  In Figure 3-25b, the “inhibition profile”s of ten individual samples (containing 
erythromycin) introduced to the potency equivalent protocol for measurement of 
antimicrobial activity are shown.  
 
 These tools allow for effective description of the residual antimicrobial activity 
throughout water treatment; by plotting percent inhibition and parent compound 
concentration against treatment dose or time, the relationship between parent compound 
concentration and antimicrobial activity can be determined.  Furthermore, the impact of 
intermediate oxidation products and/or advanced oxidation byproducts can be assessed by 
comparing the standard inhibition profile with that of the treated samples.  The potency 
equivalents protocol allows for greater elucidation of the impact of early (i.e., the first 
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products formed by ozone/hydroxyl radical attack on the parent compound) intermediate 
oxidation products on residual antimicrobial activity.   
 
 
Figure 3-25. Representative data and model fits (solid lines) collected from (a) the 
inhibition profile protocol (with ciprofloxacin) and (b) the potency 






Both protocols have advantages.  In the inhibition profile protocol, the change in 
antimicrobial activity throughout treatment can be easily conveyed; as treatment occurs, 
the PhAC concentration decreases and the residual antimicrobial activity is eliminated.  
Furthermore, by plotting the antimicrobial activity of treated samples, the contributions 
of intermediate oxidation products to the residual antimicrobial activity can be identified.  
In the serial dilution protocol, deviations from the 1:1 relationship of potency equivalents 
with the normalized PhAC concentration suggest positive or negative contributions of 
intermediate products with respect to residual pharmacological activity.  This protocol is 
especially relevant at high PhAC concentrations (e.g., ones that demonstrate >90% 
inhibition) because it allows quantitative analysis of the residual antimicrobial activity.  
Regardless, for some compounds, the antimicrobial activity stemming from the presence 
of intermediate oxidation products may be masked in the serial dilution scheme.  
Substantial discussion regarding the employment of these two techniques for 
measurement of antimicrobial activity is provided in Chapters 5-6 within the context of 







CHAPTER 4: OZONATION OF CYCLOPHOSPHAMIDE AND 
IFOSFAMIDE:  DETERMINATION OF RATE CONSTANTS, 
IMPACT OF ORGANIC MATTER, AND IDENTIFICATION 
OF MAJOR INTERMEDIATE PRODUCTS 
 
ABSTRACT 
A novel continuous aqueous ozone addition reactor was employed to determine the rate 
constants for the transformation of two environmentally-relevant chemotherapy agents, 
cyclophosphamide and ifosfamide, by ozone and hydroxyl radicals.  The rate constants 
for cyclophosphamide and ifosfamide transformation with ozone were determined to be 
3.23(±0.71) M-1s-1 and 6.84 (±0.37) M-1s-1, respectively.  The second-order rate constants 
for cyclophosphamide and ifosfamide transformation by hydroxyl radicals were found to 
be 2.69(±0.17) ×109 M-1s-1 and 2.73(±0.16) ×109 M-1s-1, respectively; these rate constants 
were verified using a continuous peroxone addition reactor.  Batch ozone experiments 
demonstrated that NOM can significantly decrease hydroxyl radical exposure, and 
thereby, decrease transformation of cyclophosphamide and ifosfamide.  Overlap in m/z 
values of intermediate oxidation products was observed for the two chemotherapy agents, 
which are structural isomers.  The 4-keto-, 4-hydroxy-, and imino- derivatives of the 
parent compounds were the most dominant intermediate oxidation products in the applied 
ozone dose range employed in this research.  Furthermore, the active metabolites of 
cyclophosphamide and ifosfamide (phosphoramide mustard and isophosphoramide 
mustard, respectively) were also detected in treated samples.  The presence of the active 
metabolites suggests that treated solutions could retain some residual pharmacological 
activity. 
 
Key words: cyclophosphamide, ifosfamide, ozone, pharmacologically active 
compounds, reaction kinetics, intermediate oxidation products 




Recently, several authors have reported a wide range of pharmacologically active 
compounds (PhACs) in wastewater streams, surface waters, and treated drinking water 
(Ternes, 1998; Kolpin et al., 2002; Kim et al., 2007).  The list of PhACs detected in these 
water supplies includes compounds from many different pharmaceutical classes, 
including antibiotics, anti-microbials, anti-inflammatories, chemotherapy agents, and 
anti-depressants, among others.  Several authors (Kummerer et al., 1997; Steger-
Hartmann et al., 1997; Buerge et al., 2006; Johnson et al., 2007; Chen et al., 2008) have 
indicated concern for chemotherapy agent presence in the environment because of the 
tendency for such chemicals to exhibit toxic effects.  This paper concentrates on ozone-
based treatment processes for removing two chemotherapy agents, cyclophosphamide 
and ifosfamide, from water. 
 
Cyclophosphamide and ifosfamide are structural isomers as shown in Table 4-1.  
These compounds are prodrugs, meaning that cyclophosphamide and ifosfamide, 
themselves, are inactive; the compounds are converted into their active forms during 
metabolism.  First, the two compounds are converted to 4-hydroxycyclophosphamide and 
4-hydroxyifosfamide, respectively, which are also prodrugs (Low et al., 1983).  The 4-
hydroxy derivatives are further metabolized to the reactive mustards, phosphoramide 
mustard (cyclophosphamide) and isophosphoramide mustard (ifosfamide), respectively, 
and acrolein (Low et al., 1983).  The reactive mustards are cytotoxic and work by 
alkylating DNA, prohibiting separation of DNA strands during replication (Fleming, 
1997).  No research into whether treatment processes or environmental degradation 
pathways lead to the active compounds formed through metabolism has yet been 
performed; furthermore, the excretion of metabolic products is not typically reported.  As 
the parent compounds are not pharmacologically active, characterization of intermediate 





In addition to being cytotoxic, cyclophosphamide and ifosfamide are teratogenic, 
mutagenic, and carcinogenic (Bus et al., 1973; Murthy et al., 1973; Mohn and 
Ellenberger, 1976).  The concentrations associated with cyclophosphamide and 
ifosfamide toxicity are organism-dependent.  Currently, the contribution of trace 
concentrations of cyclophosphamide and ifosfamide to the ultimate ecotoxicological 
activity of a water are unknown; however, some researchers (Pomati et al., 2006; Pomati 
et al., 2007; Pomati et al., 2008) have investigated the impact of environmentally-
relevant concentrations of a suite of 11 pharmaceuticals, including cyclophosphamide, on 
inhibition of E. coli, ovarian cancer cells (OVCAR3), human embryonic kidney cells 
(HEK-293), and zebrafish liver cells.  Pomati et al. (2006) found that HEK-293 
proliferation can be inhibited by up to 30% in the presence of trace concentrations of 
pharmaceuticals.  Nevertheless, the ecotoxicological impact of trace concentrations of 
cyclophosphamide and ifosfamide is not yet fully understood.  
 
Table 4-1. Properties of ifosfamide and cyclophosphamide. 
Property Cyclophosphamide Ifosfamide 
Molecular Formula C7H15Cl2N2O2P C7H15Cl2N2O2P 




log Kow 0.63 0.86 
pKa 2.84-6.5 * 1.45-4.0 ** 
CAS number 50-18-0 3778-73-2 
* Mahoney et al., 2003; Sottani et al., 2008; Wang et al., 2009 
** Mahoney et al., 2003; Sottani et al., 2008 
 
The log Kow for cyclophosphamide and ifosfamide are 0.63 and 0.86 (Hansch et 
al., 1995), respectively; hence, these compounds can be expected to pass through 
traditional wastewater treatment processes without being adsorbed onto particles or 
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microorganisms.  Steger-Hartmann et al. (1997) found that cyclophosphamide is poorly 
removed in sewage treatment plants (STPs); additionally, Kiffmeyer et al. (1998) 
concluded that cyclophosphamide is not biodegradable.  Unsurprisingly, 
cyclophosphamide and ifosfamide have been detected in various water sources over the 
past 15 years.  Ifosfamide (5-338 ng/L) and cyclophosphamide (2-21 ng/L) have been 
detected in hospital wastewater (Steger-Hartmann et al., 1997; Thomas et al., 2007).  
Cyclophosphamide and ifosfamide have also been detected at concentrations of 1-143 
ng/L in STPs (Steger-Hartmann et al., 1997; Metcalfe et al., 2003; Zuccato et al., 2005; 
Buerge et al., 2006; Thomas et al., 2007).  Significant concentrations of these two 
compounds have been detected in landfill leachate:  97-192 ng/L for cyclophosphamide 
and 32-42 ng/L for ifosfamide (Jjemba, 2008). 
 
Ozonation has proven an effective treatment process for removal of PhACs 
(Huber et al., 2003; Ternes et al., 2003; von Gunten, 2003; Westerhoff et al., 2005).  
Several authors have investigated ozone treatment of cyclophosphamide and ifosfamide 
in various water sources (McDowell et al., 2005; Venta et al., 2005; Chen et al., 2008; 
Garcia-Ac et al., 2010).  Venta et al. (2005) investigated cyclophosphamide degradation 
in a gaseous ozonation reactor; the authors reported the pseudo-first order rate constant 
for cyclophosphamide degradation in the peroxone process (the molar ratio of H2O2/O3 
was varied from 0.15 to 0.39) system and identified 4-ketocyclophosphamide as an 
intermediate oxidation product; detection of the reactive mustards was not reported.  
Garcia-Ac et al. (2010) determined the second-order rate constant for cyclophosphamide 
reaction with ozone in ultrapure water to be k”O3,CYP = 3.3 M
-1s-1; in contrast, Chen et al. 
(2008) determined the second-order rate constant for cyclophosphamide transformation 
by ozone to be nearly two orders of magnitude greater (k”O3,CYP = 143 M
-1s-1) than that 
determined by Garcia-Ac et al. (2010).  In both of these studies, highly concentrated 
aqueous ozone was injected into a batch solution containing cyclophosphamide; samples 
were taken over time and analyzed for ozone and cyclophosphamide concentrations.  
Both papers report similar values for the second-order rate constant for 
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cyclophosphamide transformation by hydroxyl radicals:  2.0×109 M-1s-1 (Garcia-Ac et al., 
2010) and 2.1×109 M-1s-1 (Chen et al., 2008).  The work of McDowell et al. (2005) 
demonstrates removal of cyclophosphamide and ifosfamide as a function of applied 
ozone dose.  Of the nine compounds investigated by these investigators, 
cyclophosphamide and ifosfamide exhibited the lowest percent transformation for all 
applied ozone doses.  The transformation kinetics of ifosfamide with ozone and hydroxyl 
radicals has not previously been reported. 
 
In this paper, we report on the use of a novel continuous liquid ozone addition 
reactor to determine the kinetics of cyclophosphamide and ifosfamide transformation 
through reactions with ozone (O3) and hydroxyl radicals (HO·).  This method for 
determining kinetics is especially relevant for compounds that react slowly with ozone, 
because ozone concentrations can be effectively controlled without the limitations 
incurred by ozone decay or the complications associated with modeling of aqueous ozone 
concentrations.  In addition, the impact of natural organic matter (NOM) on the 
transformation of cyclophosphamide and ifosfamide at specific applied ozone doses was 
investigated.  Finally, we provide initial characterization of major intermediate oxidation 
products produced during ozone and hydroxyl radical oxidation of cyclophosphamide and 
ifosfamide.  The value of studying both of these closely related compounds was to 
determine how the placement of the two chloroethyl functional groups affects both the 
transformation kinetics with ozone and hydroxyl radicals and the structures of the 
resultant intermediate oxidation products.  
 
MATERIALS AND METHODS 
Chemicals and stock solutions.  Cyclophosphamide monohydrate and ifosfamide were 
purchased through VWR from MP Biomedicals (Solon, OH) and US Pharmacopeia 
(Rockville, MD), respectively.  Stock solutions of cyclophosphamide (CYP) and 
ifosfamide (IFO) were prepared at 1 mg/mL in deionized water and stored in amber 
bottles in the dark at 4°C.  para-chlorobenzoic acid (pCBA) stock solutions (100 µM) 
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were made in deionized water and stored in the dark at 4°C.  LC-MS grade methanol and 
water were employed in LC-MS and LC-MS/MS analysis of cyclophosphamide and 
ifosfamide.  HPLC grade methanol was employed in HPLC-UV analysis of pCBA.  
NOM was isolated from Lake Austin (Austin, TX) using the procedures described by 
Aiken et al. (1992).  The hydrophobic organic acids (HPOA) fraction of Lake Austin 
NOM was isolated using XAD-8 resin.  Lake Austin HPOA was chosen as a 
representative NOM source; furthermore, because the Lake Austin HPOA was available 
in extract form, the DOC concentration could be controlled.  A stock solution of 
hydrogen peroxide was made from 30% H2O2; the H2O2 stock solution (0.105 M H2O2) 
was placed in an amber bottle and stored in the dark at 4°C.   
 
Ozone reactor setup.  A schematic of the ozone supply system and reactor is shown in 
Figure 4-1a.  Oxygen gas flowed into the ozone generator at 30 cm3/min; a fraction of 
that oxygen was converted to ozone.  This combined gas stream was directed into a gas-
washing bottle, which served as a stock ozone solution.  The ozone stock solution was 
maintained on ice (Tsolution ~ 0.5°C) to increase the solubility of ozone.  After 4-6 hours, 
the ozone concentration in the stock solution reached a plateau at 50-60 mg O3/L.  In this 
research, the ozone stock solution was employed in three different ozone reactors:  
continuous aqueous ozone addition, continuous peroxone addition, and batch ozone 
experiments.  The continuous aqueous ozone addition experiments were used to calculate 
the rate constants for cyclophosphamide and ifosfamide transformation by ozone and 
hydroxyl radicals; the rate constants for cyclophosphamide and ifosfamide transformation 
with hydroxyl radicals were verified using the continuous peroxone addition reactor.  The 
batch ozone experiments were utilized to (1) describe the impact of NOM on 
cyclophosphamide and ifosfamide transformation and (2) characterize the intermediate 





Figure 4-1. (a) Schematic of the continuous liquid ozone addition reactor; (b) 
Behavior of ozone concentrations and ozone exposure throughout a 
continuous ozone addition experiment.  (In (b), the solution is composed 
of 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, and 10
-2 M t-BuOH at pH 6.3.  
At time equal to zero, 3.83×10-7 M cyclophosphamide and 3.83×10-7 M 





Continuous ozone addition experiments.  The ozone stock solution was pumped into the 
2-L reactor for 30 minutes; the aqueous ozone concentration in the 2-L reactor was 
controlled by adjusting the pumping rate from the stock reservoir.  After 30 minutes of 
pre-ozonation, a small volume of solution (400 µL) containing cyclophosphamide 
(1.92×10-3 M) and ifosfamide (1.92×10-3 M) was dosed into the 2-L reactor to achieve 
concentrations of 3.83×10-7 M of cyclophosphamide and 3.83×10-7 M  of ifosfamide.  
Samples were taken at regular time intervals and analyzed for ozone, cyclophosphamide, 
and ifosfamide concentrations, as described below.  An example of ozone concentrations 
and ozone exposure (∫[O3]dt) throughout a typical experiment is shown in Figure 4-1b.  
Clearly, the ozone exposure in the continuous liquid addition reactor increases in a linear 
fashion throughout experimentation.  In contrast, for a batch ozonation experiment aimed 
at determining the kinetics for compounds that react slowly with ozone (k”app,O3,PhAC < 10
2 
M-1s-1), the ozone exposure approaches an asymptote as the aqueous ozone concentration 
decreases to zero.  The continuous ozone reactor provides a unique advantage over more 
traditional methods for determining the kinetics of compounds that react slowly with 
ozone because the ozone concentration in the reactor is controllable and non-zero for an 
extended time.  Nevertheless, batch kinetics experiments are useful for determining the 
transformation kinetics of compounds that react quickly with ozone (Marron, 2010; 
Huang, 2011).  Batch experiments are also useful for determining removal efficiency as a 
function of applied ozone dose (transformation as a function of the molar ratio of applied 
ozone to the initial PhAC concentration) as indicated below.  
 
Continuous peroxone addition experiments.  A stock hydrogen peroxide solution was also 
employed in the continuous peroxone addition experiments.  The molar ratio of hydrogen 
peroxide to ozone was essentially controlled by the pumping rates of the ozone stock 
solution ( ) and the hydrogen peroxide stock solution ( ), since the ozone and 
hydrogen peroxide concentrations are measured.  Then, using Eq. 4-1, the molar ratio of 






















 Eq. 4-1 
 
Batch ozone experiments.  Small aliquots of ozone stock solution were added to culture 
tubes containing a small volume (2-7 mL) of solutions containing cyclophosphamide 
and/or ifosfamide in the background matrix of choice.  After ozone addition, samples 
were immediately shaken, capped, and placed in a dark environment for 24 hours before 
analysis to ensure that the applied ozone was completely exhausted.  Samples were 
measured for residual ozone concentrations using the indigotrisulfonate method (APHA 
et al., 2006); as expected, no samples demonstrated residual ozone after the reaction 
period.  This type of experiment was used to determine the transformation of 
cyclophosphamide and ifosfamide in different NOM matrices and to generate 
intermediate oxidation products for LC-MS characterization.  For experiments 
investigating the impact of organic matter on the transformation of cyclophosphamide 
and ifosfamide, the initial concentrations of cyclophosphamide and ifosfamide 
were 1.15×10-5 M; the applied ozone dose varied from 0 to 1.09×10-4 M.   Experiments 
used to characterize intermediate oxidation products employed initial cyclophosphamide 
and ifosfamide concentrations of 3.83×10-4 M; ozone doses were calculated to achieve 
molar ratios of applied ozone to initial PhAC in the range of 0 to 7.5 mol/mol.   
 
Analytical Procedures.  Dissolved ozone concentrations of stock solutions were 
measured directly at 258 nm on a UV-VIS spectrophotometer (Agilent).  Aqueous ozone 
concentrations in the 2-L continuous liquid ozone addition reactor were measured using 
the indigo blue method (Bader and Hoigné, 1981) and employing Indigo Reagent II 
(Standard Method 4500.B; APHA et al., 2006).  Hydrogen peroxide concentrations were 
measured using the potassium permanganate titration (Schumb et al., 1955). 
 
Cyclophosphamide and ifosfamide samples pertaining to kinetics and the impact 
of organic matter on percent transformation experiments were measured with LC-MS/MS 
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(Thermo Finnigan, TSQ Quantum).  The injection volume was 10 μL and the flow rate 
was 700 μL/min.  HPLC separation was achieved with a C18 (Shimadzu 150×4.6 mm; 
particle size, 5 µm) column; the eluent gradient was 5% MeOH, 95% H2O (0-3 min); 
ramp to 80% MeOH, 20% H2O (3-10 min); 80% MeOH, 20% H2O (10-12 min); ramp to 
100% MeOH, 0% H2O (12-12.1 min); 100% MeOH, 0% H2O (12.1-16 min); ramp to 5% 
MeOH, 95% H2O (16-16.1 min); 5% MeOH, 95% H2O (16.1-18 min).  The electrospray 
ionization tandem mass spectrometer was operated in positive ion mode.  Method 
parameters include the following:  parent mass, 261.0 mg; product mass, 139.8 mg (CYP) 
and 153.9 (IFO); collision gas pressure, 1.5 mTorr; collision energy, 20 V; spray voltage, 
4000 V; vaporizer temperature, 400 °C; sheath gas pressure, 50 psi (CYP) and 30 psi 
(IFO); and auxiliary gas pressure, 30 psi (CYP) and 10 psi (IFO).  Ifosfamide was eluted 
at 11.7 minutes; cyclophosphamide was eluted at 12.0 minutes. 
 
Samples from the batch experiments employed for characterization of 
cyclophosphamide and ifosfamide intermediate oxidation products were analyzed using 
LC-MS; the measured m/z range was 30–1500.  The injection volume was 20 μL and the 
flow rate was 350 μL/min.  The eluent gradient was 5% MeOH, 95% H2O (0-15 min); 
ramp to 80% MeOH, 20% H2O (15-22 min); 80% MeOH, 20% H2O (22-29 min); ramp 
to 100% MeOH, 0% H2O (29-29.1 min); 100% MeOH, 0% H2O (29.1-33 min); ramp to 
5% MeOH, 95% H2O (33-33.1 min); 5% MeOH, 95% H2O (33.1-35 min).  The 
electrospray ionization tandem mass spectrometer was operated in positive ion mode.  
Method parameters include the following:  parent mass, 261.0 mg; collision gas pressure, 
1.5 mTorr; collision energy, 20 V; spray voltage, 4000 V; vaporizer temperature, 400 °C; 
sheath gas pressure, 25 psi (CYP) and 15 psi (IFO); and auxiliary gas pressure, 15 psi 
(CYP) and 5 psi (IFO). 
 
The hydroxyl radical probe compound, pCBA, was measured at 234 nm using an 
HPLC (Waters Corporation) with photo-diode array (PDA).  HPLC separation was 
achieved with a C18 column (Sonoma C18(2), 3µ 100 Å).  The eluent, 60% MeOH, 40% 
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 In this section, the results of the transformation kinetics experiments using the 
continuous aqueous ozone addition reactor are presented.  The impact of NOM on the 
transformation of cyclophosphamide and ifosfamide achievable for a specific ozone dose 
and characterization of the intermediate oxidation products formed during ozonation of 
cyclophosphamide and ifosfamide are also discussed. 
 
Kinetics 
The continuous peroxone addition reactor was employed to determine the second-
order rate constant for PhAC transformation with hydroxyl radicals.  In this system, 
hydroxyl radicals are the dominant oxidant; therefore, the change in PhAC concentration 
with respect to time can be described by Eq. 4-2. 
 
 









[PhAC] is the pharmaceutical concentration at time, t; k”HO·,app,PhAC is the second-order 
rate constant for PhAC transformation by hydroxyl radicals; and, [HO·] is the hydroxyl 

















The term, ∫[HO·]dt, is called the hydroxyl radical exposure, and it can be calculated using 
data from transformation of the hydroxyl radical probe compound, para-chlorobenzoic 
acid (pCBA).  The second-order rate constants for pCBA with ozone and hydroxyl 
radical are known from the literature:  k”O3,pCBA = 0.15 M




9 M-1s-1 (Buxton et al., 1988).  Because of the low reactivity with 
ozone, changes in [pCBA] in a batch reactor (with respect to pCBA) are attributed solely 
to reaction with hydroxyl radicals.  Then, the transformation of pCBA with respect to 
time is similar to Eq. 4-3; thus, the hydroxyl radical exposure at any time, t, can be 





















Using the hydroxyl radical exposure determined from the pCBA transformation data with 
the PhAC transformation data allows calculation of the second-order rate constant for 
PhAC transformation by hydroxyl radicals. 
 
Two separate solutions containing 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, 10
-5 
M pCBA, and 7.66×10-7 M of either cyclophosphamide or ifosfamide were created.  The 
pH of both solutions was 8.2.  The ozone concentration in the ozone stock solution was 
measured, and pumping rates were set for the O3 and H2O2 systems.  For both 
experiments, the H2O2 to O3 molar ratio was set at 0.88.  At time, t = 0, both pumps were 
started and measurements commenced, i.e., pre-ozonation was not performed due to rapid 
hydroxyl radical decomposition.  The results from these experiments can be seen in 
Figure 4-2.  The slope of the data plotted in Figure 4-2 is equal to the second-order rate 
constant for PhAC transformation by hydroxyl radicals as demonstrated by Eq. 4-3.  In 
this case, the second-order rate constants (with 95% confidence intervals) for 
cyclophosphamide and ifosfamide transformation by hydroxyl radicals were 





Figure 4-2. Determination of second order rate constant for hydroxyl radical 
reaction with cyclophosphamide (a) and ifosfamide (b) using the 




The aqueous ozone concentrations were found to be below the detection limit (8.0×10-8 
mol/L using the indigo method with indigo reagent II) throughout these experiments.  
Given these observations, the maximal ozone exposure for the experiments shown in 
Figure 4-2 is approximately 1.44×10-4 M-s, which would only correspond to ~0.1% 
PhAC removal efficiency; clearly, the majority of the transformation, then, is due to 
PhAC transformation by hydroxyl radicals.  These observations reflect the rapid reaction 







OHOOHO sMk  

 Rxn. 4-1 
 
The rate constants for cyclophosphamide and ifosfamide transformation by ozone 
were found using the continuous liquid ozone addition reactor.  The aqueous ozone 
concentration was built up, and then the PhACs were dosed into the reactor.  To isolate 
PhAC reaction with ozone, 10 mM t-BuOH was added to the reactor solution.  t-BuOH 
reacts slowly with ozone (k”O3,t-BuOH = 0.003 M
-1s-1; Hoigné and Bader, 1983a) but 
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quickly with hydroxyl radicals (k”HO·,t-BuOH = 6×10
8 M-1s-1; Buxton et al., 1988).  For this 
reason, t-BuOH does not affect the aqueous ozone exposure but, at sufficient 
concentration, will scavenge virtually all of the hydroxyl radicals in solution.  At a 
concentration of 10mM t-BuOH, the molar ratio of t-BuOH to the total PhAC 
concentration (3.83×10-7 M) is over 26,000; for this molar ratio, t-BuOH will scavenge 
99.998% of hydroxyl radicals in solution.  Therefore, in these experiments, any changes 
in cyclophosphamide or ifosfamide concentration can be attributed to reaction with 
ozone, as described in Eq. 4-5.  Integration of Eq. 4-5 with respect to time yields Eq. 4-6. 
 
 

























It should be noted that the reactor volume varies with time in these experiments 
due to the continuous flow of ozone stock solution into the reactor and sample 
withdrawal.  Here, a modified constant volume equation was employed; in this case, the 
effects of dilution on PhAC concentrations were accounted for in the data analysis by 
multiplying the pharmaceutical concentration by the ratio of the initial reactor volume to 
the reactor volume at time, t.  Appendix E demonstrates that this assumption has a 
negligible impact on calculation of the rate constant for pharmaceutical transformation by 
ozone; therefore, the modified constant volume model was used here. 
 
By plotting ln [PhAC]/[PhAC]o vs. the ozone exposure (∫[O3]dt), the second order 
rate constant for PhAC transformation by ozone (k”O3,app,PhAC) can be measured.  Figure 
4-3 shows determination of the second-order rate constants for cyclophosphamide 
([CYP]o = 3.83×10
-7 M) and ifosfamide ([IFO]o = 3.83×10
-7 M) transformation by ozone; 
the background matrix includes 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, 10
-2 M t-
BuOH, and the pH was 6.3.  Similar experiments were completed at pH 4.4 and 8.3 (not 
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shown), the second-order rate constant for ifosfamide and cyclophosphamide with ozone 
was similar at all pH values studied.  The ozone concentration was held at different 
concentrations for each experiment; those concentrations ranged from 1.6–4.6×10-5 M.  
Recall from Table 4-1 that the pKa values for cyclophosphamide and ifosfamide reported 
by different investigators show some discrepancies; regardless, no differences in the rate 
constants were found in the investigated pH range.  For the experimental results shown in 
Figure 4-3, the rate constants were found to be k”O3,app,CYP = 2.27(±0.31) M
-1s-1 and 
k”O3,app,IFO = 6.07(±0.44) M
-1s-1, respectively.  Experiments were conducted at other pH 
values in the range of 4.4-8.3 to yield specific rate constants (with 95% confidence 
intervals) of k”O3,app,CYP = 3.03 (± 0.48) M
-1s-1 and k”O3,app,IFO = 7.38 (± 0.27) M
-1s-1, 
respectively.  The specific rate constants (and 95% confidence intervals) were determined 
using the cumulative data from all experiments. 
 
  
Figure 4-3. Determination of cyclophosphamide and ifosfamide second-order rate 
constants with ozone.  (The data in this figure correspond to a background 
solution containing 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, 10
-2 M t-





The apparent rate constants for cyclophosphamide and ifosfamide transformation 
by hydroxyl radicals at pH 8.2 and the average rate constants for cyclophosphamide and 
ifosfamide transformation by ozone across the investigated pH values are shown in Table 
4-2.  The second-order rate constant for the reaction of cyclophosphamide with ozone 
(k”O3,CYP = 3.03 (± 0.48) M
-1s-1) found in this study is reasonably similar to that found by 
Garcia-Ac et al. (2010), 3.3 M-1s-1, and almost two orders of magnitude less than that 
found by Chen et al. (2008), 143 M-1s-1.  The second-order rate constant for 
cyclophosphamide reaction with hydroxyl radicals (k”HO·,CYP  = 2.69 (± 0.17) ×10
9 M-1s-1) 
compares reasonably well with the values found by both Garcia-Ac et al. (2010), 2.0×109 
M-1s-1, and Chen et al. (2008), 2.1×109 M-1s-1. 
 
Table 4-2. Rate constants for cyclophosphamide and ifosfamide with ozone and 
hydroxyl radicals. 
Rate constants Cyclophosphamide Ifosfamide 
k”O3,PhAC (M
-1s-1) 3.03 (± 0.48) 7.38 (± 0.27) 
k”HO·,PhAC (M
-1s-1) 2.69 (± 0.17) ×109 2.73 (± 0.16) ×109 
 
 
The validity of these rate constants was verified by running the continuous ozone 
addition reactor under conditions where both oxidants (O3 and HO·) are significant.  For 
these experiments, the 2-L reactor contained 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, 
10-5 M pCBA, 3.83×10-7 M cyclophosphamide, and 3.83×10-7 µg/L ifosfamide at the pH 
of interest; as above, the pH range investigated was 4.4-8.3.  In this scenario, Eq. 4-4 can 


















Elovitz and von Gunten’s (1999) Rct term (Eq. 4-8), which is defined as the molar ratio of 

































 Eq. 4-9 
 
Then, Rct can be calculated as the slope of a plot of ln [pCBA]/[pCBA]o versus k
”
HO·,pCBA 
× ∫[O3]dt, as shown in Figure 4-4a.  In this case, the value of Rct is 2.16×10




Figure 4-4. (a) Determination of Rct and (b) plots of ozone and hydroxyl radical 
exposure corresponding to ozonation of a solution containing 1.71×10-3 
M NaCl, 2.38×10-3 M NaHCO3, 10
-5 M pCBA, 3.83×10-7 M 





Figure 4-4b presents the ozone (0-1.6×10-2 M-s) and hydroxyl radical (0-3.7×10-10 
M-s) exposure throughout this experiment.  The presence of non-negligible ozone and 
hydroxyl radical exposure indicates that ozone and hydroxyl radicals are available for 
reaction with cyclophosphamide and ifosfamide and so both must be accounted for in the 
reaction rate expression (Eq. 4-10): 
 
 



























 Eq. 4-11 
 
This equation was used to test whether the rate constants found above could be used to 
predict what would occur in scenarios where both oxidants are present.  The results 
shown in Figure 4-5 correspond to a solution containing 1.71×10-3 M NaCl, 2.38×10-3 M 
NaHCO3, 10
-5 M pCBA, 3.83×10-7 M cyclophosphamide, and 3.83×10-7 µg/L ifosfamide 
at pH 8.3. The lines labeled “model” employ the rate constants listed in Table 4-2, which 
were determined from other experiments besides those modeled here, and the Rct 
determined in Figure 4-4, which stems from analysis of pCBA concentrations in this 
experiment.  The 95% confidence intervals were calculated by propagating the 95% 
confidence intervals associated with k”O3,PhAC, k
”
HO·,PhAC, and Rct.  In this case, the rate 
constants for cyclophosphamide and ifosfamide transformation by ozone and hydroxyl 
radicals do an excellent job of describing the transformation of cyclophosphamide and 





Figure 4-5. Transformation of cyclophosphamide and ifosfamide in a system that 
demonstrates ozone and hydroxyl radical exposure.  (The solution 
composition is 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, 10
-5 M pCBA, 
3.83×10-7 M cyclophosphamide, and 3.83×10-7 µg/L ifosfamide at pH 8.3.  
The lines labeled “model” employ the rate constants listed in Table 4-2 and 




The transformation of cyclophosphamide (1.15×10-5 M) and ifosfamide 
(1.15×10-5 M) was studied in three background matrices:  (1) DI with 1.71×10-3 M NaCl, 
2.38×10-3 M NaHCO3, 10
-5 M pCBA, (2) solution (1) with 0.276 mg/L DOC (2.3×10-5 M 
as C) from Lake Austin hydrophobic organic acids (HPOA), and (3) solution (1) with 
27.6 mg/L DOC (2.3×10-3 M as C) from Lake Austin HPOA.  The pH of all solutions 
was adjusted to 8.30.  Solution 1 contained no organic matter; in solutions 2 and 3, the 
molar ratio of dissolved organic carbon (as mol C) to the total moles of 
cyclophosphamide and ifosfamide was 1 and 100 mol C (from LA HPOA) / mol PhACs, 
respectively.  pCBA was included in all solutions to determine the hydroxyl radical 
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exposure associated with specific applied ozone doses.  Incremental volumes of highly 
concentrated ozone from a stock solution (8.75×10-4 M O3) were added to 7-mL of 
solutions 1-3 to get applied ozone doses in the range of 0 to 1.1×10-4 M O3.  Dilution 
effects were accounted for in subsequent calculations.  Hence the data in Figure 4-6 
represents the transformation of cyclophosphamide and ifosfamide, as well as the 
hydroxyl radical exposure, obtained for a given applied ozone dose. 
 
From Figure 4-6a, the impact of the increasing concentrations of DOC from Lake 
Austin HPOA is clearly observable; as the DOC concentration increases, less 
cyclophosphamide is transformed.  The same trend exists for ifosfamide (Figure 4-6b).  
In Solution 3 (100 mol DOC (as C) / mol PhAC), the transformation efficiencies of 
cyclophosphamide and ifosfamide for an ozone dose of 9.92×10-5 M were approximately 
38% and 28%, respectively, of the transformations observed in the no DOC solution 
(Solution 1).  Hence, the impact of DOC at environmentally relevant concentrations can 
be significant for compounds that react slowly with ozone.  That impact also extends to 
advanced oxidation processes (AOPs).  The change in pCBA concentration was used to 
calculate the hydroxyl radical exposure (Eq. 4-4).  As seen in Figure 4-6c, the hydroxyl 
radical exposure observed in Solution 3 was significantly lower than that in Solutions 1 
and 2.  For the ozone dose discussed above (9.92×10-5 M), the hydroxyl radical exposure 
observed in Solution 3 was only 19% of that observed in Solution 1.  For all ozone doses 
but two, the hydroxyl radical exposure in Solution 3 was 19-23% of that observed in 
Solution 1; the other two samples exhibited 29% and 38% of the hydroxyl radical 
exposure.  It is important to note that although the reduction of hydroxyl radical exposure 
in the presence of DOC (Solution 3) was only 20%, the reduction of the removal of CYP 
and IFO were 38% and 28%, respectively.  Predicted removals of CYP and IFO (using 
the calculated values of hydroxyl radical exposure and known rate constants for reaction 
with hydroxyl radicals) were somewhat lower than measured removals.  For example, for 
an applied ozone dose of 9.92×10-5 M in Solution 1, the predicted CYP and IFO 
remaining were 33.1(±2.2)% and 32.6(±2.1)%, respectively; measured values of CYP 
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and IFO remaining were 38.7% and 40.3%, respectively.  Regardless, the reduction in 
hydroxyl radical exposure seems to be the major contributor to the reduced 
transformation of cyclophosphamide and ifosfamide observed in Figure 4-6.  
 
 These results are interesting in the context of the ozone demand of the NOM 
matrix.  Cyclophosphamide and ifosfamide do not react quickly with ozone; therefore, 
most of the cyclophosphamide and ifosfamide transformation observed in these 
experiments derives from reaction with hydroxyl radicals.  At a molar ratio of 1 mol C 
(from DOC) to 1 mol PhAC, the effects of NOM on hydroxyl radical exposure are minor; 
however, as that ratio shifts up to 100 mol C (from DOC) / mol PhAC, the impact of 
NOM on the treatment process becomes more important.  In this scenario, a significant 
portion of the applied ozone likely reacts with NOM; this situation results in a lower 
hydroxyl radical exposure (due to less ozone available for decomposition) and a changed 
ozone decomposition rate (due to ability for NOM to inhibit and/or propagate ozone 
decomposition; Figure 2-2).  For these reasons, it would be interesting to employ the 
continuous ozone (or peroxone) addition reactor toward CYP and IFO treatment in the 
context of how different NOM matrices affect the transformation of these compounds.  In 
Chapter 5, the ability for the continuous aqueous ozone addition reactor to treat 




Figure 4-6. The impact of three different concentrations (0, 0.28, and 27.6 mg/L 
DOC) of organic matter (Lake Austin HPOA) on (a) Cyclophosphamide 
and (b) Ifosfamide removal as a function of the applied ozone dose 
(mol/L).  (The hydroxyl radical exposure (M-s) for solutions (1)-(3) is 
plotted against the applied ozone dose in (c).  The molar ratio of LA HPOA 
(as mol C / L) to the total concentration of PhACs is 0, 1, and 100 for 
solutions (1)-(3), respectively.) 
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Intermediate Product Identification 
To study the formation and transformation of intermediate oxidation products 
generated by ozone and hydroxyl radical reaction with cyclophosphamide and 
ifosfamide, solutions containing 3.83×10-4 M of cyclophosphamide or ifosfamide were 
prepared.  Four separate solutions were employed; two (pH 2.5 and pH 9.6) containing 
cyclophosphamide and two (pH 2.5 and pH 9.6) containing ifosfamide.  All solutions 
contained 1.71×10-3 M NaCl, 2.38×10-3 M NaHCO3, and 3.83×10
-4 M of either 
cyclophosphamide or ifosfamide.  Solution pH was adjusted by adding a small volume of 
5N H2SO4 or 5N NaOH.  The low pH solutions contained 10 mM t-BuOH to isolate O3-
based transformative mechanisms.  On the other hand, 10 µM pCBA was added to the 
high pH solutions to quantify the hydroxyl radical exposure.  At pH 9.6, ozone decay 
kinetics are fairly fast (kd,O3 = 4.70×10
-2 s-1, extrapolated from Elovitz et al., 2000); the 
fast ozone decay kinetics combined with the slow reaction between ozone and 
cyclophosphamide (k”O3,CYP = 3.03 (± 0.48) M
-1s-1) and ifosfamide (k”O3,IFO = 7.38 (± 
0.27) M-1s-1) allow us to examine hydroxyl radical-initiated transformations.   
 
Small (2-mL) aliquots of each of these four solutions were dosed with incremental 
volumes of ozone stock solution (1.15×10-3 M O3), corresponding to a specific applied 
ozone dose.  The response associated with select m/z values versus the molar ratio of 
applied ozone to initial cyclophosphamide (Figure 4-7a-b) and initial ifosfamide (Figure 
4-7c-d) confirm the presence of several intermediate oxidation products.  A number of 
other intermediate oxidation products were identified; however, m/z values that did not 
demonstrate at least one data point that was at least 10% of the initial cyclophosphamide 
or ifosfamide response were not included in this analysis.  From these plots, it is clear 
that several major intermediate oxidation products are formed during the transformation 
of cyclophosphamide and ifosfamide via ozone- and hydroxyl radical-based pathways.  
Furthermore, a large overlap existed in the m/z values that were observed between ozone 
and hydroxyl radical pathways.  Given the structural similarity of cyclophosphamide to 
ifosfamide, it is not surprising that many of the m/z values for intermediate oxidation 
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products formed from cyclophosphamide transformation (Figure 4-7a-b) are also 
observed for ifosfamide oxidation (Figure 4-7c-d). 
 
 
Figure 4-7. Cyclophosphamide transformation and production of intermediate 
products as a function of the molar ratio of applied ozone to the initial 
cyclophosphamide concentration (mol O3/ mol CYP) at a.) pH 2.5 and 
b.) pH 9.6.  Ifosfamide transformation and production of intermediate 
products as a function of the molar ratio of applied ozone to the initial 
ifosfamide concentration (mol O3/ mol IFO) at c.) pH 2.5 and d.) pH 9.6.  
(All solutions also contained 100 mg/L NaCl and 200 mg/L NaHCO3; pH 
was adjusted using 5N H2SO4 or 5N NaOH.  The pH 2.5 solutions contained 
10mM t-BuOH to isolate O3-based transformative mechanisms.  The pH 9.6 
solutions contained an initial concentration of 10 µM pCBA, to quantify the 
hydroxyl radical exposure as seen in b.) and d.).) 
 
While these experiments were allowed to proceed until completion, the rate 
constants found above can provide some insight to the data.  In comparing Figure 4-7a-d, 
119 
 
it is clear that more ifosfamide is transformed for a given ozone dose as compared to 
cyclophosphamide at both low and high pH.  The molar ratios of applied ozone to initial 
PhAC corresponding to 50% transformation of cyclophosphamide (Figure 4-7a-b) and 
ifosfamide (Figure 4-7c-d) were 2.93, 4.61, 1.29, and 3.67 mol O3/ mol PhAC, 
respectively.  As expected, the ratio of the 50% transformation values for ifosfamide to 
cyclophosphamide at low pH (0.44) is similar to the ratio of the second order ratio 
constant for ifosfamide with ozone to that of cyclophosphamide with ozone (0.47).  
Additionally, the ratio of the 50% transformation values for ifosfamide to 
cyclophosphamide at high pH (0.80) is similar to the ratio of the second order ratio 
constant for ifosfamide with hydroxyl radicals to that of cyclophosphamide with 
hydroxyl radicals (0.71).  These results are consistent with the higher rate constants for 
ifosfamide transformation by ozone and hydroxyl radicals, as compared to 
cyclophosphamide. 
 
For the most part, the formation and transformation of m/z = 274.9 and m/z = 
276.9 are closely related.  These species appear to be the dominant intermediate products 
for ozone-based reaction of cyclophosphamide and ifosfamide in the range of ozone 
doses reported.  The m/z = 198.9 peak was only identified in the high pH solutions, 
suggesting that this compound is formed primarily through HO· attack on 
cyclophosphamide and ifosfamide.  One major difference between the intermediate 
products identified for cyclophosphamide transformation, as compared to ifosfamide 
transformation, is the magnitude of the m/z = 258.9 peak; the formation of this compound 
is more pronounced in cyclophosphamide oxidation for the ozone- and hydroxyl radical-
initiated scenarios.   
 
Venta et al. (2005) investigated treatment of cyclophosphamide using peroxone; 
in that study the intermediate oxidation product associated with the m/z = 274.9 peak was 
identified as 4-ketocyclophosphamide.  In this study, that peak was identified for both 
cyclophosphamide and also ifosfamide; given the structural similarity of these 
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compounds, we postulate that the m/z = 274.9 peak corresponds to 4-ketoifosfamide, 
which is formed through ozone attack on the C4 atom.  Another peak was observed at m/z 
= 276.9 for both compounds; this m/z value corresponds to the addition of one oxygen 
atom into the molecule.  Given, the production of 4-ketocyclophosphamide and 4-
ketoifosfamide, it is likely that the m/z = 276.9 peaks correspond to 4-
hydroxycyclophosphamide and 4-hydroxyifosfamide.  The m/z = 198.9 peak, which is 
only significant for the high pH solution containing ifosfamide, appears to form due to 
the loss of one chloroethyl group from the parent cyclophosphamide and ifosfamide 
structures.  An attack on the hydroxyl group of the 4-hydroxy derivative of 
cyclophosphamide or ifosfamide results in the loss of an H2O molecule and the formation 
of a double bond between the C4 and C5 atoms; this compound corresponds to m/z = 
258.9.  The proposed structures of these intermediate oxidation products are shown in 
Table 4-3.  The other major intermediate product shown in Table 4-3 is m/z = 330.9.  A 
proposed molecular formula for this compound is provided in Table 4-3; however, at this 




Table 4-3. Proposed intermediate products formed via ozonation of 







Proposed structure             
(from cyclophosphamide) 

















































































































While the m/z values shown in Figure 4-7 and Table 4-3 correspond to those 
products that demonstrated the most significant instrument response, m/z ratios of 221.0 
and 56.1 were also monitored.  These m/z values correspond to phosphoramide and 
isophosphoramide mustard (m/z = 221.0) and acrolein (m/z = 56.1).  Recall that 
cyclophosphamide and ifosfamide are prodrugs that are first metabolized into the 4-
hydroxy derivatives and then further metabolized to the active form of the drugs, 
phosphoramide mustard and isophosphoramide mustard, respectively.  The ratio of the 
response for m/z = 221.0 to the response of the initial PhAC concentration (for the 
corresponding data set) for all four data sets are plotted in Figure 4-8.  No peaks were 
observed for m/z = 56.1; however, that might be a function of the LC-MS method, which 
was optimized for cyclophosphamide and ifosfamide elution.  For cyclophosphamide and 
ifosfamide, similar trends were observed in the formation/transformation of the m/z 
=221.0 peak.  At high pH, the m/z = 221.0 peak demonstrated relatively high formation 
for molar ratios of ozone to the initial PhAC concentration ranging from 1.0‒3.5 mol O3 / 
mol PhAC.  The highest response (as a percent of the initial PhAC response) was 
approximately 5%.  As the molar ratio of ozone to cyclophosphamide/ifosfamide was 
increased the peak at m/z = 221.0 declined.  However, at low pH, no apparent formation 
of the reactive mustards occurred.  It should be noted that while the peak areas were 





Figure 4-8. Formation and transformation of m/z = 221.0, which corresponds to 
phosphoramide mustard (cyclophosphamide) and isophosphoramide 




Recently, Li et al. (2010) investigated the metabolism of cyclophosphamide and 
ifosfamide in a mouse model.  That research identified several metabolites of 
cyclophosphamide and ifosfamide, including those discussed above, with the exception 
of m/z = 330.9.  The overlap between the intermediate products identified in this study 
with the metabolites found in Li et al.’s (2010) work is of special interest because it 
demonstrates that ozone- and hydroxyl radical- based water treatment processes have the 
potential to replicate metabolic transformative processes in terms of what products are 
formed.  In fact, Hohorst et al. (1976) employed ozone to synthetically generate the 4-
hydroxy derivatives, 4-hydroxycyclophosphamide and 4-hydroxyifosfamide (Low et al., 
1983; Fleming, 1997).  Furthermore, the chloroethyl group, lost from cyclophosphamide 
and ifosfamide during formation of the m/z = 198.9 peak, may form chloroacetaldehyde, 
which is a known alkylating agent (Guengerich et al., 1979).  The potential for ozonation 
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to form pharmacologically active intermediate products is a topic of debate in the field of 
environmental engineering.  For prodrugs, this scenario is of increasing interest due to the 
potential of water treatment to actually increase the toxicological activity of a water.  
Here, initial characterization of intermediate oxidation products resulting from ozonation 
of cyclophosphamide and ifosfamide was described; the literature suggests that some of 
these compounds can exert pharmacological activity.  These results suggest that further 
research to explore the residual pharmacological activity of cyclophosphamide and 
ifosfamide intermediate oxidation products throughout ozone treatment processes is 
justified.  Attempts were made to measure the residual pharmacological activity of 
treated solutions containing cyclophosphamide and ifosfamide; however, the 
corresponding cytotoxicity assay was never successfully employed (Appendix D). 
 
In the next Chapter, the residual pharmacological activity associated with 
ciprofloxacin and its intermediate oxidation products was measured and the results were 
used to draw conclusions regarding the ability of intermediate oxidation products to 





Figure 4-9. Typical LC-MS peaks for (a) cyclophosphamide and phosphoramide 
mustard and (b) ifosfamide and isophosphamide mustard.  (The total ion 
current for these samples are provided for magnitude comparison.  The 
sample demonstrated in (a) corresponds to a sample containing 1.71×10-3 M 
NaCl, 2.38×10-3 M NaHCO3, 10
-5 M pCBA, and 3.83×10-4 M 
cyclophosphamide (at pH 9.6) that was dosed with 1.53 mol O3 / mol CYP.  
In (b), the sample contained the same background compounds, but with 
3.83×10-4 M ifosfamide rather than cyclophosphamide; the ozone dose for 





CHAPTER 5: EFFECTS OF NATURAL ORGANIC MATTER ON 




Elimination of the fluoroquinolone antibiotic, ciprofloxacin, was evaluated during 
aqueous ozonation in the presence of natural organic matter from various sources.  The 
impacts of natural organic matter (NOM) concentration, source (Lake Austin, TX and 
Claremore Lake, OK), and composition (hydrophobic organic acids and transphilic 
organic acids) on ciprofloxacin transformation were determined.  Additionally, the 
residual pharmacological activity of treated samples was determined using an 
antimicrobial susceptibility assay.  Two metrics, ciprofloxacin transformed and 
antimicrobial activity eliminated, were used to describe treatment efficiency.  Each NOM 
source, at equivalent dissolved organic carbon (DOC) concentrations, was found to alter 
the applied ozone dose required to remove 50% of the initial ciprofloxacin and 
antimicrobial activity.  DOC concentration and NOM composition also affected the 
required applied ozone dose.  The inhibition profile of treated samples suggests that 
pharmacologically active intermediate oxidation products were formed during treatment. 
 
Key words: ciprofloxacin, natural organic matter, ozone, antimicrobial activity, 










Ciprofloxacin, a second generation fluoroquinolonic antibiotic, has been detected 
in water supplies around the world (Golet et al., 2002; Kolpin et al., 2002; Zuccato et al., 
2005; Larsson et al., 2007).  Ciprofloxacin inhibits the DNA gyrase and topoisomerase 
IV enzymes, which are involved in the DNA replication process of many microorganisms 
(Drlica and Zhao, 1997).  The widespread detection of ciprofloxacin in water supplies 
reflects its longstanding popularity as a prescribed drug (Prescription, 2009); by 2006, 
ciprofloxacin had recorded a lifetime sales profit of $19 billion dollars (Finch and Hunter, 
2006).  The structure and properties of ciprofloxacin are shown in Table 5-1. 
 
Table 5-1. Salient properties of ciprofloxacin and depiction of structure-activity 
relationship for quinolones. 
Property Ciprofloxacin 
Generalized Quinolone 








Molecular Weight (g/mol) 331.35 
pKa1 6.2 
pKa2 8.8   
 
 
Due to ciprofloxacin’s widespread popularity and use, it is not surprising that 
ciprofloxacin has been detected in raw wastewater, treated wastewater, and surface 
waters (Golet et al., 2002; Kolpin et al., 2002; Zuccato et al., 2005; Larsson et al., 2007).  
Golet et al. (2002) tracked ciprofloxacin concentrations in raw wastewater (300-600 
ng/L), treated wastewater (60-110 ng/L), and in downstream river locations (5-18 ng/L) 
throughout the Glatt River Valley in Switzerland.  Similarly, Zuccato et al. (2005) found 
ciprofloxacin concentrations as high as 251 ng/L in wastewater effluents and 14-26 ng/L 
in two Italian river systems.  A 2002 USGS study (2002) identified ciprofloxacin in three 
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of the 139 surface water sampling locations across the continental United States; the 
highest concentration detected was 30 ng/L.  In at least one case, high ciprofloxacin 
concentrations have been discharged to the environment; specifically, Larsson et al. 
(2007) found 28-31 mg/L of ciprofloxacin in effluent from an industrial wastewater 
treatment plant near Hyderabad, India. 
 
The release of pharmacologically active compounds (PhACs), such as 
ciprofloxacin, into the environment is thought to have negative effects on environmental 
and human health.  Pomati and coworkers (2006; 2008) have investigated the effects of 
13 pharmaceuticals on Escherichia coli, human embryonic kidney, and human ovarian 
carcinoma cells.  These investigators found that environmentally relevant levels of 
pharmaceuticals can inhibit the proliferation of human embryonic kidney cells by up to 
30% (Pomati et al., 2006) and that the pharmacological activity of drug mixtures can vary 
from that predicted solely on the basis of additive effects for individual compounds 
(Pomati et al., 2008).  While the impact of trace levels of pharmaceuticals on human 
development is still widely debated, concern over the contribution of low levels of 
antibiotics in wastewater to the acceleration of antibiotic resistance is increasing 
(Kummerer, 2004).  Evidence of antibiotic resistant organisms and antibiotic resistance 
genes in wastewater and wastewater treatment plants (Schwartz et al., 2003; 
Szczepanowski et al., 2009) corroborates these concerns.  Finally, increasing attention is 
being paid to characterization of the sub-lethal effects on bacterial cells caused by 
PhACs, and antibiotics in particular; the ability of antibiotics to act as signaling agents 
may have negative environmental impacts (Davies et al., 2006; Fajardo and Martínez, 
2008). 
 
With the emerging concern over this class of contaminants, several research 
efforts have focused on removing pharmaceuticals from water using a variety of 
separation treatment processes: ion exchange, activated carbon, or membrane-based 
technologies (Adams et al., 2002; Westerhoff et al., 2005; Xu et al., 2005).  While 
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reverse osmosis treatment provided good removal (>90%) of all test compounds, the 
other processes offered widely variant removal efficiencies (0-98%) due to the range of 
polarity and hydrophobicity of different pharmaceutical compounds.  However, process 
flexibility, ease of installation, and competitive economics have propelled oxidation 
processes to the forefront of this emerging field. 
 
Given the superior capabilities of oxidation processes for treatment of trace 
organic contaminants, several research efforts have focused on the ability of ozone and 
ozone-based advanced oxidation processes to remove PhACs from water and wastewater 
streams.  Huber et al. (2003) investigated the ability of aqueous ozone to treat nine 
pharmaceuticals in batch reactors; their results indicated that pharmaceutical structure, 
solution alkalinity, and the dissolved organic carbon (DOC) concentration of the water 
source are the most important variables in determining the percent of parent compound 
transformed during batch ozonation.  Ternes and coworkers (2002; 2003) conducted full- 
and pilot-scale studies with various ozone-based advanced oxidation processes (AOPs) 
and showed successful removal of over twenty pharmaceuticals.  Hua et al. (2006) 
operated two side-by-side pilot plants, one with coagulation, flocculation, and 
sedimentation followed by GAC filtration and the other with pre-ozonation before the 
same processes.  The pilot plant containing ozone treatment demonstrated better removal 
of the four PhACs (carbamazepine, cotinine, caffeine, and atrazine). 
 
Because of its widespread popularity and use, ciprofloxacin has emerged as a 
model PhAC and has been previously studied in the context of ozone-based treatment 
processes (Dodd et al., 2006; DeWitte et al., 2008; DeWitte et al., 2009; Dodd et al., 
2009).  The reaction kinetics of ciprofloxacin with ozone and hydroxyl radicals has been 
studied in gaseous addition (DeWitte et al., 2009) and liquid addition (Dodd et al., 2006) 
schemes.  Dodd et al. (2006) observed significant variations in the second order (i.e., first 
order with respect to both ozone and ciprofloxacin) rate constants for the protonated 
(dominant at pH < 6.2), zwitterionic (dominant at 6.2 < pH < 8.8), and deprotonated 
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(dominant at pH > 8.8) ciprofloxacin species:  4.0×102 M-1s-1, 7.5×103 M-1s-1, and 
9.0×105 M-1s-1, respectively.  The second order rate constant for ciprofloxacin with 
hydroxyl radicals was determined to be 4.1×109 M-1s-1 at pH 7.  In that work, Dodd et al. 
(2006) postulate that ozone and hydroxyl radicals attack ciprofloxacin at sites other than 
the pharmacophore (see Table 5-1 for the structure-activity relationship for 
fluoroquinolones).  This hypothesis is of great interest due to the potential for 
pharmaceutical metabolites and intermediate oxidation products (i.e., those compounds 
formed as products of PhAC reaction with ozone or hydroxyl radicals) to exert the same 
pharmacological activity as the original parent compound in environment systems. 
 
Lemke and Williams (2008) delineated the structure-activity relationship for 
quinolonic compounds, as seen in Table 5-1.  The pharmacophore is the core structure 
required for the compound to exert pharmacological activity; furthermore, three 
important functional groups that determine the pharmacological capabilities of the 
compound.  The R6 group contributes to the ability of the compound to penetrate cell 
walls; fluoroquinolones, such as ciprofloxacin, have a fluoro group at R6.  The R7 group 
relates to the compound’s spectrum of activity, i.e., this functional group establishes what 
microorganisms will be affected by the compound.  The R group determines the relative 
potency of the compound.  Recent work by DeWitte and coworkers (2008; 2009) 
suggested structures for intermediate oxidation products formed during gaseous 
ozonation of ciprofloxacin.  Of the twelve intermediate oxidation products determined by 
DeWitte et al. (2008), all twelve structures retained the fluoro group on R6, all twelve 
compounds retained the same potency group as ciprofloxacin, and six intermediate 
oxidation products retained the pharmacophore.  The majority of oxidative 
transformations target the piperazinyl group (R7) (DeWitte et al., 2008; 2009), which 
may change the spectrum of microorganisms affected by the compound but does not 
necessarily remove pharmacological activity.  Therefore, the potential for formation of 




In the past few years, several researchers (Suarez et al., 2007; Baeza, 2008; Dodd 
et al., 2009; Paul et al., 2010) have used an antimicrobial susceptibility assay (NCCLS, 
2004) to describe treatment efficacy in terms of pharmacological activity.  Suarez et al. 
(2007) treated triclosan with aqueous ozone and showed that antibacterial activity against 
E. coli ATCC 23716 closely followed triclosan concentration.  Baeza (2008) used this 
assay (with E. coli ATCC 25922) in combination with UV photolysis and photochemical 
UV/H2O2 treatment of four antimicrobials to demonstrate that the impact of the 
background water matrix varied depending on the treatment conditions.  Dodd et al. 
(2009) employed an antimicrobial susceptibility assay (with E. coli ATCC 23716 and 
Bacillus subtilis ATCC 6051) to track the pharmacological activity of 14 antimicrobial 
compounds, including ciprofloxacin, during ozone treatment; in this work, the authors 
concluded that ciprofloxacin intermediate products did not demonstrate any quantifiable 
antimicrobial activity.  These findings seemingly contradict the hypothesis put forth in 
Dodd et al.’s earlier work (2006), which suggested that because ozone and hydroxyl 
radicals mainly attack at ciprofloxacin’s piperazinyl group (R7, spectrum of activity) the 
intermediate oxidation products may demonstrate antimicrobial activity.  A recent paper 
by Paul et al. (2010) indicates that ciprofloxacin degradation products from photolytic 
(UV) and photocatalytic (UV-TiO2) processes exert some antimicrobial activity against 
E. coli ATCC 23716.  In summary, many questions still surround the pharmacological 
activity of ciprofloxacin’s intermediate oxidation products. 
 
The objectives of the present study were threefold: (1) to determine the impact of 
different NOM matrices on ciprofloxacin transformation by continuous addition of a 
high-strength aqueous ozone solution, (2) to employ an antimicrobial activity assay to 
track residual antimicrobial activity throughout treatment, and (3) to compare 
ciprofloxacin transformation with elimination of antimicrobial activity.  This work should 
be considered an extension of the work already performed by others (Dodd et al., 2006; 
DeWitte et al., 2008; DeWitte et al., 2009; Dodd et al., 2009; Paul et al., 2010) on 
ciprofloxacin oxidation.  The data presented in this paper offers key insights on the use of 
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ozone for transformation of ciprofloxacin and removal of residual antimicrobial activity, 
in the presence of NOM.  This two-pronged approach of measuring ciprofloxacin 
concentration and residual antimicrobial activity allows determination of the treatment 
required to remove pharmacological activity and provides a framework for treatment of 
other antimicrobial PhACs encountered in water treatment plants. 
 
MATERIALS AND METHODS 
 
Chemicals and stock solutions.  Stock solutions of ciprofloxacin were prepared at 10 
mg/L in deionized water and stored in the dark at 4°C.  HPLC-grade acetonitrile (ACN) 
and ACS-grade phosphoric acid (H3PO4) were used for HPLC analysis of ciprofloxacin.  
Mueller-Hinton broth (MHB) was purchased in powder form and was prepared according 
to the manufacturer’s guidelines, autoclaved at 121°C for 20 minutes, and stored in the 
dark at 4°C. 
 
Natural organic matter sources.  NOM was isolated from Lake Austin (Austin, TX) 
and Claremore Lake (Claremore, OK) using the procedures described by Aiken et al. 
(1992).  Lake Austin NOM was available as the hydrophobic organic acids (HPOA) 
fraction, which was isolated using XAD-8 resin.  Organic matter isolation of the 
Claremore Lake NOM was completed with XAD-8 followed by XAD-4.  The XAD-8 
isolate represents the HPOA fraction and contains aliphatic carboxylic acids of 5-9 
carbons, one- and two-ring aromatic carboxylic acids, one- and two-ring phenols, and 
aquatic humic substances.  The XAD-4 isolate contains the transphilic organic acids 
(TPIA), i.e., polyfunctional organic acids and aliphatic acids with five or fewer carbon 
atoms.  Characteristics, including SUVA254, of the NOM and HPOA / TPIA isolates are 




Table 5-2. Source water and NOM characteristics. 
Parameter Claremore Lake Lake Austin 
pH 7.52 8.01 
Alkalinity (mg CaCO3/L) 57 164.5 
DOC (mg/L) 6.4 3.5 
SUVA254 (L/mg-m) 2.89 1.76 
HPOA (%) 45 35 
HPOA SUVA254 (L/mg-m) 3.7 2.9 
TPIA (%) 19 20 
TPIA SUVA254 (L/mg-m) 2.9 1.7 
 
Ozone reactor setup.  Oxygen gas flowed into the ozone generator at 30 cm3/min; some 
fraction of that oxygen was converted to ozone.  This combined gas stream was directed 
into a 500-mL gas-washing bottle, which served as a stock ozone solution.  The ozone 
stock solution was kept on ice to increase the solubility of ozone.  After 4-6 hours, the 
ozone concentration in the stock solution reached a plateau at 55-65 mg/L O3.  A 
schematic of the ozone supply system and reactor is shown in Figure 3-15.   
 
Two types of ozonation experiments, namely, continuous liquid addition and 
batch, are described in this paper.  In the continuous liquid addition experiments, the 
ozone stock solution was pumped at rates between 2.2 and 4.5 mL/min into a 2-L 
solution in a closed reactor, which contained ciprofloxacin and the background matrix of 
choice.  No drop in aqueous ozone concentration was observed between the stock 
solution and the tubing entering the reactor.  Experiments were run for 30 minutes with 
continuous ozone addition from the stock solution; the flow rate of that solution was 
adjusted for different experiments to capture the treatment window of ciprofloxacin in 
different background matrices.  Changes in volume were accounted for and ciprofloxacin 
concentrations were normalized.  The applied ozone dose ([O3]applied) was computed by 
dividing the product of the flow rate of the stock solution, the ozone concentration of the 
stock solution, and the time that the sample was taken by the volume of solution in the 
reactor.   
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For the batch kinetics experiments, a small aliquot of ozone stock solution, 
corresponding to a specific ozone dose, was introduced into a 1-L reactor containing 
ciprofloxacin and the background matrix of choice.  A bottle-top dispenser with Teflon 
tubing was used to rapidly sample at small time intervals.  Two types of batch 
experiments were conducted.  The first type of experiment involved the introduction of 
10 mM t-BuOH, a recognized hydroxyl radical scavenger (Dodd et al., 2006), into the 1-
L reactor.  Hence, this experiment allows determination of the second order rate constant 
for ciprofloxacin reaction with ozone.  The apparent rate constant (corresponding to a 
specific pH) can be calculated by plotting the transformation of ciprofloxacin (ln 















 Eq. 5-1 
 
The other batch experiment employed 1 µM pCBA, which is known to react 
minimally with ozone (k”O3,pCBA = 0.15 M
-1s-1; Yao and Haag, 1991), but quickly with 
hydroxyl radicals (k”HO·,pCBA = 5.2×10
9 M-1s-1; Neta and Dorfman, 1968).  By monitoring 
the transformation of pCBA, Rct (∫[HO·]dt / ∫[O3]dt) can be determined (Elovitz and von 
Gunten, 1999).  Rct is calculated by dividing the slope of ln [pCBA]/[pCBA]o) vs. ∫[O3]dt 















 Eq. 5-2 
 
Finally, the second order rate constant between ciprofloxacin and hydroxyl 
radicals was determined by plotting ln [CIP]/[CIP]o) vs. ozone exposure for the pCBA 
experiment.  In this case, both O3 and HO· contribute to the transformation of 
ciprofloxacin, and so both terms are included in Eq. 5-3.  The slope of Eq. 5-3 can be 
manipulated to yield k”HO·,app,CIP since k
”

















 Eq. 5-3 
 
Modeling ciprofloxacin transformation in the continuous aqueous ozone addition 
reactor.  The NOM in solution exerts a large ozone demand.  Essentially, as each drop of 
ozone stock solution is introduced into the reactor, it quickly reacts with ciprofloxacin 
and the DOC matrix.  In such scenarios, hydroxyl radical exposure is negligible.  Then, 
ciprofloxacin transformation can be modeled according to Eq. 5-4. 
 
 
     3,,3 OCIPkdt
CIPd
CIPappO   Eq. 5-4 
 
[CIP] is the ciprofloxacin concentration, kO3,app,CIP is the apparent rate constant for 
ciprofloxacin reaction with ozone, and [O3] is the aqueous ozone concentration.  In this 
case, the aqueous ozone concentrations were low due to rapid ozone reaction with 
ciprofloxacin and NOM.  Then, over the course of an experiment (or until ciprofloxacin 
and the reactive fraction of the NOM matrix are exhausted), the ozone concentration in 
the reactor will remain nearly steady at a very low value.  In this case, samples were 
analyzed using the indigo blue method; however, no change in absorbance was observed, 
that is, the concentration of aqueous ozone in the reactor was below detection (6×10-8 M) 
for solutions containing DOC.  For the synthetic water (without DOC), the aqueous 
ozone concentration was directly proportional to the applied ozone dose in the region of 
ciprofloxacin transformation.  For these reasons, a proportionality constant (kprop) was 





















 Eq. 5-5 
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The aqueous ozone exposure is the integration of the aqueous ozone concentration in the 
reactor with respect to time, whereas the applied ozone exposure is the integration of the 
applied ozone dose (constant) over time.  Therefore, kprop describes the proportion of the 
applied ozone exposure that is available as aqueous ozone exposure.  Lower values of 
kprop correspond to high ozone demands from the background water matrix (i.e., NOM). 
 
Integration of Eq. 5-4 with substitution of Eq. 5-5 yields the model represented in 
Equation 5-6. 
 













exp  Eq. 5-6 
 
 Application of this model provided a good (R2 > 0.93, in all cases) fit to all 
experimental data for ciprofloxacin; that is, the curves in these figures represent fits of 
Eq. 5-6 to the data, with the only fitting parameter being kprop.   
 
Analytical procedures.  The ozone concentration of the stock solution was calculated 
directly using the absorbance at 258 nm and the molar absorptivity of ozone (3000 
M-1cm-1; Acero and von Gunten, 2000).  Aqueous ozone measurements for kinetics 
experiments were measured using the indigo blue method (Bader and Hoigné, 1981). 
 
Ciprofloxacin was measured by high performance liquid chromatography (HPLC; 
Waters 2795, Waters Corporation, Milford, MA) with a fluorescence detector; a 
Phenomenex (Torrence, CA) Luna 5u C18(2) (250×4.6mm, 5µm) column was utilized for 
analyte separation.  50-μL aliquots were injected directly into the HPLC.  The analytical 
method is based on the procedure developed by Golet et al. (2001) but several changes 
were made to optimize the response on our instrument.  The eluent gradient was 7% 
acetonitrile (ACN), 93% 25-mM H3PO4 for 2 min; 3 min ramp to 12% ACN, 88% 25-
mM H3PO4; 2 min ramp to 15% ACN, 85% 25-mM H3PO4; 3 min ramp to 20% ACN, 
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80% 25-mM H3PO4; 10 min isocratic.  The flow rate was 0.70 mL/min, and the column 
temperature was set at 40°C.  Excitation and emission wavelengths were set at 278 nm 
and 445 nm, respectively. 
 
Microorganisms.  Escherichia coli #25922 was purchased from the American Type 
Culture Collection (ATCC).  A small amount of the freeze-dried E. coli was scraped into 
10-mL of MHB and incubated in ambient air at 37°C for 24 hours.  After the incubation 
period, the E. coli suspension was mixed 1:1 with 50% glycerol and stored at -80°C.  
Before experimentation, a small amount of the frozen E. coli stock was scraped into 10 
mL of MHB and incubated aerobically at 37°C for 12-18 hours.  To prepare the 
inoculum, the stock E. coli solution was diluted with MHB to obtain the same absorbance 
(ABS) at 600 nm as a BaSO4 turbidity standard equivalent to a 0.5 McFarland standard. 
 
Antimicrobial susceptibility assay.  The antimicrobial susceptibility assay, which was 
based on the NCCLS protocol (2004), was run in 96-well microplates.  Wells were 
partially filled with 50 μL of either a standard containing a known concentration of 
ciprofloxacin in the background matrix of choice or a sample from ozonation 
experiments; then, 50 μL of the E. coli inoculum was added to each well.  Positive 
growth controls consisted of 50 μL of the background matrix without the drug and 50 μL 
of inoculum; negative growth controls contained 50 μL of the background matrix and 50 
μL of MHB.  All standards and samples were prepared in triplicate.  Microplates were 
covered in Parafilm to prevent evaporative water loss and incubated in ambient air at 
37°C for 20 hours, while being shaken at 75 rpm; no condensation appeared on the inside 
of the Parafilm.  After this incubation period, plates were shaken for 5 minutes in a 
microplate reader (BioTek), and the wells were aspirated using a micropipette.  The 
absorbance at 600 nm was recorded.  The absorbance at 600 nm for the positive/negative 




 This assay has been employed previously in two different ways to describe the 
removal of antimicrobial activity associate with antimicrobial compounds throughout 
water treatment processes.  Some researchers (Dodd et al., 2009; Paul et al., 2010) have 
serially diluted individual samples to describe residual antimicrobial activity as a 
stoichiometric measure of ciprofloxacin remaining using potency equivalents (PEQ = 
IC50,standard / IC50,sample).  This technique allows description of the residual antimicrobial 
activity for PhAC concentrations that are greater than the minimum concentration 
required to completely inhibit microbial growth, as the serial diluted samples will still 
demonstrate a spectrum of inhibitory activity.  If intermediate oxidation products do not 
contribute to the residual antimicrobial activity, the PEQ data should be equivalent to the 
fraction of ciprofloxacin remaining in solution ([CIP]/[CIP]o); however, if intermediate 
oxidation products exert some antimicrobial activity, then the PEQ data will fall above 
the 1:1 line.  This approach is especially useful for quantifying the contribution of early 
intermediate products to residual antimicrobial activity when the concentrations of the 
parent compound and intermediates are high. 
 
 The assay has also been employed for triclosan, sulfamethoxazole, sulfamethazine, 
sulfadiazine, trimethoprim, bisphenol-A, and diclofenac without serial dilution of 
individual samples (Suarez et al., 2007; Baeza, 2008).  The variation of antimicrobial 
activity as a function of extent of treatment is measured for samples containing undiluted 
concentrations of parent and intermediate oxidation products.  In this scenario, the 
percent of E. coli inhibition (i.e., the residual antimicrobial activity) is plotted as a 
function of the aqueous concentration of the parent compound or applied ozone dose.  
Antimicrobial activity contributions from intermediate oxidation products can be 
assessed via the presence of shifts in the inhibition profile of treated samples as compared 
to the inhibition profile of standard solutions obtained from serial dilution of the parent 
compound in the background matrix.  As the focus of this research was to demonstrate 
ciprofloxacin transformation and antimicrobial activity removal in the presence of 
different background water matrices, this assay configuration was employed.   
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RESULTS AND DISCUSSION 
 
Ciprofloxacin oxidation.  Synthetic water was prepared by adding 200 mg/L NaHCO3, 
100 mg/L NaCl, and 100 μg/L ciprofloxacin to deionized water; the solution pH was 
approximately 8.3.  Two other solutions were created by adding 2 mg/L DOC and 4 mg/L 
DOC of Lake Austin HPOA to the synthetic water recipe; the pH was 8.4 for both of 
these solutions.  Ozone was applied to these solutions using the continuous liquid 
addition process described above, and represented in Figure 3-15.  The ciprofloxacin 
degradation for these three solutions as a function of applied ozone dose is shown in 
Figure 5-1.  For the synthetic water matrix (no organic matter), the aqueous ozone 
concentration was found to be directly correlated to the applied ozone dose in the region 
of ciprofloxacin transformation.  In contrast, aqueous ozone concentrations in solutions 
containing organic matter were below detection ([O3] < 6×10
-8 M) with the indigo blue 
method throughout experimentation due to the high ozone demand of the NOM; the low 
aqueous ozone concentration is discussed in more detail below.  For these reasons, the 
applied ozone dose was used as the principal descriptor of ozone introduced to the 
reactor.  The data in Figure 5-1 represent the extent of reaction for the specific ozone 





Figure 5-1. The impact of NOM source (no organic matter, Lake Austin HPOA, 
and Claremore Lake HPOA) and concentration (0, 2, and 4 mg/L DOC) 
on ciprofloxacin oxidation.  (Symbols represent experimental data; curves 




In the synthetic water (no DOC), ciprofloxacin was transformed at a low applied 
dose of ozone, with 50% removal at an applied ozone dose of approximately 0.06 mg/L.  
The water samples containing 2 and 4 mg/L DOC of Lake Austin HPOA showed 
markedly higher 50% removal treatment requirements, 0.33 and 0.54 mg/L applied O3, 
respectively.  These differences manifest because the HPOA exert an ozone demand, 
thereby decreasing the amount of ozone (and its primary degradation product, hydroxyl 
radicals) available to react with ciprofloxacin.  At higher DOC concentrations, the 
number of organic matter sites available for reaction with ozone increases yielding a 
higher degree of competition between NOM and ciprofloxacin for ozone.  Therefore, a 
smaller fraction of the applied oxidant is available for ciprofloxacin oxidation in the 
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presence of 4 mg/L DOC from Lake Austin HPOA as compared to 2 mg/L DOC, and 
higher applied ozone doses are required to remove ciprofloxacin. 
 
The results from ozonating solutions containing Claremore Lake HPOA (pH 8.4) 
are shown along with the Lake Austin HPOA data sets in Figure 5-1.  The solutions 
containing 2 mg/L DOC and 4 mg/L DOC from Claremore Lake HPOA demonstrated 
50% removal treatment requirements of 0.41 and 0.69 mg/L applied O3, respectively; 
these treatment requirements are higher than the corresponding values for the Lake 
Austin HPOA solutions.  Recall from Figure 5-1 that the SUVA254 of Claremore Lake 
HPOA (3.9 L/mg-m) is markedly greater than that of the Lake Austin HPOA 
(2.5 L/mg-m).  The data suggest a relationship between the SUVA254 of the HPOA and 
the 50% treatment requirement.  Such a relationship follows from the work of Westerhoff 
et al. (1999a), who demonstrated that the oxidant rate parameters for NOM reaction with 
ozone and hydroxyl radicals are directly related to SUVA254.  Therefore, NOM with 
higher SUVA254 are expected to exert a greater ozone demand than those with lower 
SUVA254.  Then, the increased organic matter reactivity (with respect to ozone and 
hydroxyl radicals) causes greater oxidant consumption by the Claremore Lake HPOA as 
compared to Lake Austin HPOA.  The difference in NOM reactivity with ozone results in 
less oxidant reaction with ciprofloxacin in the Claremore Lake HPOA matrix, and hence, 
less ciprofloxacin transformation for a given applied ozone dose.  Figure 5-1, then, 
demonstrates the significance of Westerhoff et al.’s (1999a) findings regarding NOM 
reactivity with ozone and hydroxyl radicals for oxidation processes targeting trace 
organic contaminants.  While these results are expected, it is interesting to note that in an 
ozone limited treatment scenario, such as that presented here, NOM can have major 
impacts (i.e., the 50% treatment requirements varied widely for the 0 mg/L DOC, 4 mg/L 
DOC from LA HPOA, and 4 mg/L DOC from CL HPOA cases:  0.06, 0.54, and 0.69 




It is interesting to consider these 50% treatment requirements as a function of the 
mass ratio of applied ozone to DOC.  While the required ozone dose depends on the DOC 
composition, mass ratios of applied ozone to DOC of 1-2 mg O3/mg DOC are generally 
recommended for ozonation processes (van der Kooij et al., 1989; Langlais et al., 1991).  
In this case, 50% removal was observed at applied ozone to DOC mass ratios ranging 
from 0.14-0.21 mg applied O3/mg DOC.  These results indicate that ciprofloxacin 
competes rather well with Lake Austin HPOA and Claremore Lake HPOA for reaction 
with ozone. 
 
The competition between NOM and ciprofloxacin for the oxidant is a function of 
the transformation kinetics of these compounds by ozone and hydroxyl radicals.  To 
demonstrate that the transformation kinetics of ciprofloxacin with ozone and hydroxyl 
radicals does not change in the presence of organic matter, kinetics tests were run in the 
absence and presence of Claremore Lake HPOA.  Figure 5-2 shows data and model fits 
for the two types of batch kinetics experiments described above.  The second order rate 
constants for ciprofloxacin reaction with ozone (k”O3,app,CIP = 1.55(±0.13)×10
4 M-1s-1 at 
pH 7.0) and hydroxyl radicals (k”HO·,app,CIP = 1.19(±0.69)×10
10 M-1s-1 at pH 7.0) do not 
significantly change in the presence of 0.5 mg/L DOC from Claremore Lake HPOA 
(k”O3,app,CIP = 1.33(±0.25)×10
4 M-1s-1; k”HO·,app,CIP = 1.32(±0.55)×10
10 M-1s-1).  No 
significant difference in the rate constants for ciprofloxacin with ozone and hydroxyl 
radicals were observed in presence/absence of NOM.  These results confirm that the 
differences between the data sets shown in Figure 5-1 derive from the oxidant demand 





Figure 5-2. Kinetics of ciprofloxacin reaction with ozone and hydroxyl radical at 
pH 7 with 1mM NaHCO3. in two solutions, one without organic matter 
and one with 0.5 mg/L DOC from Claremore Lake HPOA.  (Symbols 
represent experimental data; curves represent second-order kinetics model 
fits.  Initial ciprofloxacin concentration = 100 µg/L) 
 
 
These values are comparable to rate constants available in the literature.  For 
example, Dodd et al. (2006) found an apparent second order rate constant of 1.9×104 
M_1s-1 for the reaction between ciprofloxacin and ozone at pH 7.  An et al. (2010) 
conducted pulse radiolysis experiments to obtain a value of 2.15(±0.1)×1010 M-1s-1 for 
k”HO·,app,CIP.; contrarily, Dodd et al. (2006) reported a value of 4.1(±0.3)×10
9 M-1s-1,  The 
value found in this work, k”HO·,app,CIP = 1.19(±0.69)×10
10 M-1s-1 (at pH 7.0), falls between 
these two reported values.  Ultimately, the high rate constant for ciprofloxacin 
transformation by ozone indicates that ozone processes can effectively treat water sources 
containing ciprofloxacin; furthermore, as demonstrated above, this reaction is also 




The impact of NOM composition was also investigated using the continuous 
liquid ozone addition reactor.  Figure 5-3 shows ciprofloxacin transformation for the 
synthetic water and 2 and 4 mg/L DOC from Claremore Lake HPOA and TPIA.  The 
50% removal treatment requirement for the solutions containing 2 and 4 mg/L DOC from 
Claremore Lake TPIA were 0.29 and 0.42 mg/L applied O3, respectively, as compared to 
0.41 and 0.69 mg/L applied O3 for the solutions with 2 and 4 mg/L DOC from Claremore 
Lake HPOA.  Table 5-2 lists the SUVA254 values for the Claremore Lake HPOA and 
TPIA isolates as 3.9 and 2.5 L/mg-m, respectively.  As noted above, Westerhoff et al. 
(1999a) demonstrated that the reactivity of NOM with ozone and hydroxyl radicals is 
directly related to SUVA254.  The data in Figure 5-3, and the resulting treatment 
requirements, agree with this relationship; however, to more fully describe this 
relationship more NOM sources should be studied.  Regardless, it is clear that NOM 
composition can have a significant influence on the treatability of PhACs with ozone.  
Finally, it is important to note that the applied ozone to DOC mass ratio required for 50% 





Figure 5-3. The impact of NOM composition (hydrophobic organic acids and 
transphilic organic acids fractions) and pH (8.4 and 6.5) of Claremore 
Lake organic matter on ciprofloxacin oxidation.  (All data sets 
correspond to pH 8.4, unless otherwise noted.  Symbols represent 
experimental data; curves represent model fits using Eq. 5-6.  Initial 
ciprofloxacin concentration = 100 μg/L) 
 
 
Solution pH can also play a significant role in ciprofloxacin transformation in 
different organic matter matrices because the second-order rate constant between 
ciprofloxacin and ozone is species dependent.  Recall that the second-order rate constants 
found by Dodd et al. (2006) of the zwitterionic (6.2 < pH < 8.8) ciprofloxacin species 
with ozone is 7.5×103 M-1s-1 and that of the deprotonated (pH > 8.8) species is 9.0×105 
M-1s-1; therefore, the rate constant is almost two orders of magnitude smaller at pH 6.5 
than at pH 8.4.  A set of continuous liquid ozone addition experiments (Figure 5-3) was 
run with 100 mg/L NaCl, 200 mg/L NaHCO3, 100 µg/L ciprofloxacin, and 4 mg/L DOC 
from Claremore Lake HPOA at two distinct pH values:  6.5 and 8.4.  The data in Figure 
5-3 show that lower applied ozone doses are required to treat ciprofloxacin at pH 8.4, as 
compared to pH 6.5.  Indeed, the 50% treatment requirement increased from 0.69 mg/L at 
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pH 8.4 to 1.29 mg/L applied O3 at pH 6.5.  Even though the apparent second-order rate 
constant for the reaction between ciprofloxacin and ozone is over 30 times lower at pH 
6.5 than at pH 8.4, the ozone dose required to remove 50% of the ciprofloxacin only 
increases by a factor of approximately 1.9.  As the aqueous ozone that is introduced to the 
reactor is used rapidly (i.e., no significant buildup of aqueous ozone concentrations in the 
reactor throughout the experiment), no significant impact from the faster ozone 
decomposition rate at pH 8.4 (as compared to pH 6.5) can be expected.  That is, as an 
excess of ozone is not available, ozone reaction with NOM and ciprofloxacin outcompete 
ozone decay.  Hence, these results indicate that it is possible to effectively transform 
ciprofloxacin in the presence of high DOC concentrations for the pH range of interest 
(even when the second order rate constant with ozone varies within the 103-105 M-1s-1 
range) to water treatment processes. 
 
Inhibition profile.  The inhibition profile of ciprofloxacin can be constructed by 
performing the antimicrobial susceptibility assay over a range of ciprofloxacin 
concentrations to determine regions of inhibition, partial inhibition, and no inhibition.  In 
a specific background matrix, the inhibition profile will indicate the maximum drug 
concentration that shows no effect on the test microorganism, the minimum concentration 
that leads to complete inhibition (no growth of the microorganism), and an intermediate 
region with partial inhibition.  The ciprofloxacin inhibition profile for E. coli ATCC 
#25922 in a background matrix containing 100 mg/L NaCl, 200 mg/L NaHCO3, and 4 
mg/L of Lake Austin DOC is shown in Figure 5-4. Note that the concentrations listed on 






Figure 5-4. E.coli inhibition profiles with ciprofloxacin for standards (“without 
oxidation”) and ozonated samples (“with oxidation”).  (The curves 
represent the Hill equation fit to the data (R2 = 0.966 for both data sets); the 




The Hill curve (Equation 5-7) has been shown to describe dose-response curves 
(Suarez et al., 2007; Baeza, 2008; Dodd et al., 2009; Paul et al., 2010) for antimicrobial 









































 Eq. 5-7 
 
Imin is the minimum inhibition (0%), Imax is the maximum inhibition (100%), IC50 is the 
ciprofloxacin concentration that corresponds to 50% inhibition, Csample is the sample’s 
ciprofloxacin concentration, and H is the Hill slope.  The fitting parameters for this 
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equation are the values of IC50 and H.  GraphPad Prism (GraphPad Software, Inc.) was 
used to solve for IC50 and H.  The focus of the current discussion is on the data set 
labeled, “without oxidation”; the “with oxidation” data set is discussed subsequently.  
The values of the “without oxidation” model line in Figure 5-4 are IC50 = 9.0 µg/L and H 
= 0.42 (R2 = 0.966); the surrounding dotted lines represent the 95% confidence intervals 
determined by GraphPad Prism.  Use of this equation provides a convenient way to 
quantify the effects of other parameters (such as the treatment conditions or NOM 
content) on the inhibition profile.  Furthermore, by substituting Eq. 5-6 into Eq. 5-7, we 
can measure the antimicrobial activity (in terms of E. coli inhibition) as a function of the 
applied treatment, i.e., applied ozone dose.   
 
The most important facet of Figure 5-4 is that the relationship between 
ciprofloxacin concentration and antimicrobial activity follows a sharp S-shaped curve.  
This characteristic results in a narrow window of partial activity; for ciprofloxacin with 
E. coli #29522, that window is only about 7 μg/L wide (Figure 5-4).  For other 
pharmaceuticals and personal care products, the width of that region of partial 
antimicrobial activity may differ (Suarez et al., 2007; Baeza, 2008; Dodd et al., 2009; 
Paul et al., 2010).   
 
Removal of antimicrobial activity.  With the ability to monitor antimicrobial activity 
through the antimicrobial susceptibility assay, the relationships between applied ozone 
dose, ciprofloxacin concentration, and antimicrobial activity can be described.  Figure 5-5 
shows model fits for ciprofloxacin remaining and data and model fits for antimicrobial 
activity (as a percent of E. coli inhibition, see Eq. 5-7) as a function of the applied ozone 
dose for the synthetic and Lake Austin HPOA solutions shown in Figure 5-1.  For all 
three solutions, the antimicrobial activity remains nearly constant (100(±10)% E. coli 
inhibition) until the ciprofloxacin remaining approaches approximately 20% (i.e., 20 
µg/L) for the 0 and 2 mg/L DOC solutions and approximately 15% for the 4 mg/L DOC 
solution.  At those points, the antimicrobial activity drops from 100% to 0% over a 
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narrow window of applied ozone dose (approximately 0.1-0.2 mg/L applied O3).  The 
treatment requirements for 50% removal of antibiotic activity for the synthetic (0 mg/L 
DOC) and Lake Austin HPOA (2 and 4 mg/L DOC) solutions are shown in Table 5-3.  
Clearly, the impact of organic matter on ciprofloxacin transformation is the major cause 
for the differences in the applied ozone dose required to remove the antimicrobial activity 
from these three solutions. 
 
 
Figure 5-5. Simultaneous removal of ciprofloxacin (heavy curves; corresponding to 
the model fits from Figure 5-1) and antimicrobial activity (hollow 
symbols) in the synthetic (0 mg/L DOC) and Lake Austin HPOA (2 and 
4 mg/L DOC) solutions.  (The Hill curve (R2 > 0.91 in all cases) and 
accompanying 95% confidence bands (light curves) are shown for the 
antimicrobial activity data.  Initial ciprofloxacin concentration = 100 μg/L) 
 
 
The effects of NOM concentration, source, and composition on elimination of 
antimicrobial activity with ozone are further expounded in Figure 5-6, which shows the 
antimicrobial activity history for ciprofloxacin in the synthetic water, the Lake Austin 
150 
 
HPOA solution (4 mg/L DOC), and the Claremore Lake HPOA and TPIA solutions (4 
mg/L DOC); in all cases the R2 associated with the Hill curve was greater than 0.91.  As 
expected from Figure 5-1 and Figure 5-3, the ciprofloxacin solution containing 
Claremore Lake HPOA requires the greatest applied ozone dose to eliminate 
antimicrobial activity; excepting the synthetic water, the lowest treatment requirement 
was observed in the Claremore Lake TPIA matrix.  The elimination of antimicrobial 
activity in the solutions containing 2 mg/L DOC exhibited lower ozone treatment 
requirements than the 4 mg/L DOC solutions and followed the same order (i.e., 
Claremore Lake TPIA < Lake Austin HPOA < Claremore Lake HPOA) in all cases; these 
data were not included in Figure 5-6 to maintain clarity. 
 
 
Figure 5-6. Elimination of antimicrobial activity in the synthetic (0 mg/L DOC), 
Lake Austin HPOA (4 mg/L DOC), and Claremore Lake HPOA and 
TPIA (4 mg/L DOC) water matrices.  (The Hill curve (R2 > 0.91 in all 
cases) and accompanying 95% confidence bands are shown.  Initial 





The treatment requirements for 50% removal of ciprofloxacin and antibiotic 
activity for the synthetic (0 mg/L DOC), Lake Austin HPOA (2 and 4 mg/L DOC), and 
Claremore Lake HPOA and TPIA (2 and 4 mg/L DOC) waters are shown in Table 5-3.  
The treatment requirements for 50% removal of ciprofloxacin correlate well to the 
treatment requirements for 50% removal of antimicrobial activity (R2 = 0.992; not 
shown).  This result would be expected if ciprofloxacin is the most potent compound 
present in solution.  The treatment required for 50% removal of ciprofloxacin and 
antimicrobial activity in the 0 mg/L DOC solution was subtracted from that of the 2 and 4 
mg/L DOC solutions.  Then, the ratio of the normalized 50% treatment requirements was 
calculated (not shown).  The ratio of the treatment requirement for 50% removal of 
ciprofloxacin in the 2 mg/L DOC solution to that of the 4 mg/L DOC solution was 
approximately 59%; for antimicrobial activity, the value of the ratio is 51%.  With only 
three NOM sources, no conclusive relationships can be made regarding these treatment 
requirement ratios; however, these data suggest that the 50% treatment requirements for 
antimicrobial activity scale relatively well with DOC concentration. 
 
Table 5-3. Applied ozone dose (mg/L) necessary for 50% removal of ciprofloxacin 
and antimicrobial activity for a variety of NOM matrices. 
Solution 
50% Removal of 
ciprofloxacin 
50% Removal of 
antimicrobial activity 
Synthetic (0 mg/L DOC) 0.06 0.11 
Claremore Lake TPIA (2 mg/L DOC) 0.29 0.45 
Lake Austin HPOA (2 mg/L DOC) 0.33 0.53 
Claremore Lake HPOA (2 mg/L DOC) 0.41 0.76 
Claremore Lake TPIA (4 mg/L DOC) 0.42 0.74 
Lake Austin HPOA (4 mg/L DOC) 0.54 1.04 
Claremore Lake HPOA (4 mg/L DOC) 0.69 1.37 
Claremore Lake HPOA (4 mg/L DOC; pH 6.5) 1.29 2.54 
 
 
Impact of intermediate products on antimicrobial activity.  While the data in Figure 
5-5 suggest that ciprofloxacin is the major contributor to antimicrobial activity in these 
experiments, the pharmacology fundamentals discussed earlier demonstrate the potential 
for forming pharmacologically active intermediate oxidation products.  This issue can be 
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more closely investigated by comparing ciprofloxacin inhibition profiles deriving from 
standards and ozonated samples.  In Figure 5-4, the “without oxidation” curve represents 
the inhibition profile of standard solutions while the “with oxidation” curve corresponds 
to the inhibition profile of treated samples.  Therefore, the “with oxidation” data 
exemplifies not only the antimicrobial activity of ciprofloxacin at the concentrations 
listed on the abscissa but also any pharmacological impact from intermediate oxidation 
products and/or treatment byproducts.  The IC50 for the “no oxidation” data set is 9.0 
μg/L, while the IC50 for the “with oxidation” data set was 6.6 μg/L.  Furthermore, the 
partially inhibited region was “stretched” in the “with oxidation” data set as evidenced by 
the smaller Hill slope value: 0.42 and 0.26 for “no oxidation” and “with oxidation,” 
respectively.  The shift in the data indicates that equivalent antimicrobial activities 
manifest in the presence of lower ciprofloxacin concentrations within ozone treated 
samples, suggesting that some other compounds are exerting pharmacological activity.  It 
should be noted that samples from control experiments run by ozonating the three NOM 
sources did not exert any antimicrobial activity, i.e., the inhibition profile and the 
resultant shift were observed for all background water matrices.  In similar experiments, 
Dodd et al. (2009) did not find evidence of pharmacologically active intermediate 
products from ciprofloxacin ozonation; however, Paul et al. (2010) recently reported that 
early ciprofloxacin intermediate products formed through photolysis (UV) and 
photocatalysis (UV/TiO2) did exert some pharmacological activity.  Both of these studies 
employed the serial dilution scheme (see Chapter 3 and Appendix C) for running the 
antimicrobial activity assay. 
 
In the serial dilution scheme employed by Dodd et al. (2009) and Paul et al. 
(2010), ciprofloxacin concentrations are being serially diluted, but so are intermediate 
oxidation products.  As the region of partial inhibition for ciprofloxacin is narrow 
(approximately, 7 µg/L), it is reasonable to assume the region of partial inhibition for 
intermediate products is also narrow.  Hence, if the antimicrobial potency of intermediate 
oxidation products is less than that of the parent compound and the inhibition profile is 
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sharp, any antimicrobial activity stemming from the presence of intermediate oxidation 
products may be masked in the serial dilution scheme.  This is an important point, 
because it acknowledges the utility of the serial dilution scheme for employing the 
antimicrobial activity assay at high antibiotic concentrations but it also suggests that the 
employment of this technique at lower drug concentrations may mask the contributions of 
intermediate oxidation products to the ultimate antimicrobial activity.  For ciprofloxacin, 
the serial dilution scheme is more useful at ciprofloxacin concentrations greater than 11 
µg/L, and the direct antimicrobial activity measurement scheme is most useful at 
concentrations lower than 11 µg/L. 
 
Another reason for the difference between our results and those of Dodd et al. 
(2009) lies in the inherent difference in the initial ciprofloxacin concentration employed.  
In the Dodd et al. (2009) and Paul et al. (2010) papers, the initial ciprofloxacin 
concentration was 330-1650 and 33,100 µg/L, respectively; we used initial ciprofloxacin 
concentrations of 100 µg/L.  In the Paul et al. (2010) paper, the data suggests a slight 
contribution of intermediate oxidation products to the residual antimicrobial activity; 
however, Dodd et al. (2009) saw no impact from ciprofloxacin’s intermediate oxidation 
products.  This difference may be due to the initial ciprofloxacin concentrations 
employed.  The higher initial concentration in the Paul et al. (2010) study would result in 
higher concentrations of intermediate oxidation products.  Therefore, dilution of those 
samples would result in greater intermediate oxidation product concentrations being 
introduced into the assay, allowing the contribution of those products to the residual 
antimicrobial activity to be observed.  Although our initial ciprofloxacin concentration 
(100 µg/L) was lower than that employed in the Dodd et al. (2009) and Paul et al. (2010) 
papers, intermediate oxidation products were not diluted and, therefore, the contribution 
of those compounds to the residual antimicrobial activity was observed.  Both methods 
for running the antimicrobial activity assay have merit and provide meaningful data; 
however, it is clear that the best method for characterizing the antimicrobial potency of 
intermediate products is through isolation of those compounds and developing their 
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individual inhibition profiles.  For that reason, further investigation is necessary to 
positively identify the cause for the shift in the inhibition profile of partially treated 
samples observed in Figure 5-4. 
 
The organic matter source, concentration, and composition have all been shown to 
impact ciprofloxacin transformation in ozonation.  That impact significantly affects the 
removal of antimicrobial activity.  Furthermore, the presence of pharmacologically active 
intermediate oxidation products has been shown to be theoretically possible, and the data 
presented above suggests that active intermediate products are present in experimental 
samples.  The combined determination of ciprofloxacin concentration and antimicrobial 
activity throughout treatment provides a useful metric for determining the treatment 
requirement.  Ultimately, the application of an ozone model that incorporates the kinetics 
of ozone decomposition and oxidation of NOM should be able to predict destruction of 
parent PhACs; however, the development of such a model will eventually have to include 










CHAPTER 6: OZONATION OF ERYTHROMYCIN:  RATE CONSTANTS, 




Ozone experiments were run with erythromycin A, which is the only antibiotic/ 
antimicrobial compound listed on the US EPA Candidate Contaminant List 3.  The rate 
constant for erythromycin A transformation by ozone was found to be 4.36(±0.14)×106 
M-1s-1.  Additionally, the rate constant for anhydroerythromycin A, the common form of 
erythromycin present in the environment, with ozone was determined to be 
6.00(±0.25)×106 M-1s-1.  The dominant intermediate oxidation products for erythromycin 
A and anhydroerythromycin A were determined to be erythromycin A N-oxide and 
anhydroerythromycin A N-oxide.  An antimicrobial activity assay was employed to 
determine the inhibition profile of erythromycin A against E. coli (ATCC 25922), and an 
IC50 of approximately 4.87(±0.55)×10
-5 M was determined.  Treated samples were 
introduced to an antimicrobial activity assay; however, the presence of intermediate 
oxidation products did not alter the residual antimicrobial activity, that is, the 
intermediate oxidation products were not pharmacologically active.  Ozonation 
effectively removed the antimicrobial activity associated with erythromycin A; 
furthermore, the antimicrobial activity of anhydroerythromycin A was determined to be 
negligible.  That fact, along with the irreversible formation of anhydroerythromycin A 
(from erythromycin A), downplay the need for treatment of anhydroerythromycin A.  
 
Key words: erythromycin A, anhydroerythromycin A, ozone, residual antimicrobial 
activity, reaction kinetics, intermediate oxidation products 




The U.S. Environmental Protection Agency recently released its Candidate 
Contaminant List 3 (CCL3; EPA, 2009).  Of the 104 chemical compounds present on that 
list, erythromycin is the only antimicrobial; most compounds are pesticides, herbicides, 
insecticides, or estrogenic chemicals (EPA, 2009).  Erythromycin is a macrolide 
antimicrobial compound containing a large 14-membered lactone ring with two sugar 
moieties (C-3 L-cladinose and C-5 D-desosamine).  Under environmental conditions, 
erythromycin exists as two major forms:  erythromycin A, which is the conventional 
structure of erythromycin, and anhydroerythromycin A, which is an acid-catalyzed 
degradation product of erythromycin A.  Salient information for erythromycin A and 
anhydroerythromycin A is presented in Table 6-1.  In this paper, erythromycin 
corresponds to the total erythromycin (i.e., the sum of erythromycin A and 
anhydroerythromycin A) present in solution; however, the individual behavior of 
erythromycin A and anhydroerythromycin A throughout treatment processes is also 
described.   
 
Table 6-1. Salient information for erythromycin. 
Property Erythromycin A Anhydroerythromycin A 
Chemical Formula C37H67NO13 C37H65NO12 
Molecular Weight (g/mol) 733.93 715.92 




pKa 8.8 8.8 * 



































































Erythromycin was discovered in 1952 when it was isolated from the metabolic 
products of a strain of Streptomyces erythreus (McGuire et al., 1952).  Since the 
discovery of erythromycin, a number of other macrolide compounds have been 
developed, including clarithromycin (1970s), azithromycin (1980), roxithromycin (1987), 
and telithromycin (1998), among others; generally, for the most part macrolides 
containing 14-membered rings are employed in the United States, whereas 16-membered 
rings are popular in Europe (Lemke and Williams, 2008).  Over 2000 macrolides have 
been identified, including at least 153 and 362 compounds with 14- and 16-membered 
rings, respectively; research into the isolation and synthesis of new macrolide compounds 
is ongoing (Omura, 2002).  Regardless of the development of these other macrolides, 
erythromycin is one of the most successful drugs of all time (Pal, 2006).  Erythromycin is 
used to treat bacterial infections like bronchitis; diphtheria; Legionnaires’ disease; 
pertussis; pneumonia; and ear, urinary tract, and skin infections (Wishart et al., 2008).  
Macrolides are bacteriostatic and work by binding to the 23S rRNA in the 50S 
subparticle and thereby inhibit production of peptidyltransferase (Mao and Robishaw, 
1972).  Lemke and Williams (2008) indicated that the C-5 D-desosamine moiety is 
particularly important in inhibition, and that removal of the C-3 L-cladinose results in an 
100-fold decrease in biological activity.  Therefore, ozone attack at these sites is likely to 
significantly decrease the ultimate antimicrobial activity of solutions containing 
erythromycin. 
 
With an annual production of approximately 4000 tons (Minas, 2004), 
erythromycin is one of the most popular macrolides prescribed.  Given that popularity, it 
is not surprising that trace concentrations of erythromycin have been detected in 
wastewater supplies.  Hirsch et al. (1999) detected 6 µg/L of erythromycin in a German 
sewage treatment plant.  In a critical review by Oulton et al. (2010), erythromycin was 
shown to exhibit one of the lowest removal efficiencies of the 43 compounds investigated 
in traditional wastewater treatment plants; therefore, erythromycin is expected to pass 
through wastewater treatment and enter the environment.  In a 2002 US Geological 
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Survey (USGS) survey, erythromycin was detected at 21.5% of the 139 streams tested; 
the maximum erythromycin concentration detected was 1.70 µg/L (Kolpin et al., 2002).  
Only one antibiotic (trimethoprim) exhibited a higher detection frequency (27.4%; 
Kolpin et al., 2002).  In another USGS-sponsored study, Kinney et al. (2006) measured 
erythromycin concentrations up to 611 ng/L in reclaimed wastewater; the soil irrigated 
with that reclaimed wastewater demonstrated erythromycin concentrations of 1-6 ng/g.  
Given the widespread presence of erythromycin in the environment and the listing of 
erythromycin on the EPA CCL3, investigation of water treatment processes aimed at 
removing erythromycin is merited. 
 
Ozone-based treatment processes have demonstrated potential for transforming 
erythromycin.  In their landmark paper, Ternes et al. (2003) treated 0.62 µg/L 
erythromycin in sewage treatment plant effluent to below 50 ng/L with an ozone dose of 
5 mg/L.  Westerhoff et al. (2005) investigated the abilities of several water treatment 
processes to remove trace organic contaminants from water supplies; approximately 33%, 
54%, and 97% of erythromycin was removed through addition of alum, addition of 
powdered activated carbon, and ozonation, respectively.  Erythromycin has also been 
shown to be more effectively treated using conventional ozonation as compared to 
advanced oxidation through the peroxone (O3/H2O2) system (Lin et al., 2009).   
 
Some research efforts have identified the rate constants for other macrolide 
compounds with ozone and hydroxyl radicals (Huber et al., 2005; Dodd et al., 2006; 
Lange et al., 2006); however, to our knowledge, the kinetics of erythromycin 
transformation with ozone have not been reported previously.  Lange et al. (2006) 
reported that the free tertiary amine present on the D-desosamine moiety of most 
macrolide antibiotics (including erythromycin, clarithromycin, roxithromycin, and 
azithromycin, among others) reacts with ozone with a rate constant near 4×106 M-1s-1; 
that site is the main ozone attack site and controls the kinetics of the transformation of 
most macrolides with ozone.  In that same paper, Lange et al. (2006) provided the 
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apparent second order rate constant of clarithromycin with ozone at pH 7 as 7×104 M-1s-1.  
The literature yields pKa values for clarithromycin ranging from 8.6–9.0 (Gustavson et 
al., 1995; Liu and Ren, 2006), meaning that the specific rate constant for clarithromycin 
with ozone is 2.9–7.1×106 M-1s-1.  The specific rate constants for roxithromycin (k”O3,RX = 
1.0(±0.1)×107 M-1s-1) and azithromycin (k”O3,AZ = 6.0(±1.1)×10
6 M-1s-1) were reported by 
Dodd et al. (2006).  The apparent rate constant for roxithromycin at pH 7 was listed as 
7×104 M-1s-1 by Huber et al. (2005); taking the pKa of roxithromycin (pKa = 8.8) into 
account, the specific rate constant for roxithromycin would be 4.49×106 M-1s-1.  
Discrepancies exist between the rate constants for macrolide interaction with ozone 
reported in the literature; however, Lange et al.’s (2006) prediction that these rate 
constants would be clustered around 4×106 M-1s-1 seems to be consistent. 
 
Increasingly, antimicrobial activity assays have been employed to describe 
treatment of antimicrobial pharmaceuticals and to determine if intermediate oxidation 
products exert antimicrobial activity (Suarez et al., 2007; Baeza, 2008; Dodd et al., 2009; 
Paul et al., 2010).  Dodd et al. (2009) investigated ozonation of other macrolide 
compounds, namely, roxithromycin, azithromycin, and tylosin.  The chemical structures 
of roxithromycin and azithromycin are similar to that of erythromycin A.  For most 
macrolides, the free tertiary amine located on the desosamine moiety (see Table 6-1) 
represents the primary ozone attack site.  Using the serial dilution technique, Dodd et al. 
(2009) concluded that intermediate oxidation products formed via ozonation of the 
macrolides listed above did not exert any significant residual antimicrobial activity.  To 
our knowledge, no work has been completed regarding the elimination of antimicrobial 
activity of erythromycin in water treatment processes.  In this paper, the intermediate 
oxidation products of erythromycin transformation by ozone are identified, and the 
theoretical antimicrobial activity of those products is compared with measured values of 
residual antimicrobial activity.  Therefore, this paper provides the first documentation of 
how the antimicrobial activity associated with erythromycin, and erythromycin 
intermediate oxidation products, changes throughout ozone treatment. 
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Given the documented evidence of erythromycin presence in water supplies, as 
well as the importance of erythromycin with regard to the EPA CCL3, erythromycin 
transformation in an ozone-based water treatment process was studied.  In this work, we 
discuss the importance of erythromycin speciation between erythromycin A (EA) and 
anhydroerythromycin A (AEA) from environmental detection and antimicrobial activity 
standpoints, the transformation kinetics of EA and AEA with aqueous ozone, the 
characterization of primary oxidation products formed through ozone reaction with EA 
and AEA, and the residual antimicrobial activity of treated waters containing EA, AEA, 
and their intermediate oxidation products.  Ultimately, we hope to demonstrate effective 
treatment of erythromycin using ozone-based processes not only in terms of 
erythromycin transformation, but also in terms of elimination of residual antimicrobial 
activity. 
 
MATERIALS AND METHODS 
Chemicals.  Erythromycin (50 mg/mL in ethanol) was purchased from VWR; that 
solution was kept in a dark environment at -20°C.  Working solutions of 1 mg/mL were 
made by diluting the erythromycin stock solution into DI water; working solutions were 
stored in the dark at 4°C to prevent erythromycin degradation.  LC-MS grade acetonitrile 
was employed in LC-MS and LC-MS/MS analysis of erythromycin.  LC-MS analysis 
also required 0.1% formic acid, which was made by diluting 88% formic acid with DI.  
NOM was isolated from Lake Austin (Austin, TX) and Claremore Lake (Claremore, OK) 
using the procedures described by Aiken et al. (1992).  The details of these NOM sources 
have been described earlier (Chapters 3 and 5), and as the role of NOM is not crucial to 
the results presented in this paper, the characteristics of these NOM isolates are not 
discussed here. 
 
Ozone Stock Solution and Analysis.  An ozone generator (Yanco Industries) was used 
to generate an aqueous ozone stock solution.  Oxygen gas was introduced to the ozone 
generator at a flow rate of 30 cm3/min.  The ozone generator was set to the maximum 
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setting, which resulted in a mass ozone flow rate of approximately 4.08 mg/min.  The 
combined (oxygen and ozone) gas stream was bubbled into deionized water in a 500-mL 
gas washing bottle, which was placed in an ice bath.  The temperature of the solution in 
the gas-washing bottle was approximately 0.5°C.  The aqueous ozone concentration of 
the ozone stock solution quickly increased; the ozone concentration was greater than 40 
mg/L after only 30 minutes of ozonation.  The aqueous ozone concentration continued to 
increase to approximately 60 mg/L after three hours of ozonation.  The ozone reactor is 
shown in the schematic presented in Figure 6-1a, and the development of the aqueous 
ozone concentration in the stock solution is shown in Figure 6-1b. 
 
 
Figure 6-1. (a)  Ozone reactor setup; (b) aqueous ozone concentration with time. 
 
Aqueous ozone concentrations were measured in two ways:  direct measurement 
at 258 nm and indirect measurement of indigotrisulfonate at 600 nm (Bader and Hoigné, 
1981).  The ozone concentration of the stock solution was always measured directly at 
258 nm because of the high steady state ozone concentrations reached in that reactor 
(typically, 45-55 mg/L).  For batch kinetics experimentation, the aqueous ozone 
concentrations were measured using indigotrisulfonate as an ozone probe compound.  
Indigotrisulfonate reacts quickly with ozone (k”O3,indigo = 9.4×10
7 M-1s-1; Munoz and von 
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Sonntag, 2000); therefore, as long as a molar excess of indigotrisulfonate to ozone is 
added to the solution, the indigotrisulfonate compound, which absorbs light at 600 nm, 
can be used as an ozone probe compound.  In this work, Indigo Reagent II (Standard 
Method 4-104; APHA et al., 2006) was employed to measure low (6×10-8 M < [O3] < 
1.04×10-4 M) aqueous ozone concentrations with a 4-cm quartz cuvette. 
 
Batch Experimentation.  Ozone experiments were run in two different configurations.  
In the first configuration, a predetermined ozone dose (2.92–8.32×10-6 M) was introduced 
into a 2-L reactor containing 1.36×10-6 M erythromycin and the background matrix of 
interest to determine the kinetics of erythromycin A transformation with ozone.  
Experiments were run with 10-2 M t-BuOH to isolate ozone kinetics from that associated 
with hydroxyl radicals.  The 2-L reactor was equipped with a bottle-top dispenser to 
enable rapid sampling; the first sample was generally taken approximately 11-13 seconds 
after introduction of aqueous ozone, and several samples were taken during the short 
period of one to two minutes after ozone introduction.  Samples were analyzed for 
aqueous ozone using the indigotrisulfonate method (Bader and Hoigné, 1981) and for 
anhydroerythromycin A using the LC-MS/MS method described below.   
 
The other experimental configuration consisted of adding specific applied ozone 
doses to solutions containing 1.36×10-4 M erythromycin and a background matrix of 
interest.  In this case, the predetermined ozone dose was introduced to the sample; 
samples were kept in a 21°C dark environment for at least 12 hours, allowing complete 
aqueous ozone degradation ([O3] < 6×10
-8 M).  At this time, samples were analyzed for 
residual ozone concentration using the indigotrisulfonate method (Bader and Hoigné, 
1981) to ensure complete ozone degradation; erythromycin A, anhydroerythromycin A, 
and erythromycin intermediate oxidation products were analyzed using the LC-MS 
method described below.  This experimental configuration was employed to calculate the 
rate constant for anhydroerythromycin A transformation with ozone and to identify the 
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intermediate oxidation products corresponding to ozonation of erythromycin A and 
anhydroerythromycin A. 
 
Erythromycin Analysis.  Erythromycin A was measured using an LC-MS/MS (Thermo 
Finnigan, TSQ Quantum) method based on that employed by Calamari et al. (2003).  The 
injection volume was 20 µL and the flow rate was 700 µL/min.  LC separation was 
achieved with a C18 column (Shimadzu Premier C18 5µ 150×4.6-mm); the eluent 
gradient was 100% 0.1% Formic acid (FA), 0% Acetonitrile (ACN) (0-3 min); ramp to 
88% 0.1% FA, 12% ACN (3-10 min); 75% 0.1% FA, 25% ACN (10-12 min); ramp to 
50% 0.1% FA, 50% ACN (12-12.1 min); 50% 0.1% FA, 50% ACN (12.1-16 min); ramp 
to 50% 0.1% FA, 50% ACN (16-16.1 min); 12% 0.1% FA, 88% ACN (16.1-18 min).  
The electrospray ionization tandem mass spectrometer was operated in positive ion mode.  
Method parameters include the following:  parent mass, 716.4 mg; product mass, 558.3 
mg; collision gas pressure, 1.5 mTorr; collision energy, 24 V; spray voltage, 4000 V; 
vaporizer temperature, 400 °C; sheath gas pressure, 25 psi; and auxiliary gas pressure, 5 
psi.  The parent mass of 716.4 corresponds to anhydroerythromycin A, which was formed 
from erythromycin A due to the low pH of samples containing Indigo Reagent II (from 
aqueous ozone measurement).  At low pH, erythromycin A is quickly degraded into 
anhydroerythromycin A.  Erythromycin A was eluted at 15.6 minutes. 
 
Erythromycin A and anhydroerythromycin A were also analyzed in LC-MS mode 
to characterize the formation and transformation of intermediate oxidation products 
resulting from erythromycin reaction with ozone.  The injection volume was 20 µL and 
the flow rate was 350 µL/min.  The eluent gradient was 100% 0.1% FA, 0% ACN (0-2 
min); ramp to 88% 0.1% FA, 12% ACN (2-12 min); 75% 0.1% FA, 25% ACN (12-16 
min); ramp to 50% 0.1% FA, 50% ACN (16-21 min); 50% 0.1% FA, 50% ACN (21-28 
min); ramp to 50% 0.1% FA, 50% ACN (28-30 min); 88% 0.1% FA, 12% ACN (30-35).  
The electrospray ionization tandem mass spectrometer was operated in positive ion mode 
and the m/z range of 150–1500 was monitored.  Method parameters include the 
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following:  parent mass, 734.4 mg; collision gas pressure, 1.5 mTorr; collision energy, 24 
V; spray voltage, 4000 V; vaporizer temperature, 400 °C; sheath gas pressure, 25 psi; and 
auxiliary gas pressure, 20 psi.  Erythromycin A, anhydroerythromycin A, and their major 
intermediate oxidation products were generally eluted between 25 and 29 minutes. 
 
Antimicrobial Activity Assay.  An E. coli -based antimicrobial activity assay (NCCLS, 
2004) was employed to monitor changes in antimicrobial activity throughout treatment.  
In this work, E. coli ATCC 25922 was utilized.  After purchase, a small aliquot of the 
purchased E. coli was grown in 10 mL Mueller-Hinton Broth.  After a significant growth 
period, a streak plate was run, and an inoculation loop was used to select a single colony 
forming unit from the streak plate.  Stock E. coli solutions were created in Mueller-
Hinton Broth from that original colony forming unit.  The stock solution was incubated at 
37°C in an aerobic environment until the suspension was quite turbid, at that point, the E. 
coli suspension was mixed 1:1 with 50% glycerol and stored in a dark environment at -
80°C.  During experimentation, an E. coli working solution was maintained at 37°C in an 
aerobic environment.   
 
Antimicrobial activity assays were run in 96-well microplates.  First, standards 
and samples (100 µL) were added to the microplate wells.  After the standard / sample 
solutions were added to the wells, the E. coli inoculum was prepared by diluting the E. 
coli stock solution with Mueller-Hinton Broth to attain an absorbance at 625 nm 
equivalent to a 0.5 McFarland standard.  The inoculum (100 µL) was immediately added 
to each well.  Positive and negative growth controls were created by adding the inoculum 
(100 µL) and Mueller-Hinton Broth (100 µL) to DI (100 µL), respectively.  All samples 
were run in triplicate.  Microplates were then incubated at 37°C in an aerobic 
environment for 20 hours while being shaken at 75 rpm.  After the 20-hour incubation 
period, the absorbance at 600 nm of each well in the microplate was recorded using a 
microplate reader (BioTek).  The absorbance data was converted into percent inhibition 




















Inhibition  Eq. 6-1 
 
The resulting antimicrobial activity data was analyzed using the GraphPad Prism 





Chemical Structure of Erythromycin and Erythromycin Degradation Products 
Based on the pKa for erythromycin A, the dominant species at low pH (pH < pKa 
= 8.8) would be the erythromycin molecule with a proton on the tertiary amine located on 
the desosamine sugar, resulting in the protonated form of erythromycin shown in the 
bottom right of Scheme 6-1.  In actuality, at these lower pH values, erythromycin is acid-
catalyzed to form erythromycin A enol ether and anhydroerythromycin A (Kurath et al., 
1971; Atkins et al., 1986; Cachet et al., 1989; Vinckier et al., 1989).  Cachet et al. (1989) 
described the kinetics of the system shown in Scheme 6-1.  At pH 5.83, k1, k2, and k3 
were 0.76(±0.11)×10-4 min-1, 6.23(±1.44)×10-4 min-1, 1.20(±0.02)×10-4 min-1, 
respectively (Cachet et al., 1989).  As k2 is greater than k1, the ultimate product of 
erythromycin degradation is anhydroerythromycin A.  One other important observation is 
that the reaction between erythromycin A and anhydroerythromycin A is not reversible; 
therefore, once anhydroerythromycin A is formed, no anhydroerythromycin A conversion 






Scheme 6-1. Erythromycin degradation products (adapted from Cachet et al., 1989) 




Hirsch et al. (1999) discussed the speciation of erythromycin A and 
anhydroerythromycin A and determined that environmental samples contain mostly 
anhydroerythromycin A; given the degradation kinetics described above and oral 
administration of erythromycin (exposure to acidic conditions during digestion), this 
finding is not surprising.  Previous researchers have listed anhydroerythromycin A as 
“erythromycin” or “erythormycin-H2O,” which is often incorrectly described using the 
molecular weight and CAS number of erythromycin A.  This name is slightly misleading 
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as the water molecule that is lost from erythromycin A causes drastic structural changes 
as demonstrated by the chemical structure of anhydroerythromycin A as shown in Table 
6-1 and Scheme 6-1.  Furthermore, it is important to note that environmental sampling 
and preservation techniques may result in undesired erythromycin speciation.  For 
example, the landmark report by Kolpin et al. (2002) used an LC-MS based analytical 
technique that acidified samples to pH 3 before analytical measurement, which would 
cause erythromycin A to degrade to anhydroerythromycin A.  Given the importance of 
erythromycin with respect to the EPA CCL3 list, it is important to clarify the chemical 
structures of erythromycin and degradation products that are expected to exist in the 
environment.  The implications of erythromycin speciation with respect to antimicrobial 
activity are discussed below. 
 
Erythromycin Kinetics with Ozone 
Kinetic experiments were run at several different pH values ranging from 5.35 to 
6.81.  The solutions were composed of 1.36×10-6 M erythromycin A (EA), 1×10-3 M 
phosphate buffer, and 1×10-3 M t-BuOH.  Ozone was spiked into these solutions at 
applied doses of 2.92–8.32×10-6 M.  The ozone concentration data from each experiment 
was integrated with respect to time to yield ozone exposure (∫[O3]dt).  Then, 
ln ([EA]/[EA]o) was plotted against ozone exposure.  As hydroxyl radicals were being 
scavenged by t-BuOH, Eq. 6-2 describes erythromycin A transformation. 
 
 
    EAOk
dt
EAd
EAappO 3,,3  Eq. 6-2 
 
In Eq. 6-2, [EA] is the erythromycin A concentration at time t, [O3] is the aqueous ozone 
concentration at time t, and kO3,app,EA is the apparent rate constant for erythromycin A 
with ozone at a particular pH.  Integrating Eq. 6-2 yields Eq. 6-3. 
 















This equation can be further simplified by substituting the specific rate constants for each 
erythromycin species with ozone and the ionization factor (α0 and α1) terms for the 
apparent rate constant, as shown in Eq. 6-4. 
 












ln   Eq. 6-4 
 
In this case, α0 and α1 correspond to the fraction of protonated and deprotonated, 
respectively, erythromycin A compared to the total erythromycin A present in solution. 
 
The data from the experiments described above are plotted as ln [EA]/[EA]o vs. 
ozone exposure in Figure 6-2a.  These data were modeled using Eq. 6-3; therefore, the 
slope of the trend lines fitted to each data set represents the apparent second order rate 
constant for erythromycin A at the corresponding pH value.  The apparent second order 
rate constants for erythromycin at pH 5.35-6.81 are provided in Table 6-2. 
 
Table 6-2. Apparent second order rate constants (k”O3,app,EA) for the 
transformation of erythromycin A by ozone at pH 5.35-6.81. 
Solution pH kO3,app,EA (M
-1s-1) α1 
5.35 1.89×103 3.55×10-4 
5.66 4.45×103 7.24×10-4 
6.00 7.11×103 1.58×10-3 
6.40 2.04×104 3.97×10-3 





Figure 6-2. (a) Erythromycin transformation at different pH values; (b) 
determination of specific second order rate constant for erythromycin 
with ozone.  (The solutions contained 1.36×10-6 M erythromycin, 1×10-3 M 
phosphate buffer, and 1×10-3 M t-BuOH at the pH values listed in the 
legend.  The dotted red lines represent the 95% confidence bands.) 
 
 
Previous researchers have assumed that reaction between the protonated forms of 
other macrolides (roxithromycin, azithromycin, and clarithromycin, in particular) and 
ozone is negligible (Dodd et al., 2006; Lange et al., 2006).  This assumption stems from 
work by previous researchers demonstrating low rate constants for compounds containing 
protonated amine groups with ozone (Hoigné and Bader, 1983b; Munoz and von 
Sonntag, 2000).  In contrast, ozone reacts quickly with deprotonated amine groups due to 
the presence of a lone pair of electrons on the nitrogen atom; therefore, high apparent rate 
constants between the deprotonated form of erythromycin and ozone are expected.  For 
these reasons, we considered the reaction between the protonated form of erythromycin A 
and ozone to be negligible (k”O3,EA-H+ < 1.0 M
-1s-1).  To determine the specific second 
order rate constant for erythromycin A, the data from Figure 6-2a were replotted as ln 
[EA]/[EA]o vs. the product of the ionization factor (α1) for the deprotonated form of 
erythromycin A and ozone exposure in Figure 6-2b (Eq. 6-4).  The resultant data 
collapses into one curve.  The slope of that curve is the specific second order rate 
constant for transformation of the deprotonated form of erythromycin A by ozone; the 
rate constant (± 95% confidence interval) is 4.36 (±0.14) ×106 M-1s-1. 
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Similar experiments were run to determine the rate constant of erythromycin A 
with hydroxyl radicals, which are the most important ozone degradation product in terms 
of oxidant activity.  In those experiments, 1 µM para-chlorobenzoic acid (pCBA) was 
added to the reactor solution in the place of the 10 mM t-BuOH used to isolate ozone 
kinetics.  While erythromycin A and pCBA transformation were both observed, the 
degradation of these compounds did not occur in the same time range; that is, 
erythromycin A was completely degraded before pCBA demonstrated any removal.  
Ultimately, the high reactivity of erythromycin A with ozone precludes determination of 
k”HO·,AEA using an ozone-based method.  Other authors have employed UV- and 
radiation-based methods for determination of the second order rate constants of 
wastewater derived organic contaminants with hydroxyl radicals (Dodd et al., 2009; An 
et al., 2010).  The second order rate constant for azithromycin and roxithromycin with 
hydroxyl radicals at pH 7 were determined by Dodd et al. (2006) to be 2.9(±0.6)×109 
M-1s-1 and 5.4(±0.3)×109 M-1s-1, respectively.  Given the similarity of these macrolides 
with erythromycin A and anhydroerythromycin A, we expect the rate constants with 
hydroxyl radicals for erythromycin A (and anhydroerythromycin A) would be in the same 
range, namely 2-6×109 M-1s-1. 
 
Batch experiments were run by dosing 6.0-12.7×10-5 M of ozone into solutions 
containing 4.81-13.6×10-5 M erythromycin, 2.38 ×10-3 M NaHCO3, 1.71 ×10
-3 M NaCl, 
and 10-5 M pCBA at pH 8.4.  At this pH, the initial samples, approximately 24.5% of the 
total erythromycin in solution was present as anhydroerythromycin A and the other 
75.5% was present as erythromycin A; this speciation was determined using LC-MS.  
These solutions also contained various concentrations of DOC; the mass ratio of applied 
ozone to initial DOC ranged from 0‒0.164 mg O3 / mg DOC.  In this experiment, a select 
volume of the ozone stock solution was added to each solution to correspond to a molar 
ratio of applied ozone to initial erythromycin of 1.25 mol O3 / mol ERY (ERY is the total 
erythromycin in solution, that is the sum of erythromycin A and the anhydroerythromycin 
A).  The solutions were allowed to react over the course of at least 12 hours.  Aqueous 
171 
 
ozone concentrations were measured before measuring erythromycin concentrations via 
LC-MS; all solutions showed no ozone residual after the 12-hour reaction period.  The 
samples were analyzed in LC-MS mode and erythromycin A and anhydroerythromycin A 
concentrations were measured.  The normalized erythromycin A and 
anhydroerythromycin A (anhydroerythromycin A response divided by the initial 
erythromycin A response) remaining are plotted against the mass ratio of applied ozone 
to initial DOC in Figure 6-3.  The rapid reaction kinetics of erythromycin and DOC with 
ozone effectively quenched aqueous ozone before ozone decomposition to hydroxyl 
radicals occurred, i.e., no hydroxyl radical exposure was observed for any of the samples.  
Furthermore, the rapid transformation kinetics of erythromycin with ozone allowed 
highly effective erythromycin competition with DOC for reaction with ozone; for that 
reason, minimal differences were observed between the three DOC sources. 
 
  
Figure 6-3. Changes in erythromycin and anhydroerythromycin concentrations as 
a function of the mass ratio of applied ozone to DOC concentration.  
(The molar ratio of applied ozone to initial erythromycin was held constant 
at 1.25 mol O3 / mol ERY (ERY is the total erythromycin in solution, that is 
the sum of erythromycin A and the anhydroerythromycin A).  The 
background water quality matrix contained 1.36×10-6 M erythromycin, 2.38 
×10-3 M NaHCO3, 1.71 ×10
-3 M NaCl, and 4 mg/L DOC at pH 8.4.) 
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In Chapter 5, the rate constant for ciprofloxacin transformation by ozone did not 
change in the presence of NOM.  Here, we assume the same conclusion for erythromycin 
transformation kinetics.  This data was also used to calculate the second-order rate 
constant for anhydroerythromycin A transformation by ozone.  Using the change in 
erythromycin A (ln [EA]/[EA]o), the change in anhydroerythromycin A (ln [AEA]/[AEA]o) 
and the apparent second order rate constant for erythromycin A at pH 8.4 (α1 = 0.285; 
k”O3,app,EA = 1.24×10
6 M-1s-1), the apparent second order rate constant describing 

































,,3  Eq. 6-5 
 
The apparent rate constant for anhydroerythromycin A at pH 8.4 was determined 
to be 1.71(±0.07)×106 M-1s-1.  This approach is mathematically equivalent to calculating 
the ozone exposure using the erythromycin A data, and then using the calculated ozone 
exposure and the change in the anhydroerythromycin A (ln [AEA]/[AEA]o) to get the 
second order rate constant for anhydroerythromycin A reaction with ozone; the range of 
ozone exposures observed was 6.74×10-8 – 2.41×10-6 M-s.  As with erythromycin A, the 
apparent rate constant was divided by the ionization factor of anhydroerythromycin A at 
pH 8.4 (α1 = 0.285) to yield the specific rate constant, k
”
O3,AEA = 6.00(±0.25)×10
6 M-1s-1.  
As the primary ozone attack site is the free tertiary amine, the specific rate constants for 
erythromycin A (k”O3,EA = 4.36(±0.14)×10
6 M-1s-1) and anhydroerythromycin A (k”O3,AEA 
= 6.00(±0.25)×106 M-1s-1) are both close to the 4×106 M-1s-1 value predicted by Lange et 
al. (2006). 
 
These rate constants were verified using data from a separate experiment, in 
which ozone doses of 0-2.23×10-4 M of ozone were spiked into solutions containing 
1.36×10-4 M erythromycin, 2.38 ×10-3 M NaHCO3, 1.71 ×10
-3 M NaCl, and 10-5 M 
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pCBA at pH 8.4.  No organic matter was present in these solutions.  The molar ratio of 
the applied ozone to initial erythromycin was spread across the range of 0 to 2.12 mol O3 
/ mol erythromycin.  The LC-MS response for both erythromycin A and 
anhydroerythromycin A was measured, and those values, along with the apparent rate 
constants calculated above for pH 8.4, were employed to determine the ozone exposure.  
In this case, the ozone exposure was found using both sets of data, i.e., the erythromycin 
A data and the anhydroerythromycin A data.  Figure 6-4 shows the ozone exposure 
calculated using the erythromycin A data plotted against the ozone exposure calculated 
using the anhydroerythromycin A data.  A 1:1 dashed line is overlaid on the plot.  
Clearly, the ozone exposure calculated for each individual compound compare nicely 
with each other.  This relationship suggests that the rate constants calculated above (from 
different data sets) accurately describe erythromycin A and anhydroerythromycin A 
transformation by ozone.  In these experiments, the hydroxyl radical exposure was 





Figure 6-4. Verification of erythromycin rate constants through comparison of 
ozone exposure calculated from changes in erythromycin A and 
anhydroerythromycin A concentrations. 
 
 
Inhibition Profile of Erythromycin 
The inhibition profile E. coli ATCC #25922 for erythromycin was generated by 
performing the antimicrobial susceptibility assay over a range of erythromycin 
concentrations using standard solutions.  The inhibition profile of erythromycin standards 
prepared in sterile DI with 2.38 ×10-3 M NaHCO3 and 1.71 ×10
-3 M NaCl at pH 8.3 is 
shown in Figure 6-5.  The model line in Figure 6-5 follows the Hill equation (Eq. 6-6), 
which has been used to describe inhibition profiles (Suarez et al., 2007; Baeza, 2008; 
Dodd et al., 2009); the Hill Equation model parameters were determined by the 











































 Eq. 6-6 
 
Imin is the minimum inhibition, Imax is the maximum inhibition, IC50 is the erythromycin 
concentration that corresponds to 50% inhibition, Csample is the erythromycin 
concentration of the sample, and H is the Hill slope.  The equation used in the GraphPad 
Prism software automatically sets the minimum and maximum inhibition at 0% and 
100%, respectively; therefore, IC50 and H were the only fitting parameters.   
 
The Hill curve and the 95% confidence bands (dotted red lines) were generated 
using the “log(inhibitor) vs. normalized response – variable slope” equation in the 
GraphPad Prism software.  In Figure 6-5, the erythromycin concentrations on the abscissa 
correspond to the concentration of erythromycin present in the sample/standard solution 
added to the well; recall that 100 µL of the E. coli inoculum was added to wells 
containing 100 µL of standards/samples.  The IC50 and Hill slope (with 95% confidence 
intervals) were 4.9(±0.55)×10-5 M and 1.7(±0.32)×104, respectively; the correlation 
coefficient (R2) was 0.83.  It should be noted that erythromycin demonstrates a relatively 
large window of partial inhibition.  In Chapter 5, we discussed ozone treatment of 
ciprofloxacin and the antimicrobial activity associated with ciprofloxacin and its 
intermediate oxidation products (Chapter 5).  The region of partial inhibition (20-80% 
inhibition of E. coli) was 1.39×10-8 M for ciprofloxacin (Chapter 5); for erythromycin, 
the same region is more than two orders of concentration wider (7.00×10-5 M).  While a 
sharp inhibition profile (e.g., ciprofloxacin) elucidates a clear treatment goal, the impacts 
of the background water quality (especially, the DOC content) are more likely to be 





Figure 6-5. Inhibition profile for erythromycin A against E. coli at pH 8.3. 
 
 
Experimentation demonstrated that anhydroerythromycin A is not antimicrobially 
active in the same concentration range of erythromycin A.  Figure 6-6 shows the results 
of two experiments where specific ozone doses were applied to solutions containing 
1.36×10-4 M erythromycin, 2.38 ×10-3 M NaHCO3, 1.71 ×10
-3 M NaCl, 10-5 M pCBA, 
and 4 mg/L of DOC from Lake Austin HPOA at two distinct pH values, 8.5 and 4.1.  In 
the pH 8.5 solution, approximately 24.5% of the erythromycin was present as 
anhydroerythromycin A, whereas anhydroerythromycin A made up 94.7% of the total 
erythromycin present in the pH 4.1 solution.  Aliquots of these solutions were dosed with 
ozone (the molar ratio of applied ozone to initial erythromycin was 0-2.47 mol O3 / mol 
ERY) and samples were kept in a dark environment at room temperature for at least 12 
hours before LC-MS analysis.  All samples demonstrated no ozone residual and no 





Figure 6-6. Difference between solutions containing erythromycin A and 
anhydroerythromycin A as the dominant species in solution on the E. 
coli-based antimicrobial activity assay.  (In (a) samples were ozonated at 
pH 8.5 and erythromycin A was the dominant erythromycin species; in (b), 
samples were ozonated at pH 4.1 and anhydroerythromycin A was the 
dominant species.  For both cases, the initial erythromycin concentration 
was 1.36×10-4 M erythromycin.) 
 
 
These samples were also run in the antimicrobial activity assay; it should be noted 
that even though experimental samples were at pH 8.5 and 4.1, the MHB growth medium 
is sufficiently buffered at pH ~7.2.  Hence, the pH of experimental samples did not lead 
to differences in the biological response measured in the antimicrobial activity assay.  
The most interesting aspect of Figure 6-6 is that the initial sample did not demonstrate 
any significant antimicrobial activity.  These data suggest that anhydroerythromycin A is 
not antimicrobially active.  Kibwage et al. (1985) provided minimum inhibitory 
concentrations (MICs) for erythromycin A and anhydroerythromycin A against a number 
of gram-positive and gram-negative bacteria; in all cases, the MIC of 
anhydroerythromycin A was greater than that of erythromycin A.  For E. coli ATCC 
25922, the MIC of erythromycin A and anhydroerythromycin A were listed as 32 and 
>64 µg/mL, respectively.  As the highest concentration employed in that study was 64 
µg/mL, it is difficult to compare the relative antimicrobial activity of 
anhydroerythromycin A to that of erythromycin A for E. coli ATCC 25922; however, for 
two other gram-negative bacteria (Neisseria meningitides 1 and Pasteurella ureae) the 
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MIC listed for anhydroerythromycin A was over 60 and 500 times greater, respectively, 
than that listed for erythromycin A (Kibwage et al., 1985).  These findings align well 
with the results shown in Figure 6-6 and demonstrate the importance of erythromycin 
speciation with respect to antimicrobial activity. 
 
Recall that the reaction from erythromycin A to anhydroerythromycin A is not 
reversible; hence sampling/preservation protocols that acidify environmental samples will 
convert erythromycin A to anhydroerythromycin A, thereby eliminating antimicrobial 
activity.  Therefore, later analysis of the samples for residual pharmacological activity 
may not accurately describe the environmental sample.  While the antimicrobial activity 
of other macrolide antibiotics and their degradation products is outside of the scope of 
this research, it should be noted that other macrolides (clarithromycin and azithromycin, 
among others) do not undergo the type of acid-catalyzed transformations described in 
Scheme 6-1 (Hirsch et al., 1999).  Hence, the effects of sampling/preservation techniques 
on the speciation of these compounds are not expected to generate drastic changes in 
antimicrobial activity. 
 
Antimicrobial Activity of Erythromycin Intermediate Oxidation Products 
Figure 6-7 shows the antimicrobial activity (as percent E. coli inhibition) versus 
the erythromycin A concentration of the treated samples that were plotted earlier in 
Figure 6-3.  These samples were generated by dosing 0–2.47×10-4 M of ozone into 
samples containing 1.36×10-4 M erythromycin, 2.38 ×10-3 M NaHCO3, 1.71 ×10
-3 M 
NaCl, 10-5 M pCBA, and 4 mg/L of DOC (with the exception being the “No NOM” data 
set, which did not contain any DOC).  As described earlier, this dosing scheme resulted in 
applied ozone to initial erythromycin molar ratios of 0–2.42 mol O3 / mol ERY.  On this 
type of plot, any contribution of intermediate oxidation products to the overall 
antimicrobial activity would cause a shift up in the percent inhibition data; however, if 
the intermediate oxidation products do not exert any significant antimicrobial activity, the 
data should fall on the inhibition profile shown in Figure 6-5.  In Figure 6-7, it is clear 
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that most of the data from these four data sets fall within or quite close to the 95% 
confidence bands of the erythromycin A inhibition profile.   
 
 
Figure 6-7. Antimicrobial activity data for experimental samples overlaid on the 
inhibition profile of erythromycin.  (The data correspond to samples 
containing 1.36×10-4 M erythromycin, 2.38 ×10-3 M NaHCO3, 1.71 ×10
-3 M 
NaCl, and 4 mg/L of DOC (with the exception being the “No NOM” data 
set, which did not contain any DOC) that were dosed with 0–2.47×10-4 M of 
ozone.) 
 
Recall from Chapter 5 that the intermediate oxidation products generated by 
ozonation of ciprofloxacin resulted in a shift in the inhibition profile of ciprofloxacin.  In 
that work, the IC50 of the standard inhibition profile exhibited an IC50 of 9.0 µg/L and an 
H of 0.42; the inhibition profile of treated samples (i.e., those containing ciprofloxacin 
and intermediate oxidation products formed through ciprofloxacin reaction with ozone) 
had an IC50 of 6.6 μg/L and an H of 0.26.  The difference in IC50 illustrates the 
contribution of intermediate oxidation products to the residual antimicrobial activity, 
while the change in the Hill slope corresponds to a wider region of partial inhibition, 
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presumably due to a difference in potency between ciprofloxacin and its antimicrobially 
active intermediate products.  For erythromycin, model (Hill curve with 95% confidence 
bands) fits to the four data sets all intersect; therefore, we can conclude that the 
intermediate oxidation products generated from ozone attack on erythromycin A do not 
demonstrate considerable antimicrobial activity.  Furthermore, the differences observed 
for ciprofloxacin and erythromycin demonstrate the need to consider the transformation 
chemistry of individual compounds when considering residual pharmacological activity.  
 
As intermediate oxidation products did not appear to exert any antimicrobial 
activity, we investigated the chemical structures of the compounds produced through 
ozone attack to determine if the structures of the intermediate oxidation products agree 
with experimental evidence suggesting that they do not express antimicrobial activity.  
LC-MS analysis of the samples previously plotted in Figure 6-3 and Figure 6-7 
demonstrated four major m/z peaks:  733.9, 715.9, 749.9, and 731.9; these peaks are 





Figure 6-8. Peaks for intermediate oxidation products generated by ozonation of 
erythromycin and anhydroerythromycin.  (The individual 
chromatograms stem from two different samples: one at pH 8.5 where 
erythromycin A dominates, and the other at pH 4.1, where 
anhydroerythromycin A dominates.  The m/z = 733.9 and m/z = 749.9 
chromatograms come from a sample that was dosed with ozone to achieve a 
molar ratio of applied ozone to erythromycin of 0.97 mol/mol; the pH of the 
sample was 8.5.  The total ion current, m/z = 715.9, and m/z = 731.9 
chromatograms correspond to a sample that was dosed with ozone to 
achieve a molar ratio of applied ozone to erythromycin of 1.46 mol/mol; the 





The 733.9 and 715.9 m/z peaks correspond to erythromycin A and 
anhydroerythromycin A, respectively; the m/z = 749.9 and m/z = 731.9 peaks correspond 
to intermediate oxidation products.  Lange et al. (2006) identified clarithromycin-N-oxide 
(MW = 764 g/mol) as a major product of clarithromycin (MW = 748 g/mol) reaction with 
ozone.  In this case, ozone attacks the lone pair of electrons on the tertiary amine present 
on the desosamine group, resulting in addition of a double-bonded oxygen onto the 
nitrogen atom in the desosamine sugar (Lange et al., 2006).  In that work, Lange et al. 
(2006) postulated that formation of the macrolide-N-oxide product can be expected for 
erythromycin, roxithromycin, and “all the other macrolide drugs.”  From the major peaks 
identified in our samples, the m/z = 749.9 peak would correspond to the addition of an 
oxygen atom to the m/z = 733.9 peak.  Furthermore, the difference between the m/z = 
715.9 peak (anhydroerythromycin A) and the m/z = 731.9 peak is also 16 units, which 
corresponds to addition of an oxygen atom to the molecule.  Both of these products can 
be described by the same ozone attack mechanism that was proposed by Lange et al. 
(2006).  For these reasons, the evidence suggests that the two major oxidation products 
identified in this work correspond to erythromycin A N-oxide (CAS #992-65-4) and 
anhydroerythromycin A N-oxide (CAS #63950-90-3).  In Scheme 6-2, we show the 
proposed site of ozone attack on the erythromycin A and anhydroerythromycin A 





Scheme 6-2. Erythromycin A and anhydroerythromycin A oxidation mechanisms. 
 
 
These transformations essentially remove the antimicrobial activity of the 
erythromycin molecule as demonstrated above in Figure 6-6 and Figure 6-7.  This result 
corresponds well to the known pharmacology of macrolides.  As described earlier, Lemke 
and Williams (2008) indicated that the C-5 D-desosamine moiety is especially important 
to inhibition.  As the transformation from erythromycin A to erythromycin A N-oxide 
affects the predominant active site of the D-desosamine functional group, it is not 
surprising that binding to the 23S rRNA would be affected, thereby, eliminating 




The behavior of erythromycin was studied throughout an oxidative treatment process: 
 At acidic pH, erythromycin A degrades to form anhydroerythromycin A; 
 While erythromycin A demonstrates antimicrobial activity (IC50 = 
4.87(±0.55)×10-5 M, H = 1.72(±0. 32)×104 for E. coli ATCC #25922), 
anhydroerythromycin A is a much less potent antimicrobial compound and no 
significant activity was observed in this study; 
 The specific rate constants for erythromycin A and anhydroerythromycin A 
transformation by ozone were determined to be 4.36(±0.14)×106 M-1s-1 and 
6.00(±0.25)×106 M-1s-1, respectively.  These rate constants correspond to the 
deprotonated species; rate constants for the reaction of protonated erythromycin 
species with ozone are negligible (< 1 M-1s-1); 
 Both erythromycin A and anhydroerythromycin A underwent the same oxidative 
mechanism, namely, the addition of an oxygen atom on the free tertiary amine 
located on the D-desosamine moiety to form erythromycin A N-oxide 
(C37H67NO14, MW = 749.9 g/mol) and anhydroerythromycin A N-oxide 
(C37H65NO13, MW = 731.9 g/mol), respectively;  
 The intermediate oxidation products identified in this study did not contribute to 
the residual antimicrobial activity of samples, that is, erythromycin A was the 
only antimicrobially active substance present in our samples. 
 
The implications of this research for the field of environmental engineering 
demonstrate that not only does erythromycin degrade to form anhydroerythromycin A, 
which is much less antimicrobially potent than erythromycin A, but also erythromycin 
intermediate oxidation products do not possess antimicrobial potency.  These findings 
relieve some of the concern over erythromycin presence in the environment because it 
demonstrates that ozone-based treatment of erythromycin will eliminate most (due to the 
rapid reaction of erythromycin with ozone) of the corresponding antimicrobial activity.  
The rapid erythromycin transformation kinetics with ozone allow for highly effective 
185 
 
erythromycin treatment in ozone processes; in advanced oxidation processes, 
erythromycin will not compete as well because transformation will be a direct function of 
the relative concentration of erythromycin with respect to background NOM.  Questions 
still abound regarding non-lethal concerns of antimicrobial presence in the environment 
especially with regards to antibiotic resistance (Kummerer, 2004) and interruption of cell-







CHAPTER 7 – CONCLUSIONS 
 
 
In The Sea Around Us, Rachel Carson, arguably the mother of the environmental 
movement, stated “For all at last returns to the sea…” (Carson, 1951)  As technology, 
chemical production, and pharmaceutical development progresses, we must remember 
that the chemicals that we produce and consume do indeed find their way into our water 
supplies.  To protect environmental and human health, water and wastewater treatment 
processes that are capable of removing the threat from trace organic contaminants need to 
be developed and tested.  The ability of ozone-based treatment processes to transform 
four model pharmaceuticals was demonstrated in this research.  The scientific 
understanding of how those chemicals are transformed and the potential for the 
intermediate oxidation products to exert pharmacological activity was investigated.  
Additionally, novel methods for employing ozone-based processes to determine the 
transformation kinetics of PhACs with ozone and hydroxyl radicals were presented.  
Below, three sets of bulleted lists describing the major conclusions drawn from the 
research results from Chapters 4-6 are presented below.  Those lists describe major 
conclusions stemming from ozone experimentation with four pharmaceuticals:  
cyclophosphamide (Chapter 4), ifosfamide (Chapter 4), ciprofloxacin (Chapter 5), and 
erythromycin (Chapter 6).  These compounds were chosen for a variety of reasons, 
including their predicted reactivity with ozone and their pharmacological mechanisms of 
action.  Subsequent to the summation of findings for individual pharmaceuticals, an 
overview that ties these separate results together into a unified story of the significance of 
the research is given.   
 
Based on the experimental findings presented in Chapter 4, which focuses on 
determination of the transformation kinetics of cyclophosphamide and ifosfamide by 
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ozone and hydroxyl radicals, identification of the impact of NOM on cyclophosphamide 
and ifosfamide transformation, and characterization of intermediate oxidation products, 
the following conclusions were reached. 
 A highly concentrated ozone stock solution can be continuously pumped into a 
separate reactor, and the aqueous ozone concentration and ozone exposure can be 
controlled by the flow rate. 
 A similar experimental design, with inclusion of continuous addition of hydrogen 
peroxide, can be employed to achieve a controllable level of hydroxyl radical 
exposure. 
 The rate constants for cyclophosphamide and ifosfamide reaction with hydroxyl 
radicals were determined using the continuous peroxone addition reactor.  The use 
of this reactor to determine transformation kinetics of PhACs with hydroxyl 
radicals is novel.  The rate constants for the transformation cyclophosphamide and 
ifosfamide by hydroxyl radicals are 2.69(±0.17) ×109 M-1s-1 and 2.73(±0.16) ×109 
M-1s-1, respectively. 
 The continuous ozone reactor can be employed to determine the rate constants for 
compounds that react slowly with ozone (i.e., cyclophosphamide and ifosfamide), 
and this methodology is an improvement over standard batch reactors with a 
single ozone addition at time zero due to the ability to control the ozone 
concentration throughout experimentation.  The rate constants for the 
transformation of cyclophosphamide and ifosfamide with ozone are 3.03(±0.48) 
M-1s-1 and 7.38 (±0.27) M-1s-1, respectively. 
 The presence of NOM impacts the rate of transformation of cyclophosphamide 
and ifosfamide mainly through NOM reaction with ozone, which reduces the 
achievable hydroxyl radical exposure for a specific ozone dose. 
 Many intermediate oxidation products are observed for cyclophosphamide and 
ifosfamide, and an overlap exists for the m/z values associated with 
cyclophosphamide and ifosfamide transformation products; furthermore, these 
products are similar to known metabolites of cyclophosphamide and ifosfamide, 
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including the 4-keto-, 4-hydroxy-, and imino- derivatives of the parent 
compounds. 
 The pharmacologically active metabolites of cyclophosphamide (phosphoramide 
mustard) and ifosfamide (isophosphoramide mustard) were formed at pH 9.6 but 
not pH 2.5; these results suggest that the pharmacological activity associated with 
these compounds was not removed by ozonation. 
 
In Chapter 5, the ability of the continuous ozone addition reactor to treat ciprofloxacin 
and its associated antimicrobial activity in the presence of NOM was demonstrated.  The 
major conclusions from that work include the following. 
 Ciprofloxacin reacts quickly with ozone (k”O3,app,CIP = 1.55(±0.13)×104 M-1s-1 at 
pH 7) and hydroxyl radicals (k”HO·,app,CIP = 1.19(±0.69)×10
10 M-1s-1 at pH 7). 
 In the continuous ozone addition reactor, ciprofloxacin is quickly transformed in 
the absence of any background DOC. 
 In the presence of NOM, ciprofloxacin removal for particular applied ozone doses 
depended on the DOC concentration and NOM composition. 
 Of the three NOM sources tested, the hydrophobic organic acids isolated from 
Claremore Lake exerted the greatest impact on ciprofloxacin transformation.  The 
Claremore Lake transphilic organic acids isolate exerted the lowest impact on 
ciprofloxacin transformation, while the Lake Austin hydrophobic organic acids 
were intermediate in their effect.  These results are consistent with the 
composition and SUVA254 of the NOM isolates. 
 Ciprofloxacin inhibits E. coli at relatively low concentrations, and the inhibition 
profile is exceptionally sharp with the difference between complete and no 
inhibition being approximately 7 µg/L (4-11 µg/L).  The IC50 and Hill slope of the 
ciprofloxacin inhibition profile are 9.0 µg/L and 0.42, respectively. 
 The residual antimicrobial activity of samples from continuous ozone addition 
experiments was measured, and the inhibition profile of oxidized samples was 
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shifted to lower ciprofloxacin concentrations, suggesting that intermediate 
oxidation products exert a non-negligible antimicrobial activity. 
 The applied ozone dose required for complete removal of residual antimicrobial 
activity depends on the presence, concentration, and composition of the 
background NOM present in solution. 
 
The rate constants for erythromycin transformation by ozone, identification of the 
intermediate oxidation products formed through erythromycin reaction with ozone, and 
characterization of the antimicrobial activity of erythromycin and its major intermediate 
oxidation products were presented in Chapter 6.  In solution, erythromycin A readily 
degrades to anhydroerythromycin A; this reaction is irreversible.  As erythromycin A and 
anhydroerythromycin A were present in samples, experimentation addressed the points 
listed above for both compounds.  The following conclusions were reached. 
 The rate constants for transformation of the deprotonated forms of erythromycin 
A and anhydroerythromycin A by ozone were determined to be k”O3,EA = 
4.36(±0.14)×106 M-1s-1 and k”O3,AEA = 6.00(±0.25)×10
6 M-1s-1, respectively. 
 The kinetics of erythromycin transformation by ozone are so rapid that no 
hydroxyl radical exposure was observed (while erythromycin remained in 
solution). 
 The inhibition profile of erythromycin exhibited a gentler slope (i.e., a larger 
range of pharmaceutical concentrations result in partial E. coli inhibition) than 
that of ciprofloxacin.  The IC50 and Hill slope of the erythromycin inhibition 
profile were 4.87(±0.55)×10-5 M and 1.72(±0.32)×104, respectively. 
 The antimicrobial activity against E. coli of anhydroerythromycin A was found to 
be negligible compared to that of erythromycin A; therefore, one approach to 
removing the antimicrobial activity of solutions containing erythromycin A is to 
lower the pH. 
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 The major intermediate oxidation products formed via ozone attack on 
erythromycin A and anhydroerythromycin A were identified as erythromycin A 
N-oxide and anhydroerythromycin A N-oxide. 
 Erythromycin A N-oxide and anhydroerythromycin A N-oxide demonstrated 
negligible antimicrobial activity against E. coli. 
 
SIGNIFICANCE 
As comprehension of the extent of pharmaceutical contamination increases, the 
understanding of engineered processes aimed at effectively removing these compounds 
from water and wastewater sources is crucial.  In this research, the ability of ozone to 
treat four pharmacologically active compounds was demonstrated.  The dual oxidation 
mechanism (i.e., ozone and hydroxyl radicals) present in ozone processes ensures 
effective treatment of PhACs.  For this reason, ozone-based processes have a unique 
advantage with respect to treatment of wastewater-derived organic contaminants. 
 
The individual findings from Chapters 4-6 can be merged to demonstrate the 
higher level findings of this research.  From the calculated rate constants, it is clear that 
cyclophosphamide and ifosfamide react slowly with ozone and that ciprofloxacin and 
erythromycin react quickly with ozone.  The four compounds demonstrate rate constants 
for reaction with hydroxyl radicals of 2.7‒12×109 M-1s-1.  Typical values of ozone 
exposure and hydroxyl radical exposure after 30 minutes in the continuous aqueous 
ozone addition reactor were 9.1×10-3 M-s and 4.0×10-10 M-s, respectively.  At pH 7, these 
exposures would lead to complete ciprofloxacin and erythromycin transformation; the 
removal efficiencies of cyclophosphamide and ifosfamide would be approximately 66%.  
With a hydroxyl radical exposure of 2×10-9 M-s, over 99% removal of cyclophosphamide 
and ifosfamide can be achieved.  In the continuous ozone and peroxone addition reactors, 
the ozone and hydroxyl radical exposures can be easily controlled; therefore, depending 
on the PhAC composition of the untreated water, the process can be optimized.  For 
conventional ozone reactors, the applied ozone dose that corresponds to a sufficient 
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ozone exposure (and by extension, hydroxyl radical exposure) for the water of interest 
must be determined.  The rate constants for transformation of these four compounds by 
ozone span the range of expected values for a much broader array of PhACs; therefore, 
ozone-based treatment processes aimed at PhAC treatment should be capable of 
achieving an ozone exposure of at least 9.1×10-3 M-s and a hydroxyl radical exposure of 
at least of 2×10-9 M-s, even in the presence of background NOM. 
 
The findings of this study indicate that concern over the formation of 
pharmacologically active intermediate oxidation products during ozonation of 
pharmaceuticals is valid.  Erythromycin was the only compound that did not theoretically 
or experimentally demonstrate the ability to form pharmacologically active compounds 
through reaction with ozone.  During treatment of the two prodrugs, cyclophosphamide 
and ifosfamide, the active metabolites, phosphoramide mustard and isophosphoramide 
mustard, were formed.  Other metabolic products of cyclophosphamide and ifosfamide 
were also detected, indicating the ability of hydroxyl radical driven oxidation processes 
to emulate metabolic processes.  Additionally, intermediate oxidation products stemming 
from ciprofloxacin transformation contributed to the residual antimicrobial activity of 
treated samples.  For this reason, detailed analyses of other pharmaceuticals are expected 
to indicate that the potential to form pharmacologically active products is widespread.  
Therefore, this work should be considered as part of a model relating ozone and hydroxyl 
radical attacks to the structure-pharmacological activity relationships of various classes of 
drugs. 
 
The rise of wastewater reclamation and indirect water reuse has propelled the 
issue of trace organic contaminants into media and academic spotlight.  Due to mounting 
pressure from their customers, municipal water utilities are concerned about the presence 
of trace constituents in finished drinking water and wastewater.  In these treatment 
scenarios, it is important to consider compounds that compete with pharmaceuticals for 
reaction with ozone and hydroxyl radicals.  For the most part, competition will be 
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manifested through the oxidant demand of the background NOM matrix.  A major focus 
of the research presented herein was to determine the impact of organic matter on 
oxidation of the four target pharmaceuticals.  Results demonstrate that the presence and 
composition of NOM can significantly alter the applied ozone dose required to achieve 
the desired removal efficiency.  While others have demonstrated how NOM composition 
affects NOM reactivity with ozone, this research goes further to show the impact that 
NOM reaction with ozone has on not only ciprofloxacin and erythromycin removal, but 
also elimination of residual antimicrobial activity. 
 
With the increasing attention on treating trace constituents in water and 
wastewater processes, pioneering changes to traditional ozonation experiments are vital.  
Traditionally, ozone has been applied in the gaseous form, necessitating the presence of 
gaseous diffusers in the ozone contact tanks.  Moving forward, it would be interesting to 
assess the effectiveness of the continuous ozone and peroxone addition reactors in pilot-
scale projects.  These pilot-scale reactors would supply highly concentrated liquid ozone 
(and hydrogen peroxide in the case of peroxone treatment) in a similar manner as liquid 
chlorination processes.  In addition, opportunities exist for using the off-gas from the 
ozone stock solution in other stages of the treatment train, applying higher ozone doses, 
and improving occupational safety.  Given these possibilities and the operational ease of 
employing aqueous ozone, these novel ozone-based processes might demonstrate 
significant advantages in water and wastewater treatment plants. 
 
RECOMMENDATIONS FOR FUTURE WORK 
This research has demonstrated the ability for ozone-based water treatment 
processes to effectively treat four pharmaceuticals (two antimicrobials and two 
chemotherapy agents) in a variety of background water matrices.  The experimental 
design of the research activities described within this dissertation has connected key 
parameters in oxidation processes aimed at treating trace organic contaminants, and in 
particular, pharmacologically active compounds.  While key connections have been made 
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regarding the impact of organic matter on treatment of pharmaceuticals, the ability for 
pharmacologically active intermediate oxidation products to be formed in oxidation 
processes, and the removal of residual antimicrobial activity throughout treatment of 
pharmaceuticals, this field is still relatively young.  Therefore, I propose the following 
recommendations for future work aimed at furthering the scientific and engineering 
understanding of ozone-based processes aimed at water treatment of organic wastewater-
derived contaminants. 
 
1.) Isolation of intermediate products.  While the antimicrobial activity assay 
employed in this research (and that of other researchers) can suggest the impact of 
intermediate oxidation products on residual antimicrobial activity, a direct 
measure of the inhibition profile of all intermediate products will provide a clearer 
evaluation of how intermediate oxidation products contribute to the ultimate 
antimicrobial activity.  At this time, no such work has been done; however, with 
advanced analytical equipment (LC-MS/MS) and the versatile collection of solid-
phase extraction materials, isolation of individual intermediate oxidation products 
should be possible.  By isolating individual products and measuring their 
inhibition profile, a detailed library of compound potencies can be created for 
individual pharmaceuticals.  Such work would allow a more thorough 
understanding of the overall potency of intermediate oxidation products as 
compared to that of the parent pharmaceuticals. 
 
2.) Residual pharmacological activity of water sources containing multiple 
pharmaceuticals.  In this research, the behavior of the residual pharmacological 
activity of a water containing a mixture of pharmaceuticals from the same class of 
drugs (e.g., antibiotics) was not investigated.  Can the ultimate pharmacological 
activity of the mixture be determined by considering the additive effects of the 
individual pharmaceuticals?  If not, is the ultimate pharmacological activity of 
mixtures synergistic (the combined effect is greater than the additive effects of the 
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individual components) or antagonistic (the combined effect is less than the 
additive effects of the individual components)?  Furthermore, this question 
applies to the additive effects of a parent compound and its intermediate oxidation 
products.  Does the formation of intermediate oxidation products affect the 
residual antimicrobial activity on a per mole of parent compound basis? 
 
3.) Consideration of non-lethal impacts.  The work on the pharmacological activity 
of both parent compounds and transformation products presented in this 
dissertation focused only on antimicrobial activity, which was measured as a 
function of E. coli proliferation.  While such work is pioneering, the next step in 
this hybrid association of water treatment with environmental toxicology is 
consideration of non-lethal impacts that pharmaceuticals exert on environmental 
and human health.  How does the presence of anti-inflammatory, 
antihypertensive, antidepressant, anti-diabetic, and other drugs in water affect 
environmental and human health?  Furthermore, research in the antibiotic 
community has demonstrated that, at sub-lethal concentrations, antibiotics can 
affect cell-signaling processes.  As environmentally-relevant concentrations are 
typically in the sub-lethal regime, it would be interesting to extend this research 
into how water and wastewater treatment processes affect the ability of water 
containing PhACs to impact cell-signaling processes. 
 
4.) Model development for predicting PhAC transformation efficiency.  Using known 
rate constants for PhACs, PhAC intermediate oxidation products, and NOM, and 
typical values of ozone exposure and hydroxyl radical exposure experienced in 
oxidation and advanced oxidation processes, the transformation efficiency of 
PhACs can be modeled for specified systems.  Given the wide range of rate 
constants observed for PhAC transformation by ozone, this model would be 
particularly useful in delineating PhAC transformation efficiencies for solutions 
containing mixtures of pharmaceuticals. 
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5.) Pilot scale testing of the continuous aqueous ozone addition reactor.  While the 
above efforts are mainly focused on environmental toxicology extensions of this 
work, future work on the engineering aspects of this project also exist.  In 
particular, it would be interesting to study the ability of the continuous aqueous 
ozone addition reactor to operate in a pilot-scale setting.  In this case, I envisage a 
process that is similar to liquid chlorination processes.  Engineering challenges 
include (1) maintaining the stock ozone supply while introducing enough ozone to 
effectively treat trace organic contaminants in a continuous flow scheme, (2) 
efficiently using the off-gas from the ozone stock solution in other stages of the 
treatment train, and (3) conducting an energy audit of the continuous aqueous 
ozone reactor and comparing the treatment cost (kWh/1000 gallons) with a 






APPENDIX A – DISH WASHING AND AUTOCLAVE PROTOCOLS 
 
Dish Washing Protocol 
All glassware underwent stringent washing protocol.  First dishes were rinsed 
with tap water and submerged in an Alconox solution for at least 30 minutes.  Dishes 
were rinsed with Alconox solution at least three times, rinsed five times with tap water, 
and submerged in a Micro-90® (an alkaline detergent; Micro-90(R), 2009) bath 
overnight.  After rinsing at least three times with the Micro-90® solution, the dishes were 
rinsed five times with DI and submerged in a 10% nitric acid bath overnight.  The dishes 
were rinsed at least three times with the acid bath solution, rinsed five times with DI, and 
left to dry overnight.  To remove any organic carbon from the glassware, dishes were 
baked in a muffle furnace set to 550°C for at least three hours.  After cooling, dishes were 
covered with Parafilm to prevent accumulation of dust or particles in the glassware.   
 
Autoclave Procedure 
All dishware and solutions used in the antimicrobial activity assay were 
autoclaved prior to use.  The autoclave was the Sterilmatic model from Market Forge 
Industries, Inc.  Dishware was either loosely capped or covered with aluminum foil and 
autoclaved for 21 minutes using a fast temperature ramp.  Solutions, including DI and 
Mueller-Hinton Broth (MHB), were autoclaved for 21 minutes using a slower 
temperature ramp.  All solid microbial waste was collected in an autoclavable bag, 
autoclaved for at least 30 minutes, marked with a “Treated in Accordance with Section 
1.136 of the TAC Special Waste from Health Care Related Facilities Regulations” 
sticker, and disposed of into normal-use waste bins.  All liquid waste was placed into a 
bottle containing approximately 10% bleach and autoclaved for at least 30 minutes, and 
disposed of into hazardous waste bins for subsequent disposal by the University of Texas 





APPENDIX B – FLUORESCENCE EEM DATA FOR NOM ISOLATES 
 
 
Recently, several authors (Baker, 2001; 2002a; b; Chen et al., 2003; Her et al., 
2003) have used fluorescence mapping as a tool for describing the makeup of organic 
matter in water sources.  Chen et al. (2003) published a Fluorescence Excitation-
Emission Matrix (EEM) map (Figure B-1) that listed the location of several classes of 
organic compounds.  Several authors have employed this tool to show how NOM 
matrices are altered in treatment processes (Win et al., 2000; Holbrook et al., 2005). 
 
 




Below, in Figure B-2, the fluorescence maps for the Claremore Lake HPOA and 
TPIA isolates, and the Lake Austin whole water and HPOA isolate are presented.  The 
EEMs for these NOM matrices are different; also, note the difference in magnitude of the 
fluorescence signal amongst the four samples.  These Fluorescence EEMs contain a lot of 
data; therefore, several authors have taken to calculating the fluorescence index as the 
ratio of the emission at 470 nm by the emission at 520 nm at an excitation wavelength of 
370 nm (Jaffe et al., 2008).  The fluorescence indices for the NOM matrices presented in 
Figure B-2 are provided in Table B-1.   
 
 
Figure B-2. Fluorescence maps of (a) Claremore Lake HPOA, b.) Claremore Lake 





Table B-1. Fluorescence index for organic matter isolates. 
Solution Fluorescence Index 
Claremore Lake HPOA 1.31 
Claremore Lake TPIA 1.55 
Lake Austin Raw Water 1.52 
Lake Austin HPOA 1.34 
 
 
In Chapters 4-6, the impact of organic matter on oxidation of the four 
pharmacologically active compounds of concern was investigated.  As only three NOM 
isolates were available, no overriding conclusions were drawn from that data with respect 
to the Fluorescence Excitation-Emission Matrix data.  Regardless, this information is 
provided here for future researchers employing the Lake Austin and Claremore Lake 







APPENDIX C:  ANTIMICROBIAL ACTIVITY ASSAY DATA ANALYSIS 
 
 
This Appendix explains the analysis of antimicrobial activity data using the 
inhibition profile and the potency equivalents protocols that were discussed in Chapters 
5-6. 
 
Inhibition Profile Protocol 
Wells were partially filled with 100 μL of a standard or sample; then, 100-μL of 
the E. coli inoculum is added to the well.  Triplicates are run for all standards and 
samples.  The plate setup for a microplate containing standard solutions of ciprofloxacin 
is shown below; please note, that the positive and negative growth controls were present 




(µg/L) 1 2 3 4 5 6 7 8 9 10 11 12 
A 100.00 80.00 64.00 51.20 40.96 32.77 26.21 20.97 16.78 13.42 10.74 8.59 
B 100.00 80.00 64.00 51.20 40.96 32.77 26.21 20.97 16.78 13.42 10.74 8.59 
C 100.00 80.00 64.00 51.20 40.96 32.77 26.21 20.97 16.78 13.42 10.74 8.59 
D      
E 6.87 5.50 4.40 3.52 2.81 2.25 1.80 1.44 1.15 0.92 0.74 0.59 
F 6.87 5.50 4.40 3.52 2.81 2.25 1.80 1.44 1.15 0.92 0.74 0.59 
G 6.87 5.50 4.40 3.52 2.81 2.25 1.80 1.44 1.15 0.92 0.74 0.59 
H      
 
In this example, standard solutions containing various concentrations (0.59-100 
µg/L) of ciprofloxacin were added to microplate.  After 100-µL of each standard was 
added to the wells, 100-µL of the E. coli inoculum was added to each well.  The plate 
was incubated for 20 hours at 37°C in ambient air.  After the incubation period, the 
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absorbance at 600 nm for each well was read using a microplate reader.  The absorbance 
of a microplate containing no solution (i.e., a blank plate) was subtracted from the raw 
data.  The raw data and the corrected data are presented below: 
 
RAW ABSORBANCE DATA 
ABS600 nm 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.149 0.159 0.146 0.150 0.149 0.145 0.159 0.146 0.164 0.167 0.196 0.198 
B 0.146 0.143 0.139 0.142 0.144 0.136 0.152 0.146 0.144 0.144 0.161 0.213 
C 0.137 0.136 0.131 0.138 0.140 0.141 0.150 0.136 0.139 0.142 0.178 0.187 
D 0.095 0.094 0.095 0.096 0.099 0.099 0.097 0.093 0.099 0.097 0.089 0.098 
E 0.204 0.225 0.224 0.246 0.245 0.254 0.246 0.242 0.242 0.237 0.248 0.250 
F 0.216 0.230 0.240 0.239 0.234 0.235 0.243 0.221 0.247 0.242 0.241 0.257 
G 0.216 0.229 0.246 0.240 0.233 0.228 0.251 0.241 0.251 0.258 0.235 0.251 
H 0.094 0.096 0.091 0.098 0.095 0.105 0.104 0.098 0.101 0.098 0.103 0.105 
CORRECT ABSORBANCE DATA 
ABS600 nm 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.338 0.018 0.335 0.328 0.323 0.315 0.311 0.280 0.263 0.259 0.261 0.254 
B 0.325 0.012 0.273 0.196 0.196 0.226 0.289 0.221 0.258 0.258 0.250 0.227 
C 0.231 0.012 0.201 0.324 0.331 0.256 0.233 0.172 0.235 0.167 0.236 0.219 
D 0.011 0.004 0.009 0.005 0.005 0.011 0.009 0.004 0.007 0.000 0.003 -0.002 
E 0.211 0.197 0.202 0.179 0.167 0.129 0.052 0.035 0.045 0.034 0.012 0.010 
F 0.221 0.209 0.198 0.152 0.171 0.149 0.072 0.040 0.040 0.044 0.014 -0.004 
G 0.226 0.205 0.197 0.191 0.171 0.166 0.124 0.068 0.053 0.046 0.019 0.008 
H 0.013 0.009 0.008 0.010 0.010 0.015 0.011 0.010 -0.008 0.003 0.022 0.028 
 
For this example, the corrected absorbance values for the negative and positive 
growth controls were 0.033 and 0.144, respectively.  The corrected raw data was then 
normalized using Eq. C-1, and converted to percent of E. coli inhibition using Eq. C-2.  
These equations set the negative and positive growth controls to 0 and 100% inhibition, 














  Eq. C-1 
 
   %1001% .,600   normnmABSInhibition  Eq. C-2 
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Table C-1 shows the ciprofloxacin concentration, the corrected and normalized 
absorbance at 600 nm data, and the percent of E. coli inhibition for the microplate 
described above. 
 




ABS600 nm ABS600 nm,norm. Percent E. coli Inhibition 
Rep. 1 Rep. 2 Rep. 3 Rep. 1 Rep. 2 Rep. 3 Rep. 1 Rep. 2 Rep. 3 
100.00 0.0333 0.0270 0.0387 0.0012 -0.0558 0.0491 99.9 105.6 95.1 
80.00 0.0347 0.0410 0.0213 0.0132 0.0701 -0.1067 98.7 93.0 110.7 
64.00 0.0390 0.0367 0.0353 0.0521 0.0311 0.0191 94.8 96.9 98.1 
51.20 0.0360 0.0310 0.0363 0.0251 -0.0198 0.0281 97.5 102.0 97.2 
40.96 0.0297 0.0427 0.0423 -0.0318 0.0851 0.0821 103.2 91.5 91.8 
32.77 0.0217 0.0203 0.0307 -0.1037 -0.1157 -0.0228 110.4 111.6 102.3 
26.21 0.0443 0.0437 0.0450 0.1000 0.0941 0.1060 90.0 90.6 89.4 
20.97 0.0300 0.0443 0.0417 -0.0288 0.1000 0.0761 102.9 90.0 92.4 
16.78 0.0430 0.0337 0.0293 0.0881 0.0042 -0.0348 91.2 99.6 103.5 
13.42 0.0527 0.0423 0.0423 0.1750 0.0821 0.0821 82.5 91.8 91.8 
10.74 0.0863 0.0603 0.0790 0.4776 0.2439 0.4117 52.2 75.6 58.8 
8.59 0.0830 0.1067 0.0833 0.4476 0.6604 0.4506 55.2 34.0 54.9 
6.87 0.1130 0.1240 0.1203 0.7173 0.8162 0.7833 28.3 18.4 21.7 
5.50 0.1330 0.1397 0.1350 0.8971 0.9571 0.9151 10.3 4.3 8.5 
4.40 0.1260 0.1467 0.1503 0.8342 1.0200 1.0529 16.6 -2.0 -5.3 
3.52 0.1427 0.1387 0.1443 0.9840 0.9481 0.9990 1.6 5.2 0.1 
2.81 0.1490 0.1420 0.1300 1.0410 0.9780 0.8702 -4.1 2.2 13.0 
2.25 0.1510 0.1280 0.1227 1.0589 0.8522 0.8042 -5.9 14.8 19.6 
1.80 0.1400 0.1360 0.1503 0.9600 0.9241 1.0529 4.0 7.6 -5.3 
1.44 0.1457 0.1150 0.1337 1.0110 0.7353 0.9031 -1.1 26.5 9.7 
 
The first column (ciprofloxacin concentration) and the last three columns (Percent 
of E. coli Inhibition) were copied into GraphPad Prism.  The data was analyzed using the 
“log(inhibitor) vs. normalized response – Variable slope” model using a least squares fit.  
In addition to calculation of the standard error associated with the model fits on IC50 and 






Figure C-1. GraphPad Prism input/output for analysis of the ciprofloxacin and percent 
inhibition data presented above in Table C-1. 
 
In this case, the IC50 of the data is given as the LOG(IC50) value (9.338 µg/L) 
presented in Figure C-1.  The standard error on the IC50 is ±0.2423 µg/L, and the 95% 
confidence band on the IC50 ranges from 8.854 – 9.821 µg/L.  Similarly, the Hill slope 
for this data is 0.2216, with a standard error of 0.002172; the 95% confidence band for 
the Hill slope ranges from 0.1782 to 0.2650.  The coefficient of correlation provided by 
GraphPad Prism is R2 = 0.9662.  In Figure C-2, the average (of the three replicate 
samples) for the percent inhibition data is plotted against ciprofloxacin concentration.  
The Hill curve and 95% confidence bands were plotted using the fitted values for IC50 





Figure C-2. The inhibition profile of ciprofloxacin against E. coli.  (The Hill curve and the 
95% confidence bands were generated in GraphPad Prism.) 
 
 
Potency Equivalents Protocol 
In this example, a 1000 mg/L erythromycin solution was generated.  That solution 
was serially diluted ten times using a dilution factor of 0.50; the final solution contained 
1.95 mg/L ERY.  These solutions (1000 µL) were added to the first row of the microplate 
(A2 through A11).  Sterile DI water (100 µL) was added to every other well on the plate 
(A1, A12, B1:H12).  The standards in A2-A11 were then serially diluted by a factor of 
0.6.  For example, 150 µL of the solution (1000 mg/L ERY) in well A11 was added to 
well B11, which already contained 100 µL of DI, thereby generating a solution with 
27.99 mg/L ERY.  It should be noted that 100 µL of sample/standard was left in each 
well.  This process was completed for each initial standard solution (A2-A11), working 
down the plate.  Hence, seven dilutions were created.  Column 1 (A1-H1) were reserved 
for positive growth controls, while Column 12 (A12-H12) were set aside for negative 
growth controls; all of these wells contained sterile DI water and the background matrix.  





(mg/L) 1 2 3 4 5 6 7 8 9 10 11 12 
A Pos. 1.95 3.91 7.81 15.63 31.25 62.50 125.00 250.00 500.00 1000.00 Neg. 
B Pos. 1.17 2.34 4.69 9.38 18.75 37.50 75.00 150.00 300.00 600.00 Neg. 
C Pos. 0.70 1.41 2.81 5.63 11.25 22.50 45.00 90.00 180.00 360.00 Neg. 
D Pos. 0.42 0.84 1.69 3.38 6.75 13.50 27.00 54.00 108.00 216.00 Neg. 
E Pos. 0.25 0.51 1.01 2.03 4.05 8.10 16.20 32.40 64.80 129.60 Neg. 
F Pos. 0.15 0.30 0.61 1.22 2.43 4.86 9.72 19.44 38.88 77.76 Neg. 
G Pos. 0.09 0.18 0.36 0.73 1.46 2.92 5.83 11.66 23.33 46.66 Neg. 
H Pos. 0.05 0.11 0.22 0.44 0.87 1.75 3.50 7.00 14.00 27.99 Neg. 
 
After the samples were added to the plate, 100-µL of the E. coli inoculum was added to 
Columns 1-11; 100 µL of MHB was added to Column 12, which contained negative 
growth controls.  The raw data was then normalized using Eq. C-1, and converted to 
percent of E. coli inhibition using Eq. C-2.  The raw and corrected data are shown below: 
 
RAW ABSORBANCE DATA 
ABS600 nm 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.434 0.374 0.330 0.297 0.250 0.180 0.160 0.147 0.157 0.159 0.150 0.121 
B 0.406 0.363 0.343 0.308 0.258 0.243 0.157 0.145 0.152 0.149 0.150 0.114 
C 0.411 0.370 0.351 0.328 0.288 0.242 0.191 0.153 0.139 0.139 0.140 0.103 
D 0.389 0.367 0.353 0.338 0.312 0.270 0.220 0.161 0.145 0.146 0.133 0.113 
E 0.387 0.371 0.366 0.352 0.332 0.303 0.260 0.217 0.150 0.145 0.133 0.105 
F 0.380 0.380 0.360 0.352 0.345 0.316 0.291 0.239 0.210 0.146 0.132 0.105 
G 0.387 0.386 0.375 0.369 0.352 0.330 0.313 0.279 0.233 0.181 0.138 0.106 


















CORRECTED ABSORBANCE DATA 
ABS600 nm 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.315 0.250 0.222 0.184 0.126 0.052 0.046 0.030 0.042 0.043 0.040 0.007 
B 0.296 0.264 0.240 0.197 0.155 0.134 0.049 0.041 0.043 0.046 0.049 0.007 
C 0.309 0.268 0.253 0.227 0.183 0.132 0.084 0.057 0.029 0.039 0.042 0.006 
D 0.293 0.262 0.253 0.231 0.205 0.155 0.105 0.058 0.036 0.030 0.027 0.005 
E 0.291 0.270 0.262 0.246 0.229 0.197 0.152 0.112 0.042 0.040 0.038 0.007 
F 0.289 0.291 0.266 0.254 0.250 0.208 0.183 0.125 0.102 0.051 0.040 0.003 
G 0.292 0.291 0.282 0.274 0.260 0.232 0.216 0.184 0.133 0.088 0.047 0.011 
H 0.284 0.300 0.301 0.280 0.266 0.255 0.244 0.208 0.166 0.123 0.052 0.013 
 
Table C-2 shows the erythromycin concentration and the serial dilutions for each 
sample, the corrected and normalized absorbance at 600 nm data, and the percent of E. 
coli inhibition for the microplate described above. 
 
The second column (Erythromycin concentration) was plotted against the last 
column (LOG(C/Co)) for all ten data sets using GraphPad Prism®, as seen in Figure C-3.  
The data was analyzed using the “log(inhibitor) vs. normalized response – Variable 
slope” model using a least squares fit; the standard error was also computed.  The 
GraphPad Prism software was not able to fit sample set #1 (serial dilutions of 1000 mg/L) 




Table C-2. Summary of inhibition data for antimicrobial activity assay with 




ABS600 nm ABS600 nm,norm 
Percent E. coli 
Inhibition (%) 
LOG(C/Co) 
Pos. Pos. 0.296 1.000 0.0 
Neg. Neg. 0.003 0.000 100.0 
1.95 1.95 0.250 0.842 15.8 0.000 
1.17 0.264 0.891 10.9 -0.222 
0.70 0.268 0.905 9.5 -0.444 
0.42 0.262 0.884 11.6 -0.666 
0.25 0.270 0.912 8.8 -0.887 
0.15 0.291 0.983 1.7 -1.109 
0.09 0.291 0.983 1.7 -1.331 
0.05 0.300 1.013 -1.3 -1.553 
3.91 3.91 0.222 0.746 25.4 0.000 
2.34 0.240 0.809 19.1 -0.222 
1.41 0.253 0.852 14.8 -0.444 
0.84 0.253 0.852 14.8 -0.666 
0.51 0.262 0.884 11.6 -0.887 
0.30 0.266 0.896 10.4 -1.109 
0.18 0.282 0.953 4.7 -1.331 
0.11 0.301 1.016 -1.6 -1.553 
7.81 7.81 0.184 0.616 38.4 0.000 
4.69 0.197 0.662 33.8 -0.222 
2.81 0.227 0.763 23.7 -0.444 
1.69 0.231 0.777 22.3 -0.666 
1.01 0.246 0.828 17.2 -0.887 
0.61 0.254 0.855 14.5 -1.109 
0.36 0.274 0.924 7.6 -1.331 
0.22 0.280 0.946 5.4 -1.553 
15.63 15.63 0.126 0.420 58.0 0.000 
9.38 0.155 0.519 48.1 -0.222 
5.63 0.183 0.613 38.7 -0.444 
3.38 0.205 0.690 31.0 -0.666 
2.03 0.229 0.770 23.0 -0.887 
1.22 0.250 0.843 15.7 -1.109 
0.73 0.260 0.876 12.4 -1.331 
0.44 0.266 0.897 10.3 -1.553 
31.25 31.25 0.052 0.166 83.4 0.000 
18.75 0.134 0.448 55.2 -0.222 
11.25 0.132 0.440 56.0 -0.444 
6.75 0.155 0.517 48.3 -0.666 
4.05 0.197 0.661 33.9 -0.887 
2.43 0.208 0.701 29.9 -1.109 
1.46 0.232 0.782 21.8 -1.331 
0.87 0.255 0.859 14.1 -1.553 
62.50 62.50 0.046 0.146 85.4 0.000 
37.50 0.049 0.157 84.3 -0.222 
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22.50 0.084 0.276 72.4 -0.444 
13.50 0.105 0.347 65.3 -0.666 
8.10 0.152 0.508 49.2 -0.887 
4.86 0.183 0.614 38.6 -1.109 
2.92 0.216 0.726 27.4 -1.331 
1.75 0.244 0.821 17.9 -1.553 
125.00 125.00 0.030 0.093 90.7 0.000 
75.00 0.041 0.131 86.9 -0.222 
45.00 0.057 0.185 81.5 -0.444 
27.00 0.058 0.189 81.1 -0.666 
16.20 0.112 0.372 62.8 -0.887 
9.72 0.125 0.417 58.3 -1.109 
5.83 0.184 0.616 38.4 -1.331 
3.50 0.208 0.698 30.2 -1.553 
250.00 250.00 0.042 0.132 86.8 0.000 
150.00 0.043 0.135 86.5 -0.222 
90.00 0.029 0.090 91.0 -0.444 
54.00 0.036 0.111 88.9 -0.666 
32.40 0.042 0.134 86.6 -0.887 
19.44 0.102 0.337 66.3 -1.109 
11.66 0.133 0.442 55.8 -1.331 
7.00 0.166 0.557 44.3 -1.553 
500.00 500.00 0.043 0.135 86.5 0.000 
300.00 0.046 0.147 85.3 -0.222 
180.00 0.039 0.123 87.7 -0.444 
108.00 0.030 0.091 90.9 -0.666 
64.80 0.040 0.127 87.3 -0.887 
38.88 0.051 0.163 83.7 -1.109 
23.33 0.088 0.290 71.0 -1.331 
14.00 0.123 0.409 59.1 -1.553 
1000.00 1000.00 0.040 0.126 87.4 0.000 
600.00 0.049 0.157 84.3 -0.222 
360.00 0.042 0.133 86.7 -0.444 
216.00 0.027 0.083 91.7 -0.666 
129.60 0.038 0.119 88.1 -0.887 
77.76 0.040 0.127 87.3 -1.109 
46.66 0.047 0.149 85.1 -1.331 







Figure C-3. Percent inhibition plotted against LOG(C/Co) for the ten data sets described in 
Table C-2.  (GraphPad Prism was not able to fit a model to sample set #1 (1000 
mg/L) and #9 (3.91 mg/L).) 
 
 
The equivalent of IC50 (i.e., the value of LOG(C/Co) that corresponds to 50% 
inhibition) for these curves was calculated by GraphPad Prism.  Using those values, the 
potency equivalents (PEQ) were calculated according to Equation 3 (Suarez et al., 2007).  
As data set #2 did not demonstrate less than 50% inhibition, that data was not used for 
calculation of potency equivalents.  Therefore in Eq. C-3, the numerator refers to the 
antilog of the value of LOG(C/Co) that corresponds to 50% inhibition for sample set #3 
(serial dilutions of 250 mg/L); the term in the denominator corresponds to the 
corresponding value for the other sample sets.  As expected for standard solutions, the 
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  Eq. C-3 
 
 






APPENDIX D:  CYTOTOXICITY ASSAY  
 
The Promega CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay 
was utilized in attempts to measure the residual cytotoxic activity of solutions containing 
cyclophosphamide and ifosfamide.  Below, the procedures employed are documented to 
provide a starting point for future research efforts aimed at assessment of this parameter. 
 
Human embryonic kidney cells (HEK-293) were grown in Dulbecco’s Modified 
Eagles Medium (DMEM) with 10% Fetal Bovine Serum (FBS) in T25 culture flasks.  At 
approximately 80% confluence, the cells were rinsed with 3-mL of phosphate buffered 
saline (PBS).  The cells were then exposed to 2-mL of 0.53-mM EDTA-trypsin, which 
detaches the cells from the culture flask’s growing surface.  After 5 minutes of exposure 
to the EDTA-trypsin solution, the cell suspension was aspirated using a micropipette.  
The cell suspension was then centrifuged at 10000 rpm for 5 minutes.  The supernatant 
was wasted, and the cells were resuspended in 1-mL of PBS.  50-µL of the cell 
suspension was mixed with 50-µL of 0.4% trypan blue.  The trypan blue stain passes 
through the membrane of nonviable (dead) cells and colors the cells blue; therefore, the 
trypan blue stain allows counting of viable and nonviable cells.  10-µL of the cell-trypan 
blue mixture was added to a hemacytometer.  The hemacytometer was viewed at 200× 





















Figure D-1. a.) A microphotograph of a portion of the hemacytometer grid; each of 
the small boxes shown is 0.0625-mm × 0.0625-mm.  b.) An illustration of 
the grid pattern on the hemacytometer and presentation of what areas 
(A-D) are used for cell counting.
   
 
After counting the cells, the cell suspension (in PBS) was centrifuged at 10000 
rpm for 5 minutes.  The supernatant was wasted, and the HEK-293 cells were 
resuspended in 1-mL of DMEM with 10% FBS.  Next, different numbers of cells were 
added to the microplate wells in a total volume of 100-µL DMEM with 10% FBS.  In 
Figure D-2, six different cell concentrations (0, 7800, 19,500, 39,000, 58,500, and 78,000 
cells/well) were employed.  After the cells were added to the wells, the plate was 
incubated at 37°C with 5% CO2 for one hour.  Then, 20-µL of the assay solution (a 
mixture of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) and phenazine methosulfate (PMS), an electron coupling reagent) 
was introduced to the well.  Viable cells convert MTS into a formazan product that 
absorbs light at 490 nm.  Hence, the absorbance at 490 nm can be used as an indirect 
measure of the number of viable cells in each well; the absorbance at 650 nm was used as 
a reference wavelength.  After addition of the MTS/PMS solution, the microplate was 
incubated for 2 hours at 37°C with 5% CO2.  The microplate was then analyzed using a 





Figure D-2. Photograph of the solution coloring throughout the cell-response 




The calibration protocol described above and the photographs shown in Figure D-
2 only employed single measurements of six cell concentrations.  Figure D-3 represents 
the same type of calibration experiment; however, more cell concentrations were 
employed, and samples were prepared in triplicate.  The difference in the absorbance at 
490 nm and the absorbance at 650 nm is plotted against the original number of cells 
added to each well in Figure D-3.  The calibration curve demonstrates a linear fit with 
good correlation coefficient (R2 = 0.992) from 0 to 70,000 cells.  At cell counts greater 
than 70,000, the difference in absorbance at 490 nm and 650 nm leveled out.  
Observation of the strong purple color of the solutions in these wells suggests that the 
absorbance at 490 nm maxes out at these high cell counts because all of the MTS in 





Figure D-3. Calibration curve of initial number of HEK-293 cells added to the 
microplate wells with the response determined using the difference in 
absorbance at 490 nm and 650 nm. 
 
 
Unfortunately, we were unsuccessful in our attempts to standardize this assay 
with standard solutions containing cyclophosphamide.  The results of one attempt to 
build a standard calibration curve using known concentrations of cyclophosphamide are 
shown in Figure D-4.  Clearly, no trend was observed.  Based on the intermediate 
oxidation products identified in Chapter 4, we believe that future application of a similar 
assay to measure the residual pharmacological activity associated with ozonation of 





Figure D-4. Results from an attempt to standardize the response of the MTS 
cytotoxicity assay to standard solutions of cyclophosphamide.  (No 







APPENDIX E:  COMPARISON OF THE VARIABLE VOLUME, CONSTANT 
VOLUME, AND MODIFIED CONSTANT VOLUME MODELS 
FOR PHARMACEUTICAL TRASNFORMATION IN THE 
CONTINUOUS OZONE ADDITION REACTOR 
 
 
Variable Volume Model 
 
The continuous ozone addition reactor is essentially a continuous flow stirred tank 
reactor (CFSTR).  The change in concentration of any species in a CFSTR can be 
modeled using Eq. E-1.  In this case, two general assumptions were made:  sample 
withdrawal was assumed to be a flow rate, that is, the sample volume was divided by the 
sampling interval to obtain Qout; and, both flow rates (Qin and Qout) were considered to be 


















Substituting in the variables relevant to this problem yields Eq. E-2.  In this case, the 
pharmaceutical concentration is the variable of interest.  For this example, we are only 
considering pharmaceutical transformation by ozone.  As the influent is the ozone stock 
solution, [PhAC]in is zero and the influent mass flow term goes to zero. 
 
 












V is the volume of solution in the reactor, which is a function of the initial solution 
volume (Vo), influent flow rate (Qin), the effluent flow rate (Qout), and time (t), as shown 
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in Eq. E-3; [PhAC] is the pharmaceutical concentration at time t; dV/dt is the derivative 
of the volume with respect to time (Eq. E-4); k”O3,PhAC is the second-order rate constant 
for transformation of the pharmaceutical by ozone; and [O3] is the ozone concentration at 
time t. 
 









Dividing both sides of Eq. E-2 by V yields Eq. E-5. 
 
 

















Substituting Eq. E-4 into Eq. E-5 yields Eq. E-6. 
 
 
















Eq. E-3 can be substituted into Eq. E-6; rearrangement and simplification of the resulting 
equation leads to Eq. E-7. 
 
 

















































0  Eq. E-8
 
 
Integration of the left hand side of Eq. E-8 is relatively straightforward.  The right hand 



































Consider the first term on the right hand side of Eq. E-9.  The denominator can be called 
u, as shown in Eq. E-10.  The derivative of Eq. E-10 with respect to time (du) is shown in 
Eq. E-11. 
 
   tQQVu outino   Eq. E-10 
 
  dtQQdu outin   Eq. E-11 
 
Substitution of Eqs. E-10 and E-11 into the first term on the right hand side of Eq. E-9 
allows integration of that term with respect to time as shown in Eqs. E-12 and E-13. 
 
 
















































Integration of the second term on the right hand side of Eq. E-9 is relatively 
straightforward.  For this analysis the ozone concentration ([O3]) was set to a constant 
value, i.e., [O3] did not vary with time.  This assumption is well grounded in the ozone 
data from experimentation, and it allows straightforward analysis of the change in 
pharmaceutical concentration as a function of time.  Then, integration of Eq. E-9 with 


































Rearrangement of Eq. E-14 yields Eq. E-15, which can be directly compared to Eq. E-5 
to assess the effect of the constant volume assumption.  Eq. E-15 is the general solution 
for a CFSTR resembling the continuous ozone addition reactor.  The solution for a 
scenario where Qin = Qout is shown in Eq. E-15*. 
 
    






















 Eq. E-15 
 




















 Eq. E-15* 
 
Constant Volume Model 
 
The change in pharmaceutical concentration in a batch reactor (constant volume) 
can also be modeled.  In this case, the overriding assumption is that there are no inputs or 
outputs to the reactor (i.e., Qin = 0, Qout = 0).  Using these assumptions, the change in 












As expected, the volume term cancels itself out in Eq. E-16.  Substituting the 
pharmaceutical concentration at time t [PhAC] in for C, and the second-order reaction 
term in for r, Eq. E-16 becomes Eq. E-17. 
 
 






 Eq. E-17 
 















0  Eq. E-18 
 
Integration of these two terms was completed above for Eq. E-9.  The resultant 

















 Eq. E-19 
 
Rearranging Eq. E-19 allows us to solve for the pharmaceutical concentration at any 
time, t, as shown in Eq. E-20. 
 











Modified Constant Volume Model 
 
Clearly, the constant volume model (Eq. E-20) oversimplifies the mass transfer 
system present in the continuous ozone addition reactor.  However, the variable volume 
model (Eq. E-15) is complex and difficult to employ for data that demonstrates several 
time dependent parameters.  Therefore, a modified constant volume model was employed 
to describe pharmaceutical transformation in the continuous ozone addition reactor.  In 
this model, Eq. E-20 is multiplied by the ratio of the initial reactor volume to the reactor 
volume at time, t, as shown in Eq. E-21.  The inclusion of this parameter allows us to 
account for the changing volume in the reactor. 
 









  Eq. E-21
 
 
Comparison of the Three Models 
 
Typical values of the relevant parameters were employed to demonstrate the 
differences between the variable volume model (Eq. E-15), the constant volume model 
(Eq. E-20), and the modified constant volume model (Eq. E-21) that was used in 
Chapters 3-5. 
 
For the first example, consider the following values:  Qin was 2.73 mL/min, Qout 
was 1.2 mL/min; Vo was 2000 mL, [IFO]o was 3.83×10
-7 M, k”O3,IFO was 6.84 M
-1s-1, and 
[O3] was 3.90×10
-5 M.  In these scenarios, the second-order rate constant for IFO 
transformation by ozone refers to the value measured using the constant volume model; 
that value is used in the variable volume and constant volume models.  For the modified 
constant volume model, the rate constant determined in the t-BuOH experiment 
incorporates the dilution adjustment (Vo/V) that is present in Eq. E-21.  For this example, 
the second-order rate constant for IFO transformation by ozone in the modified constant 
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volume model is k”O3,PhAC = 7.38 M
-1s-1.  In this example, the volume change throughout 
experimentation is approximately 9%.  The resultant curves for the variable volume, 
constant volume, and modified constant volume solutions are shown below in Figure E-1. 
 
 
Figure E-1. Comparison of the constant volume, variable volume, and modified 
constant volume models for ifosfamide transformation. (In this example, 
the volume changed by approximately 9% during experimentation.) 
 
 
In this case, the constant volume assumption results in a rate constant 
(6.84(±0.27) M-1s-1) approximately 8.4% lower than that of the variable volume model 
(7.47 M-1s-1).  The rate constant for the modified constant volume model was found to be 
7.38(±0.27) M-1s-1, which is approximately 1.2% less than that predicted by the variable 
volume model; however, the 95% confidence interval on the rate constant found using the 
modified constant volume model overlaps the value predicted by the variable volume 




Similar results were attained for cyclophosphamide.  Consider the same example 
as that just discussed, but now the rate constants for the constant volume and modified 
constant volume models are k”O3,CYP was 2.50(±0.48) M
-1s-1 and k”O3,CYP was 3.03(±0.48) 
M-1s-1, respectively (Figure E-2).  Recall that these parameters were calculated from 
experimental data as described above.  In the variable volume model, the calculated rate 
constant is 3.05 M-1s-1.  Clearly, the modified constant volume model (with 95% 
confidence intervals) overlaps with the variable volume rate constant. 
 
 
Figure E-2. Comparison of the constant volume, variable volume, and modified 
constant volume models for cyclophosphamide transformation. 
 
Next, consider an example with a greater difference in Qin and Qout.  The values of 
the parameters were:  Qin was 3.23 mL/min, Qout was 0.27 mL/min; Vo was 2000 mL, 
[PhAC]o was 3.83×10
-7 M, k”O3,IFO was 6.84 M
-1s-1, and [O3] was 4.60×10
-5 M.  In this 
case, the total volume change is approximately 18%.  The resultant curves for the 





Figure E- 3. Comparison of the constant volume, variable volume, and modified 
constant volume models for ifosfamide transformation. (In this example, 
the volume changed by approximately 18% during experimentation.) 
 
The rate constant measured using the constant volume model (k”O3,IFO = 
6.84(±0.27) M-1s-1) is approximately 7.4% lower than that described by the variable 
volume reactor (k”O3,IFO = 7.39 M
-1s-1).  Again, the modified constant volume model 
(k”O3,IFO = 7.38(±0.27) M
-1s-1) compares well to the variable volume model. 
 
The impact of the volume change in the reactor was also studied to understand 
how the increase or decrease in reactor volume affects the rate constant (for 
cyclophosphamide) calculated in the variable volume model.  For this scenario, the same 
values for the relevant parameters were used as in the previous example.  Volume 
changes of -40%, -20%, -10%, 10%, 20%, and 40% were studied.  The negative volume 
changes were modeled by changing Qout to achieve the necessary volume change over the 
course of the experiment; the positive volume changes were achieved by adjusting Qin.  
Eq. E-15* was also plotted to describe a scenario where there is an influent stream (ozone 
stock solution) and an effluent stream (sample withdrawal) but the reactor volume 
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remains constant (e.g., V(t) = 2000 mL).  From Figure E-4, it is clear that variable reactor 
volume does affect the rate constant found using the variable volume model; however, a 
volume change of approximately +36% or -71% is required before the rate constant from 
the variable volume reactor falls outside of the 95% confidence interval for the modified 
constant volume model.  All but two of the experiments were within 10% volume change 
(one experiment exhibited an 18% change and another showed 15%); therefore, we 
expect that the modified constant volume model successfully describes pharmaceutical 
transformation in the continuous ozone addition reactor. 
 
 
Figure E-4. Comparison of the constant volume, variable volume, and modified 
constant volume models for cyclophosphamide transformation.  (In this 
example, the volume change in the reactor was controlled by adjusting Qin 
and Qout.  Note, that a scenario where volume change in 0%, but influent and 
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